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Combretastatin A1P 9 is an anti-cancer drug that works as a vascular disrupting agent.  
CA1P 9 binds to tubulin causing irreversible microtubule destabilisation and results in 
the destruction of endothelial cells that line tumour blood vessels.  The high cytotoxicity 
of CA1P 9 in vivo is thought to be due to the formation of ortho-quinone species.  Whilst 
quinone-glutathione adducts have been detected by LC-MS in murine urine and blood, 
these ortho-quinone metabolites have not been directly observed in vivo.  However, these 
short-lived metabolites can be imaged in vivo using hyperpolarised MRS.  
Hyperpolarisation is a technique that increases the sensitivity of magnetic resonance 
techniques and allows for the detection of 13C-labelled compounds and their downstream 
metabolic products in real-time in vivo.  Therefore to investigate the ortho-quinone 
metabolites of CA1P 9, a route for the synthesis of 13C-labelled CA1P [13C]-153 was 




Figure 1: Tetrasodium 9 and dipotassium 151 combretastatin A1P. 
 
 
The location of the 13C label was chosen at a site with a long T1 relaxation time in order 
to maximise the lifetime of the hyperpolarisation.  For economic reasons, the route was 
first developed using 12C material.  Attempts were first made to develop a route for the 
synthesis of CA1P by the selective reduction of a diarylalkyne.  This strategy was 
envisioned to be high yielding and 100% Z-selective.  Unfortunately, difficulties were 
had in finding efficient regioselective iodination conditions for a suitable 13C-labelled 
precursor which would be used in the formation of the diarylalkyne via a Sonogashira 





Scheme 1: Route towards the synthesis of 13C-labelled combretastatin A1P [13C]-153. 
 
The synthesis started with the regioselective insertion of a 13C label into an aromatic ring.  
This was achieved by [13C]-methylcuprate addition to the acid chloride 79, and the 
resulting ketone [13C]-80 was cyclised then aromatised.  A hydroxyl group was then 
inserted into the 2-position via a formylation and Baeyer-Villiger oxidation.  CA1 [13C]-
154 was then synthesised by a Wittig reaction with the aldehyde component [13C]-163 
synthesised from the core aromatic species containing the 13C label.  The Wittig reaction 
preceded with an E/Z ratio of 18:82 and the resulting Z-isomer [13C]-165 was deprotected 
to reveal CA1 [13C]-154.  Conversion of CA1 [13C]-154 to its prodrug [13C]-153 was 
attempted, replicating the conditions established in the 12C synthesis, however the small 
scale of the reaction prevented the clean isolation of CA1P [13C]-153.  The 12C-synthesis 
of CA1P 151 involved 13 steps and had an overall yield of 1.2%. 
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Chapter 1: Introduction 
 
1.1. Cancer treatment 
 
Cancer is a broad group of diseases defined by uncontrolled cell growth.  In humans there 
are over 200 known types of cancer that have the potential to affect every organ in the 
body and can develop in almost every type of cell.  The complexity of the diseases means 
they can be hard to treat, making cancer the leading cause of death in the developed world.  
The GLOBOCAN 2012 project estimates there were 14.1 million diagnoses and 8.2 
million deaths due to cancer in 2012 worldwide.1 
 
Understanding how cancer cells differ from normal cells is fundamental in developing 
selective treatments for cancers.  Hanahan and Weinburg proposed six hallmarks of 
cancer in their 2011 review:2 
 
1. Self-sufficiency in growth signals: Normal cell growth is controlled by appropriate 
growth factors.  Tumour cells have shown a reduced dependence on exogenous 
growth stimulation caused by having the ability to generate their own growth 
signals which leads to uncontrolled growth.  This ability also disrupts the 
important homeostatic mechanisms that dictate normal cell behaviour.   
2. Insensitivity to anti-growth signals: Normal cells have a number of growth-
inhibitor signals which are there to maintain cellular quiescence and tissue 
homeostasis.  Tumour cells either disrupt or ignore these signals allowing for 
uncontrolled growth.  
3. Limitless replicative potential: Normal cells have an intrinsic cell-autonomous 
programme that limits their multiplication i.e. once a cell has replicated a certain 
number of times it will stop replicating.  Tumour cells have a way to overcome 
this and therefore have limitless replicative potential.  
4. Evading apoptosis: Normal cells undergo apoptosis (programmed cell death) 
when damaged or old, whereas tumour cells acquire a resistance to apoptosis.  50% 
of cancers show a mutation in the p53 gene which is a gene that suppresses cell 
growth.  This mutation results in the formation of the p53 protein without the 
DNA damage sensor a key component that starts the apoptosis mechanism. 
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5. Tissue invasion and metastasis: Normal cells produce a chemical that allows cells 
to adhere to each other.  Cancer cells do not produce these substances and, 
therefore, can “float away” to other regions of the body via the blood supply or 
lymph fluid where they can form tumours in different locations where nutrients 
and space are not as limiting. 
6. Sustained angiogenesis: Normal tissue undergoes angiogenesis when growing or 
repairing damaged tissue.  In cancer tissue angiogenesis is deregulated, allowing 
new blood vessels to form even when growth or repair is unnecessary.  
Other significant differences between normal and healthy cells include:  
7. Rate of growth: Cancer cells reproduce rapidly before cells have a chance to 
mature and differentiate and, therefore, remain immature and non-specialised. 
8. Energy source: Normal cells are in an aerobic environment, so get the majority of 
their energy from the ATP produced in the Krebs cycle, and a smaller amount 
from the ATP produced via glycolysis.  Cancer cells however have a lot higher 
rates of glycolysis even in regions of high oxygen concentration.  This is known 
as the Walburg effect.   
9. Communication: Normal cells stop growing when they encounter another cell and 
there is no more free space (contact inhibition).  Cancer cells do not have the 
ability to communicate with other cells through chemical signals, and therefore 
can invade nearby tissue. 
 
Along with surgery and radiation therapy, chemotherapy is a common treatment of cancer.  
Traditional chemotherapy drugs target cells that rapidly divide; a key property of cancer 
cells.  However, these drugs are often non-selective so will also damage fast-growing 
healthy cells, causing side-effects; for example, cells in hair follicles (hair loss) and blood-
forming cells in bone marrow (low blood count).  Therefore, the ability to differentiate 
between malignant cancer cells and healthy cells is vital to increase the effectiveness of 
treatment and reduce side effects.   
 
1.2. Vascular disrupting agents 
 
Tumours are not just a collection of tumour cells; they are complex structures surrounded 
by a “tumour microenvironment” which includes a network of blood vessels, immune 
cells and fibroblast cells.  An important difference between normal and cancerous tissue 
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is their vasculature.  Oxygen and nutrients supplied by the blood supply are crucial for 
cell function and survival.  The blood supply also provides the main route for metastatic 
spread.  Almost all cells in the tissue reside within 100 m of a capillary blood vessel, so 
disruption of the blood supply in solid tumours will deprive the tumour of vital nutrients.  
Furthermore, the build-up of toxic waste could result in cell death and tumour 
degeneration.   
 
The differences in the vasculature of normal and tumour cells can be exploited, and led 
Denekamp to propose a vascular targeting approach to cancer therapy for solid tumours 
in 1982.3  Anti-cancer drugs that target the vascular system of tumours are known as 
vascular targeting agents (VTAs).  VTAs can be divided into two groups; anti-angiogenic 
drugs and vascular disrupting agents.  Anti-angiogenic drugs work by preventing 
angiogenesis, the formation of new blood vessels.  They are known as cytostatic drugs 
because they hinder the growth of new tumour cells, thereby stabilising the tumour and 
preventing metastasis.  However, this means that the already established cancer cells and 
tumour vasculature will remain undamaged and, therefore, anti-angiogenesis drugs will 
need to be used in conjunction with other chemotherapeutic methods for effective 
treatment.  Unlike anti-angiogenesis drugs, vascular disrupting agents (VDAs) selectively 
target existing tumour blood vessels rather than preventing the production of new ones.  
Disrupting existing vasculature will cause rapid occlusion of blood flow to the tumour, 
depriving the tumour of oxygen and nutrients.  VDAs target endothelial cells that line the 
vasculature throughout the entire tumour and, therefore, have the potential to affect every 
cell in the tumour.  This strategy has the advantage over the traditional treatment of 
targeting abnormal tumour cells where the drug often cannot reach the core of the tumour.  
These drugs take advantage of the many differences between normal and tumour 
vasculature. 
 
An important difference between tumour and normal tissue is the cytoskeleton of their 
vascular endothelial cells.  A cell cytoskeleton is made up of three components; 
microfilaments (actin filaments), intermediate filaments and microtubules.  The ratios of 
these components vary for normal and tumour cells.  The structure and shape of normal 
cells are supported by a scaffold of microtubules as well as a well-defined actin 
cytoskeleton due to the dense band of actin microfilaments.4  Tumour cells, however, rely 
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heavily on a tubulin-microtubule cytoskeleton.  This causes the endothelial cells in 
normal vasculature to be mature, regular and well-defined whereas the tumour endothelial 
cells are structurally disorganised and irregular, relying more on a tubulin cytoskeleton to 
maintain their shape.  As well as differences in the cytoskeleton, the endothelial cells 
lining blood vessels in tumours proliferate at a much higher rate than those in normal 
tissue, so they have a significantly increased rate of mitosis.5  The mitotic spindle is a key 
component in mitosis and is a collection of spindle fibres that form during mitosis.  
During mitosis, the two daughter chromosomes align themselves along the mitotic spindle, 
which is used to pull the duplicated chromosomes apart to opposite poles.  The mitotic 
spindle is made up of microtubules which form from the polymerisation of  and  
tubulin. 
 
1.2.1. Tubulin and microtubules 
 
Microtubules are cytoskeletal protein polymers and play essential roles within eukaryotic 
cells.  These include maintaining cell shape, cell division, motility, signalling and 
intracellular organelle transport.6  Microtubules are long, hollow, cylindrical tubes that 
are approximately 25 nm in diameter and 200 nm – 25 m in length.  They are composed 
of two protein subunits:  and  tubulin.  These subunits polymerise to form -
heterodimers which assemble head-to-toe into long protein fibres called protofilaments.  
It is these protofilaments that form the backbone of the microtubules.  The microtubules 
have polarity due to the head-to-toe assembly of the heterodimers: the -tubulin end is 
negatively charged and the  tubulin end is positively charged.  They can undergo 
highly-regulated rapid assembly and disassembly by reversible association and 
dissociation of  heterodimers to either end of the microtubule.  The microtubule 
polymerisation occurs through a nucleation-elongation mechanism.  This starts with the 
slow formation of a microtubule nucleus and is followed by fast elongation by reversible, 
non-covalent addition of tubulin subunits.  Microtubules are highly dynamic and alternate 
between periods of growing and shrinking by the addition or removal of tubulin subunits 
at the ends of the microtubule.  The energy required is provided by the hydrolysis of the 




The dynamics of microtubules are crucial for mitosis since the mitotic spindle is made up 
of microtubules.  The mitotic spindle plays a role in all stages of mitosis.  At first, the 
cytoskeletal microtubule network is dismantled, then a spindle-shaped collection of 
microtubules are formed by polymerising tubulin and this forms the mitotic spindle.  Next, 
the chromosomes are attached to the spindle and line up along the metaphase plate whilst 
still being attached to the microtubules.  These chromosomes then separate and the two 
chromatids migrate to the opposite spindle poles when the microtubules shorten, and in 
the final stage the mitotic spindle is dismantled.  The rapid dynamics of the microtubules 
are vital in the delicate movement of the chromosomes, as well as the assembly and 
disassembly of the mitotic spindle.  
 
1.2.2. Tubulin inhibitors 
 
Microtubules play an essential role in mitosis, and a characteristic of cancer cells is that 
they divide more frequently and, therefore, have an increased rate of mitosis.  Their 
importance in mitosis makes microtubules a significant target for anti-cancer drugs since 
their disruption will prevent cell division and cause cell death by apoptosis.  There are a 
large number of compounds which bind to tubulin and, therefore, inhibit cell proliferation 
and a number have progressed into clinical use.  Many of these compounds are derived 
from natural products and have been isolated from a broad range of species including 
bacteria, plants and sponges.  The majority of anti-mitotic drugs bind to soluble tubulin 
or to tubulin in the microtubules.  At high concentrations these anti-mitotic compounds 
depolymerise microtubules, but at low concentrations they work by suppressing or 
stabilising microtubule dynamics without changing microtubule mass, resulting in mitotic 
disruption and subsequently cell death.7  Tubulin-binding agents can be broadly classified 
as either microtubule-stabilising drugs (e.g. taxanes and epothilones) or as microtubule-
destabilising (e.g. vincristine, colchicine or combretastatins) and are known to bind to 
specific sites on the tubulin dimer.  They generally bind to one of three main binding sites 
on tubulin; the paclitaxel site, the vinca domain or the colchicine site, the latter being 
associated with vascular targeting agents.  
 
Tubulin polymerisation promoters (or microtubule-stabilisers) are a class of drugs that 
work by promoting the assembly of tubulin into microtubules and, therefore, interferes 
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with the breakdown of the mitotic spindle at the end of mitosis, which ultimately leads to 
cell death.  Taxanes are a type of tubulin polymerisation promoter an example of which 
is paclitaxel 1 (Taxol ®) which was approved for medical use in 1992 and has continued 
to be routinely used to treat a number of solid tumours such as ovarian, breast, lung, 
bladder and prostate (Figure 2).8  Other tubulin polymerisation promoters that have the 
same mechanism of action include a group of natural products called epothilones.  A large 
number of epothilones have been advancing in clinical trial and ixabepilone 2 has recently, 
in 2007, been approved by the FDA for the treatment of breast cancer.8 
 
Figure 2: Tubulin polymerisation promoters. 
 
Tubulin polymerisation inhibitors (or microtubule-destabilisers) work by preventing 
tubulin assembly into microtubules.  The most studied inhibitors are the vinca alkaloids 
which were isolated from the Catharanthus roseus leaves and were found to have anti-
cancer properties in the 1950s.9  The vinca alkaloid vinblastine 3 was the first tubulin 
inhibitor to go into clinical trials and is currently used to treat bladder and other cancers 




Figure 3: Tubulin polymerisation inhibitors. 
 
Colchicine 5 is also a compound that depolymerises microtubules at high concentrations 
but stabilises them at low concentrations (Figure 4).  Colchicine 5 inhibits microtubule 
depolymerisation sub-stoichiometrically so is likely to bind to the microtubule ends rather 
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than free tubulin. Colchicine 5 unfortunately has a low therapeutic ratio and high toxicity 
which has prevented it from proceeding further in clinical trials.  However, the recent 
AstraZeneca compound ZD6126 6, a colchicine analogue, has made it into clinical trials 
as a vascular disrupting agent.10  ZD6126 6 structurally resembles colchicine 5 but differs 
by containing a benzenoid ring instead of the tropolone ring in colchicine.  ZD6126 6 is 
a water-soluble pro-drug which is converted to active N-acetylcolchinol in vivo.  The final 
class of microtubule-destabilisers are the combretastatins, they bind to -tubulin at the 
“colchicine binding site” but with a higher affinity than colchicine.  Microtubule-binding 
agents are classically known for their anti-mitotic properties, however agents such as 
combretastatins have shown rapid anti-vascular effects and are being investigated as 
potential vascular disrupting agents. 
 
 




Combretastatins were first isolated from the bark of the South African bush willow tree 
Combretum caffrum by Pettit and co-workers in the late 1980s (Figure 5).11  Of the 17 
isolated compounds, combretastatin A4 7 was shown to be the most potent against a panel 
of tumour cells, with CA1 8 about one fifth as potent.  Combretastatins have been shown 
to be highly selective towards tumour vasculature and cause significant tumour damage 
with minimal side effects.  This has led to extensive studies of CA1 8 and CA4 7 as 





Figure 5: Structures of combretastatins isolated from Combretum caffrum and two combretastatin 
prodrugs CA1P 9 and CA4P 10. 
  
Combretastatins A1 8 and A4 7 show potent biological activity, however they have poor 
pharmacokinetic properties due to their low water solubility and high lipophilicity.  To 
improve bioavailability, the phosphate pro-drugs CA1P 9 and CA4P 10 were formulated.  
Interestingly, although CA4 7 is more potent than CA1 8 against human cancer cells lines 
in vitro, at equal doses the corresponding prodrug CA4P 10 is less active than CA1P 9 in 
in vivo preclinical tumour growth delay studies.  CA1 8, CA4 7 and their corresponding 
pro-drugs show a wide variety of biological activity against human cancer cell lines 
(Table 1).12–14  CA4P 10 was the first combretastatin to go into clinical trials, entering 
phase I studies under the trade name Zybrestat™, and was shown to selectively reduce 
tumour blood flow at well-tolerated doses.  CA4P 10 is currently in phase II clinical trials 
for the treatment of cervical, colorectal, lung, prostate, ovarian and thyroid cancers.15  The 
prodrug CA1P 9 (OXi4503) is currently undergoing Phase I human clinical trials for the 
treatment of primary and secondary hepatic tumours and has completed Phase I trials for 






























CA4 1.2a 0.0003b 0.39b <0.001b 0.0006b 0.061b 0.0008b 
CA4P >40a 0.0004b 0.23b 0.036b 0.029b 0.034b 0.0072b 
CA1 1.9a 0.25c 4.4c - 0.74c 0.061c 0.17c 
CA1P >40a <0.01c 1.5c 0.036c 0.038c 0.53b 0.034c 
a From reference 12, b From reference 13, c From reference 14. 
 




1.3.1. Combretastatins as vascular disrupting agents 
 
Combretastatins have been shown to rapidly disrupt the vascular network in tumours, 
which leads to secondary cell death.  They destabilise microtubules, inducing death in 
proliferating endothelial cells by damaging mitotic spindles. Combretastatins A1 8 and 
A4 9 structurally resemble the antimitotic agent colchicine 5 and are also classed as 
tubulin binding agents, and in particular, tubulin polymerisation inhibitors.6  Upon 
administration, the CA1P prodrug 9 undergoes enzymatic dephosphorylation by 
endogenous non-specific phosphatases to the active metabolite CA1 8.  Free CA1 8 
rapidly binds to  tubulin in the  tubulin heterodimer at the same site as colchicine 
5, known as the colchicine binding site, in the endothelial cells that line tumour 
vasculature.  CA4 7 has been shown to bind with a higher affinity to the colchicine 
binding site than colchicine 5 itself and unlike colchicine 5, CA4P 10 is active well below 
its maximum tolerated dose. 
 
The binding of CA1 8 or CA4 7 to tubulin suppresses the microtubule dynamics of the 
mitotic spindle, causing disruption to the mitotic spindle.  As this will now not satisfy the 
spindle checkpoint the cell will undergo mitotic arrest.16,17 Combretastatins in particular 
target tumour vascular endothelial cells and destruction causes coagulation and thrombus 
formation to occur.  This is followed by loss of blood flow, depriving the tumour of 
oxygen and nutrients which will result in secondary cell death due to malnutrition.18–20  
CA1P 9 shows severe haemorrhagic necrosis in tumours after treatment and has seen 
almost 94% tumour necrosis within 24 hours of treatment.21 
 
Treatment with CA4P 10 has been shown to result in a reduction of blood flow within the 
tumour and also results in haemorrhagic necrosis.  It has a wide therapeutic window, since 
these results can be observed at doses of one tenth of the maximum tolerated dose, which 
is in contrast to other related tubulin-binding agents.22  However, CA4P 10 induces little 
growth retardation when administered as a single dose near the maximum tolerated dose, 
which has been attributed to the survival of a narrow rim of peripheral tumour cells.  The 
existence of this “viable rim” at the end of treatment can result in rapid proliferation and 
revascularisation of the tumour.  However, these cells can be treated with additional 
chemotherapy, since the tumour periphery is easily accessed by other high molecular 
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weight drugs.  A common explanation for the existence of the “viable rim” is due to these 
cells receiving oxygen and nutrients from the surrounding undamaged normal tissue. 
However, this “viable rim” that remains after treatment with CA4P 10 is significantly 
smaller following treatment with CA1P 9. 
 
CA1P 9 has been shown to be more effective at producing tumour growth delays than 
CA4P 10.21  At a 100 mg/kg dose, CA1P 9 induced significant retardation of tumour 
growth, whereas CA4P 10 showed no significant growth retardation with a single dose 
up to 400 mg/kg.23  Therefore CA1P 9 has more potent antivascular effects when used as 
a single agent than CA4P 10.  The structural difference between CA1P 9 and CA4P 10 is 
the presence of an extra phosphoryl-protected hydroxyl group on one of the phenyl rings 
and clearly has a strong influence on the anti-tumour activity.  It is possible that the extra 
phosphate group influences the pharmacokinetic, distribution and release profile of the 
active CA1 8.  Once administered both CA1P 9 and CA4P 10 are dephosphorylated to 
CA1 8 and CA4 7 respectively by non-specific phosphatases.  
 
1.4. Combretastatin analogues 
 
The simplicity of the combretastatin skeleton has generated a vast number of analogues.  
Since CA4 7 had the most potent in vitro antitumour activity of the combretastatins 
isolated by Pettit et al., it has been used as a lead compound for the development of VDA 
drugs.  However, both combretastatin A1 8 and A4 7 show little anti-neoplastic effects in 
vivo due to poor pharmacokinetics caused by low water solubility and high lipophilicity.  
As a result, more water soluble derivatives have been synthesised in order to improve 
water solubility and perhaps even increase cytotoxicity.  Numerous water-soluble 
phosphate salts of CA1 8 have been synthesised including lithium, potassium, caesium, 
magnesium, calcium, manganese, zinc, piperazine, 3-pyridinecarboxamide, morphine, 
(+)-and (-)-cinchonan-9-ol and benzeneacetonitrile salts.24  These analogues were 
evaluated as potential pro-drugs, and the tetrasodium phosphate analogue 9 was found to 
have the best water solubility and is currently undergoing clinical trials (CA1P, OXi4503). 
 
Structure activity relationship (SAR) studies provide information on the functional groups 
responsible for the biological activity and by synthesising analogues of a bioactive lead, 
a compound with higher potency could be found.  SAR analysis of combretastatins and 
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their analogues by Pettit et al. shows that the correct alkene geometry of the 
combretastatin is essential for its cytotoxic activity; the Z-isomer has significantly greater 
cytotoxic activity than the corresponding E-isomer.11,25  The trimethoxybenzene (Ring A) 
moiety has also been shown to be essential for its activity.26  A growing library of 
combretastatin analogues have been synthesised; these analogues typically include Ring 
A alterations, bridge-modifications, and/or Ring B alterations (Figure 6). 
 
 




The search for more water-soluble derivatives that have similar or greater cytotoxic 
activity has led to the discovery of several analogues that are currently in human clinical 
trials (Figure 7).  Ohsumi and co-workers synthesised a number of CA4 10 analogues and 
evaluated their cytotoxicity effects against murine colon 26 adenocarcinoma and their 
inhibitory activity on tubulin polymerisation.27  They proposed that the introduction of a 
nitrogen containing group into CA4 10 could increase its water solubility.  Replacement 
of the hydroxyl group in the C3 position with an amino group resulted in a noticeable 
increase in water solubility and in vivo antitumour activity against murine solid tumours.  
This has led to the analogue AC-7739 11 being taken to pre-clinical development.  Other 
analogues in pre-clinical development include Oxi6196 12, where the combretastatin 
bridge has been modified, and Oxi8006 13 where Ring A has been altered.  There are also 
a number of combretastatin analogues that have progressed to human clinical trials.  
Ombrabulin (AC-7700 or AVE8062) 14 is a water soluble analogue of CA4 7 developed 
by Ohsumi and is currently in Phase I clinical trials for the treatment of advanced staged 
soft-tissue sarcoma and metastatic non-small cell lung cancer.28,29  Ombrabulin 14 is the 
prodrug and the serine group is cleaved by aminopeptides in vivo to reveal the active 
compound.  In a similar fashion to CA1 8 and CA4 7, Ombrabulin 14 binds to tubulin in 
tumour cells, depolymerising microtubules and causing vascular blood flow shutdown.  
Other analogues currently in human clinical trials include Crolibulin 15 and BNC 105P 




Figure 7: CA4 7 analogues in pre-clinical trials: Oxi8006, Oxi6196 and AC-7739 and human clinical 
trials: Crolibulin, BNC 105P and AC-7700. 
 
1.5. Synthesis of combretastatins 
 
Combretastatin molecules share several common features.  They have two aromatic rings; 
a 1,2,3-trimethoxy ring (A ring) and 2,3-substituted ring or 2,3,4-substituted (Ring B).  
These rings are linked by a Z-ethene bridge; which has been shown to have much higher 
biological activity than the E-isomer.  Therefore a convenient and stereoselective route 
for the preparation of combretastatins is needed.  CA1 8 differs from CA4 7 by only one 
hydroxyl group on the B ring and this causes them to have different biological activities 




Figure 8: Combretastatins CA1 8 and CA4 7. 
 
1.5.1. Synthesis of combretastatins by the Wittig Reaction 
 
The formation of the Z-alkene through the Wittig reaction between an aldehyde and 
phosphonium ylide is the key step in many synthesis of CA1 8 and CA4 7.  In the 1980s 
the Pettit group first isolated and synthesised combretastatins A1 8 and A4 7, which they 
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achieved using the Wittig reaction.30–32  The reaction of 3,4,5-trimethoxybenzaldehyde 
17 with the ylide derived from phosphonium bromide 18 with nBuLi afforded a mixture 
of TBS-protected stilbenes 19 and 20 in a yield of 93% with an E/Z ratio of  1.5:1 (Scheme 
2).  By reversing the components of the Wittig reaction the E/Z selectivity was improved 
to 1:3.6 and the TBS-protected stilbenes 19 and 20 were synthesised in a yield of 65%.30  
Subsequent separation by column chromatography and deprotection of the silyl ether with 
tetrabutylammonium fluoride afforded the desired Z-CA4 7.  Despite the latter method 
giving a lower overall reaction yield for both isomers, the yield for TBS protected Z-CA4 
19 after separation was higher.  
 
 
Scheme 2: Synthesis of TBS-protected Z-CA4 19 using the Wittig reaction. 
 
Combretastatin A1 8 has also been successfully synthesised through the Wittig reaction.  
Pettit and Lippert treated the phosphonium salt 21 with n-butyllithium which formed the 
corresponding ylide in situ.24  To this ylide, benzaldehyde 22 was added and resulted in 
a mixture of the E- and Z-isomers 23 and 24.  The desired Z-isomer 24 was isolated after 
column chromatography and recrystallisation in a 43% yield and underwent desilylation 






Scheme 3: Synthesis of CA1 8 using the Wittig reaction. 
 
1.5.2. Synthesis of combretastatins by Cross coupling reactions 
 
A disadvantage of the Wittig reaction is the low selectivity and the need for laborious 
chromatography separations which results in an overall low yield for the desired Z-isomer, 
thus a more stereoselective route is desirable.30  Hadfield and co-workers sought to 
develop a method with improved stereoselectivity that was also amenable to large-scale 
production.  They developed two methods, the first of which uses the commonly used 
Suzuki cross coupling reaction (Scheme 4).33  A Corey-Fuchs Wittig-like bromination of 
silyl protected 3-hydroxy-4-methoxybenzaldehyde 26 followed by deprotection yielded 
the dibromoalkene 27 in satisfactory yield, 54%.  Stereoselective reduction of 
dibromoalkene 27 using tributyltin hydride and tetrakis(triphenylphosphine)palladium (0) 
afforded the (Z)-vinyl bromide 28 in good yield.  The Pd-catalysed Suzuki cross-coupling 
of (Z)-vinyl bromide 28 with 3,4,5-trimethoxyphenylboronic acid 29 under basic 
conditions, employing tetrakis(triphenylphosphine)palladium (0) as the catalyst afforded 
the Z-isomer of CA4  7 with excellent stereoselectivity (Z:E = 99:1) and good yield.  The 
overall yield from the starting material isovanillin 25 is 16% which is comparable to the 





Scheme 4: Synthesis of CA4 7 using Suzuki cross coupling. 
 
The second method developed by Hadfield and co-workers is a two-step stereoselective 
synthesis of combretastatin A4 7 using a Perkin condensation of 3,4,5-
trimethoxyphenylacetic acid 30 and 3-hydroxy-4-methoxybenzaldehyde 29 (Scheme 
5).33  The resulting cinnamic acid 31, which was formed as a single isomer, was then 
decarboxylated using copper and quinoline to yield combretastatin A4 7 in an overall 
yield of 42% yield.  Crude GC analysis showed a Z:E ratio of  88:12, but following 
recrystallisation this increased to 99.8:0.2.  This shows that this is an efficient 
stereoselective method for the synthesis of Z-CA4 7, avoiding the use of protecting groups 
and column chromatography, and is more efficient than the Hadfield’s Suzuki method 
which had an overall yield of 16% from isovanillin 29.   
 
 
Scheme 5: Synthesis of CA4 7 via a Perkin condensation. 
 
Palladium catalysed cross coupling reactions are of central importance in organic 
chemistry for forming carbon-carbon bonds.  Suzuki-Miyaura, Sonogashira and Negishi 
reactions have been the key step in many syntheses of combretastatins.33–35  The Suzuki-
Miyaura cross coupling of an aryl boronic acid and a vinyl halide is the most common 
cross-coupling reaction used for the synthesis of combretastatins.33,34 Fürstner and 
Nikolakis developed a stereoselective method for the synthesis of CA4 7 through a 
Lindlar-based semi-hydrogenation of a diarylalkyne 32 which was synthesised through 
two consecutive Suzuki-type cross coupling reactions (Scheme 6).36  The addition of 
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sodium acetylide 33 to B(OMe)3 34 led to a mixture of borate complexes 35 and the 
subsequent reaction with 5-bromo-1,2,3-trimethoxybenzene in the presence of catalytic 
PdCl2(dppf) yielded the corresponding aryl acetylene 36 in good yield.  This acetylene 
36 underwent 9-MeO-9-BBN-mediated Suzuki-type cross coupling with the bromide 37 
and afforded the diarylalkyne 32.  Z-Selective semi-hydrogenation with a Lindlar catalyst 
(5% Pd/C, ethylenediamine) provided the silyl-protected CA4 19 in 80% yield.  
Deprotection using tetrabutylammonium fluoride led to combretastatin A4 7 in high yield.  
Despite the reaction being Z-selective, over-reduction caused the formation of the 
corresponding alkane 38 in a ratio of 86:14 (Z-combretastatin A4 7: alkane 38) and 
separation through flash chromatography was needed. 
 
 
Scheme 6: Synthesis of CA4 7 via two consecutive Suzuki-type cross coupling reactions. 
 
Another synthesis of combretastatins using Suzuki-Miyaura cross-coupling was reported 
by Hudlicky and co-workers.34  The aryl bromide component 39 of the Suzuki reaction 
was generated by the bio-oxidation of 4-bromoanisole 40 using the biocatalyst E. coli 
JM109 (pDTG602) followed by MOM protection.  The coupling of p-
bromomethoxycatechol 39 with the alkynyl-boronic ester of trimethoxyphenylacetylene 
36 under Suzuki-Miyaura conditions yielded acetylene 41 (Scheme 7).  Comparative 
studies on the reduction of the diarylalkyne 41 to the Z-MOM protected alkene showed 
the superior use of hydroboration over using Lindlar’s catalyst providing the required 
MOM-protected Z-olefin in an 84% yield.  Subsequent deprotection using dilute 





Scheme 7: Synthesis of CA1 8 via Suzuki-Miyaura coupling. 
 
Knochel and co-workers reported a mild yet stereoselective synthesis of CA4 7 using the 
Negishi cross-coupling reaction.37  The 3,4,5-trimethoxy--iodostyrene 42 intermediate 
was prepared with excellent stereoselectivity from the commercially available 3,4,5-
trimethoxybenzaldehyde 17 and Zhao’s reagent in the presence of NaHMDS.  The 
iodostyrene 42 first underwent iodide-magnesium exchange with iPrMgCl.LiCl, then 
subsequent Mg-Zn transmetallation by addition of 1 M ZnCl2 in a THF-NMP mixture to 
afford the organozinc reagent 43 with no loss in stereoselectivity.  The organozinc reagent 
43 was then subjected to in situ Negishi cross-coupling with 1-iodo-2,3-OTBS-4-
methoxybenzene 44 in the presence of the palladium catalyst (A-taPhos)2PdCl2.  The 
resulting combretastatin A4 7 was obtained with very good stereoselectivity (Z:E = 10:1). 
 
 






1.5.3. Synthesis of combretastatins by selective reduction of diarylalkynes 
 
Many synthesises of Z-combretastatins are achieved through the reduction of the 
corresponding diarylalkyne, with methods including using Lindlar’s catalyst,38 alkyne 
hydroboration,34 and the hydrolysis of a Ti(II)-alkyne complex.39  Petrov et. al. developed 
a route that uses the Colvin rearrangement to generate the diarylalkyne intermediate 45 
(Scheme 9).38  Acylation of protected-anisole 46 with 3,4,5-trimethoxybenzoic acid 47 in 
the presence of Eaton’s reagent followed by deprotection of the chloroacetyl group 
afforded the phenstatin precursor 48 in high yield.  In the key step, the Colvin 
rearrangement was carried out with the TBS-protected phenstatin 49 and 
trimethylsilyldiazomethane employing nBuLi as the base.  Final deprotection using 
tetrabutylammonium fluoride yielded the desired diarylalkyne intermediate 45 in 
excellent yield.  The partial hydrogenation of the diarylalkyne was then studied.  
Preliminary experiments for the hydrogenation of diarylalkyne 45 used Pd/C as the 
catalyst in the presence of ethylenediamine in methanol and resulted in the formation of 
fully hydrogenated corresponding alkane 38.  Hydrogenation of TBS-protected alkyne 
over Lindlar catalyst (Pd/CaCO3) with quinoline as an additive in hexanes formed the 
desired combretastatin 19 with a ratio of 82:18 (combretastatin:alkane).  However better 
results were obtained by the partial hydrogenation of the deprotected alkyne 45 in a 1:1 
solvent mixture of hexanes and toluene, giving the combretastatin 7 in a 94:6 ratio with 
its corresponding alkane 38.   
 
 




Hansen and co-workers reported the synthesis of combretastatin A1 8 via the selective 
reduction of a diarylalkyne 41 which was synthesised by the Sonogashira reaction.35  The 
Sonogashira coupling between a MOM protected iodide 50 and 3,4,5-
trimethoxyphenylacetylene 36 in the presence of Pd(PPh3)4, CuI and n-propylamine 
afforded the diarylalkyne 41 in good yield.  Hydroboration under the conditions reported 
by Hudlicky and co-workers yields the desired Z-olefin, subsequent deprotection yields 
the desired CA1 8 in high yield with no isomerisation of the Z-olefin (Scheme 10).34 
 
 
Scheme 10: Synthesis of Combretastatin A1 8 via a Sonogashira Reaction. 
 
Lara-Ochoa synthesised CA4 7 by formation of a diarylalkyne 51 followed by the 
hydrolysis of the corresponding thermally stable Ti(II)-alkyne complex 52.39  The 
diarylalkyne 51 was synthesised through the coupling of a 3,4,5-
trimethoxyphenylacetylene 36 with 5-iodo-2-methoxyphenol 53 using Pd(OAc)2 and 
triphenylphosphine and heating at reflux in pyrrolidine, following the method developed 
by Nwokogu (Scheme 11).40  Generation of the thermally stable Ti(II)-alkyne complex 
52 from diarylalkyne 51 using nBuLi and Ti(OiPr)4 results in the two aryl rings formed 
in the a cis configuration.  Subsequent hydrolysis of the Ti(II)-alkyne complex yields the 
stilbene CA4 7 with the desired Z-geometry in good yields and high purity. 
 
Scheme 11: Synthesis of CA4 7 through the hydrolysis of a Ti(II)-alkyne complex 52. 
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Hua and co-workers undertook studies in the semi-hydrogenation of internal alkynes to 
Z-alkenes.41  DMF/KOH was shown to be an efficient hydrogen source in the Pd(OAc)2 
catalysed transfer semi-hydrogenation of various functionalised alkynes to Z-alkenes in 
high yields and excellent chemo- and stereoselectivity.  They also applied these 
conditions towards the synthesis of a CA4 analogue 54. 
 
 
Scheme 12: Synthesis of CA4 analogue 55 by semi-hydrogenation with DMF/KOH. 
 
A further example of the synthesis of CA4 7 from the diarylalkyne 51 is the reduction via 
the platinum-catalysed hydrosilylation of the alkyne 55 with a silicon hydride reagent 
followed by a fluoride-mediated deprotection (Scheme 13).42 
 
 
Scheme 13: Synthesis of CA4 7 through a hydrosilylation/protodesilylation sequence. 
 
1.5.4. Synthesis of prodrugs CA1P and CA4P 
 
Having a range of methods to syntheses CA1 8 and CA4 7, the combretastatins need to 
be converted into their corresponding prodrugs as this will improve the water solubility 
and bioavailability.  The synthesis of phosphate pro-drug CA1P 9 from CA1 8 can be 
achieved via a dibenzylphosphate intermediate 56 (Scheme 14).  Treatment of CA1 8 
with dibenzyl phosphite in the presence of carbon tetrachloride, DMAP and DIPEA 
afforded tetrabenzylphosphate 56 in excellent yields.  Debenzylation of the 
benzylphosphate 56 using TMSCl resulted in a tetra-TMS-phosphate ester followed by 





Scheme 14: Synthesis of prodrug CA1P 9. 
 
An alternate strategy for the synthesis to the prodrug CA4P 10 based on the Wittig 
reaction was developed by Bedford et. al.43  3-Hydroxy-4-methoxybenzaldehyde was 
converted to the phosphate triester 57 before coupling with 3,4,5-trimethoxybenzyl 
triphenylphosphonium bromide 21 via the Wittig reaction (Scheme 15).  The two CA4 
phosphate bis-t-butyl ester isomers 58 and 59 were formed in an E:Z ratio of  1:4.  After 
separation the Z-isomer was converted into the potassium salt of CA4.   
 
 
Scheme 15: Synthesis of potassium salt of CA4 via the Wittig reaction. 
 
1.6. Combretastatin A1P metabolism 
 
Metabolic studies on pro-drug CA1P 9 revealed up to 14 metabolites being observed in 
the blood plasma.44  Some of the CA1P 9 metabolites reported include monophosphates, 
monoglucuronides, bisglucuronides as well as the active drug CA1 8 (Figure 9).  It is 
believed that partial enzymatic dephosphorylation of CA1 8 could lead to the two 
monophosphate isomers CA1MPA 60 and CA1MPB 61.45  Glucuronidation, the addition 
of glucuronic acid to a substrate by enzymatic conjugation, is a mechanism to convert 
exogenous compounds into more water-soluble metabolites for excretion and could lead 
to the two monoglucuronide isomers CA1G1 62 and CA1G2 63.46  In order for further 
biological evaluation in support of the ongoing human clinical development of CA1P 9, 
Pinney and co-workers were able to prepare regioisomeric monophosphate and 
monoglucuronide isomers of CA1 8.45,46  All isomers were synthesised using the Wittig 
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reaction and the two vicinal phenols were distinguished by using different protecting 
groups.  Biological evaluation however, showed the monophosphate derivatives to be 
inactive as inhibitors of tubulin assembly (IC50 > 40 M).  The two monoglucuronide 
isomers also showed low cytotoxicity compared to CA1P 9 against selected human cancer 
cell lines, with CA1G1 62 being slightly more potent than CA1G2 63.  
 
 
Figure 9: CA1P 9 metabolites. 
 
It is widely thought that the increased anti-tumour activity of CA1 8 compared with CA4 
7 is due to the formation of ortho-quinone intermediates.44  Quinones are known to be 
highly reactive intermediates that cause a number of damaging effects in vivo through 
different mechanisms.47  Quinones act as Michael acceptors and can cause cellular 
damage through alkylation of essential proteins, DNA, and other biological nucleophiles.  
They are also highly redox active and can undergo a redox cycle with their semiquinone 
radicals to form reactive oxygen species including superoxide, hydrogen peroxide and the 
hydroxyl radical which can lead to oxidative stress within cells.   
 
Folkes and co-workers investigated the oxidative metabolism of CA1 8 and the potential 
for the resulting quinone intermediates to bind to nucleophiles and enhance oxidative 
stress via free radicals (Scheme 16).48  CA1 8 was oxidised to the ortho-quinone 64 by 
treatment with iron (III) chloride and sulfuric acid in ethanol.  The reaction was quenched 
after one minute to prevent over-oxidation.  A 50:50 mixture of the ortho-quinone 64 and 
unreacted CA1 8 was obtained and its presence was confirmed by LC-MS and UV-vis 
absorbance.  The ortho-quinone 64 was observed to be unstable in aqueous solution and 
is believed to result in electrocyclic ring closing to form a second ortho-quinone species 
65.  However in a solution of acetonitrile the ortho-quinone 64 was said to be stable for 
24 hours.  The first ortho-quinone 64 was also observed by oxidation of CA1 8 with 
H2O2/horseradish peroxidase compound I, lactoperoxidase, tyrosinase and human pro-
myelocytic leukaemia cells (HL-60).  This shows the potential for oxidation of CA1 8 to 
ortho-quinone 64 in vivo.  Leaving the reaction of CA1 8 and iron (III) chloride and 
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sulfuric acid for a longer period gave a second ortho-quinone species 65; this species was 
found to be more stable as it was isolated in a pure form after flash column 
chromatography on silica.  Formation of the second ring-closed ortho-quinone was not 
observed without the prior formation of the initial ortho-quinone. The ortho-quinones 64 
and 65 were treated with glutathione, an antioxidant.  The first ortho-quinone 64 formed 
a quinone-glutathione adduct 66, the regioselectivity of which was not confirmed but it 
is believed that the glutathione adds to the most electropositive site on the B ring.  In 
contrast when the second ortho-quinone 65 was treated with glutathione, reduction 
occurred resulting in a hydroquinone 67 being formed.   
 
 
Scheme 16: Synthesis of the ortho-quinones 64 and 65 from CA1 8 their reaction and with the 
antioxidant glutathione. 
 
CA1P 9 was injected into mice with subcutaneous dorsal CaNT tumours, and after two 
hours blood and tissue were removed and analysed by HPLC.  They found HPLC 
retention characteristics and MS fragmentation patterns identical to the quinone-
glutathione adduct 66 as well as free CA1 8.  It is thought that glutathione-S-tranferases 
catalyses this transformation in vivo.  Folkes and co-workers showed that CA1 8 is more 
susceptible to oxidative metabolism which results in the formation of free radicals.  These 
free radicals can stimulate oxidative stress by increasing superoxide and hydrogen 
peroxide formation.  This shows that CA4P 10 and CA1P 9 have different 
pharmacological properties and gives a suggestion as to why CA1P 9 has a larger 




Pettit and co-workers were also able to confirm the presence of ortho-quinone 
intermediates by trapping them as stable phenazine derivatives (Scheme 17).49  Treatment 
of CA1 8 with sodium periodate and tetrabutylammonium bromide in dichloromethane 
for ten minutes, was followed by extraction and removal of solvent which revealed the 
ortho-quinone 64.  However, the blue ortho-quinone rapidly turned black due to 
decomposition after just 5-10 minutes.  They, therefore, trapped the ortho-quinone as a 
pyrazine 68 and dimethoxyphenylenediamine-derived phenazine derivative 69.  Pettit 
commented on the remarkable instability of the ortho-quinone intermediate 64 and 
suggested it can be attributed to the extended -system. 
 
 
Scheme 17: Synthesis of the ortho-quinone metabolite 64 of CA1 8 and its trapping as phenazine 
derivatives. 
 
Aprile and co-workers investigated the in vivo metabolic fate of CA1 8 through LC-UV 
and LC-MS analysis (Scheme 18).50  They also managed to prepare the first ortho-
quinone 64, by the treatment of CA1 8 with a polymer supported oxidant, 
(polystyrylmethyl)-trimethylammonium metaperiodate, in dichloromethane at room 
temperature.  The ortho-quinone 64 was isolated following removal of solvent and its 
identity confirmed by LC-DAD-UV, LC-ESI-MS and 1H NMR spectroscopy.  Like 
Folkes and co-workers, they also investigated the reaction of the ortho-quinone with the 
thiol-containing nucleophile glutathione. However, in contrast to the studies by Folkes, 





Scheme 18: Two quinone-glutathione adducts 68 and 70 from reacting ortho-quinone 64 with 
glutathione. 
 
Aprile and co-workers went on to analyse the metabolites of CA1 8 found in CA1-treated 
rat urine by LC-ESI-MS/MS (Figure 10).  Based on these observations, they proposed the 
structure of metabolic compounds which had undergone a number of phase I and phase 
II metabolic pathways.  These include aromatic hydroxylation, O-demethylation, 
glucuronidation, sulfation and glutathionylation of the ortho-quinone.  The cytotoxicity 
of the ortho-quinone species was investigated in a neuroblastoma cancer cell line and 
compared to CA1 8, and found to have comparable IC50 values (3.5 and 3.3 nM vs. 1.3 
nM).50  Further investigations into whether this cytotoxicity was due to the inhibition of 
tubulin polymerisation were undertaken and it was found that the second ortho-quinone 
65 retained the ability of inhibiting tubulin polymerisation but the first ortho-quinone 64 
did not, even at high concentrations.  This was thought to be due to the unstable nature of 
the first ortho-quinone 64, but this contrasts with the observation of cytotoxicity which 
requires the compound to act over a number of hours.  This suggests that the cytotoxic 
activity of ortho-quinone 64 is caused by something other than tubulin polymerisation 





Figure 10: Proposed in vivo metabolic pathway of CA1 8 determined by LC-ESI-MS/MS analysis of 
CA1 8 treated rat urine. 
 
To support the free radical mechanism for the enhanced antitumour activity observed by 
CA1 8 compared to CA4 7, Rice and co-workers investigated tumour necrosis in KHT 
sarcoma-bearing mice treated with CA4P 10 and the E- isomer of CA1P.51  The E-isomer 
should lack the antitubulinic activity as it is well reported that the Z-configuration of the 
stilbene backbone is essential in binding to tubulin, but as the E-isomer still contains a 
1,2-diol that can be oxidised to an ortho-quinone and induce some cytotoxic activity.  
Their work showed that tumour necrosis of mice treated with both CA4P 10 and E-CA1P 
was greater than with treatment of CA4P 10 alone.  These results suggest that the primary 
source of the antitumour effect of CA1 8 is its tubulin binding capacity but the generation 





1.7. Molecular imaging 
 
Molecular imaging is a way to non-invasively visualise, characterise and quantify 
molecular processes or pathways in vivo at a cellular and sub-cellular level.  There are a 
variety of methods used in molecular imaging including: positron emission tomography 
(PET), single photon emission computed tomography (SPECT), optical imaging, Raman 
spectroscopy and magnetic resonance imaging (MRI).   
 
The development of MRI, which evolved from nuclear magnetic resonance (NMR), is 
one of the major advances in biomedical imaging in the last 30 years.  MRI is now 
considered critical in the workup (diagnosis, monitoring etc.) of patients with a wide 
range of diseases and disorders.  While MRI provides morphometric information about 
the organs and diseases studied, magnetic resonance spectroscopy (MRS) is used to study 
metabolites in the tissue.  Magnetic resonance spectroscopy imaging (MRSI) offers 
metabolic data which is processed and displayed as density maps of several metabolites.  
MRS provides insight into the biochemistry and function of the tissue and has been 
commonly used for clinical scans of the brain and prostate gland.52,53  Unlike traditional 
MRI which detects changes in the density of bulk water, MRS detects multiple small, 
endogenous metabolites within cells or extracellular spaces associated with several 
metabolic pathways.   
 
Clinical use of MRI is currently restricted to studying the 1H nucleus under normal 
thermal equilibrium conditions.  This is because the 1H nucleus has a high natural 
abundance, resulting in high concentrations in the body.  Other nuclei that are also found 
in relevant metabolites within the body that have MR-active isotopes include 13C, 18O, 
14N and 31P; however, these are difficult to observe at thermodynamic equilibrium.  This 
is due to their low natural abundance and/or low gyromagnetic ratios.  These metabolites 
are present in concentrations ~10, 000 times lower than that of tissue water protons, and 
it is not possible to image them at clinical magnetic field strengths.  Despite these 
limitations, a small number of non-1H nuclei have been studied in human using MRS; 31P 
has been used to study high energy metabolites and lipid metabolism,54–57 and 23Na has 










1 1H 1/2 99.98 1 Total body MRI/MRSI 
2 13C 1/2 1.11 0.2515 Metabolic tracer injection 
using MRSI 
3 15N 1/2 0.37 0.1013 Metabolic tracer injection 
using MRSI 
4 17O 5/2 0.04 0.1355 Oxidative metabolism using 
MRSI 
5 23Na 3/2 100 0.2645 Neurodegeneration and 
cardiac imaging using MRSI 
6 31P 1/2 100 0.4048 Bioenergetics and pH using 
MRSI 
Table 2: Biomedical applications of NMR active nuclei under thermal equilibrium. 
 
The use of biomarkers or molecular probes with MR techniques allows information to be 
gained not only on the tissue morphology but also the tissue biochemistry.  However, a 
major limitation of MRS is low sensitivity; this has been overcome by a technique called 
hyperpolarisation, where the spin polarisation of a nucleus is enhanced beyond that seen 
at thermodynamic equilibrium. 13C – MRS has long been used in the investigation of 
static metabolic processes in vivo and recently, with the arrival of hyperpolarisation 
techniques, 13C – MRS/MRSI can now measure the dynamics of metabolic conversions 
in vivo. These hyperpolarisation techniques can increase sensitivity up to 10,000-fold 
allowing for detection of 13C-labelled compounds and their downstream metabolic 
products in real-time in vivo. 
 
1.8. Enhancing MR signal by hyperpolarisation 
 
The signal-to-noise ratio is a measure of sensitivity and is proportional to the 
gyromagnetic ratio  of the nucleus under study, concentration c of nuclear spins, and the 
polarisation P.  The gyromagnetic ratio is an inherent property of the nucleus and is the 
ratio of the nucleus’ magnetic dipole moment to its angular momentum. The basis of any 
magnetic resonance technique is the interaction between the magnetic field in the MR 
machine and the nuclei spins of molecules in the body.  When placed in a magnetic field, 
the spins align themselves with the magnetic field, as such they can either lie in the same 
direction as the magnetic field or opposed to it.  The population of these spins in the two 
possible states is not equal and is referred to as the polarisation.  For a spin ½ nucleus, 
such as 1H or 13C, the population (or polarisation) of the two allowed energy levels is 
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given by the Boltzmann distribution.  In normal clinical magnetic field strengths and 
temperature, this population difference is very small, but there are slightly more nuclei 
the  spin state (Figure 11a).  This difference (albeit very small) is what allows a signal 
to be detected.  
 
 
Figure 11: Pictorial representation of hyperpolarisation: an increase in the population difference between 
the and spin states. 
 
The population difference is dependent on many factors, including the strength of the 
magnetic field, temperature, the abundance of the NMR-active nucleus and the 
gyromagnetic ratio of the nucleus under study (Equation 1).  Different nuclei will have 
different sensitivities due to their different gyromagnetic ratios; for 1H,  = 26.75 107 rad 
T-1 s-1 and for 13C,  = 6.72 107 rad T-1 s-1.  So the 1H nuclei will have higher polarisation 
at thermal equilibrium than 13C nuclei.  The abundance of nuclei in a sample also affects 
the sensitivity; 1H has a natural abundance of 99.9%, whereas the natural abundance of 
13C is only 1.1% with the remainder being the NMR-inactive 12C.  This means only a 
small percentage of 13C nuclei can become polarised by the external magnetic field B0 
and are therefore available to produce an NMR signal or image.  For these reasons, 
clinical in vivo imaging techniques are usually limited to the 1H nucleus.  To improve the 
sensitivity (or polarisation), the population difference between the lower and upper 





























Equation 1: a) Definition of polarisation P (where N is the population of the  spin state, N is 
population of the  spin state) and b) definition of the thermal polarisation Pth (where tanh refers to the 
hyperbolic tangents, B0 is the external magnetic field strength,  is the gyromagnetic ratio, T is 
temperature, ħ is Planks constant, kB is Boltzmann’s constant). 
 
Hyperpolarisation methods are used to increase the sensitivity of magnetic resonance 
techniques and can result in signals being increased by more than a factor of 105 compared 
to thermal equilibrium.58  Hyperpolarisation is the general term for a method that 
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enhances the spin polarisation difference of populations of nuclei in a magnetic field 
(Figure 11b).  It involves transferring the polarisation from a highly polarised species to 
the spin of a nucleus in the molecule of interest.  This will create an artificial non-
equilibrium distribution of nuclei spins and result in increased polarisation and, therefore, 
sensitivity. 
 
1.9. Applications of hyperpolarised MR 
 
Hyperpolarisation techniques have been utilised in solid-state research for a number of 
years but recently due to the advances in the dissolution methods, injectable 
hyperpolarised solutions can be generated which are suitable for in vitro and in vivo 
studies. The signal enhancement caused by hyperpolarisation allows less sensitive nuclei 
such as 13C to be studied using magnetic resonance imaging (MRI), allowing molecules 
to be observed in vivo that were previously inaccessible.   
 
The hyperpolarisation of 13C-labelled cell metabolites allows them to be imaged in vivo 
and more importantly their metabolic conversion can be measured in real-time.  Therefore, 
the visualisation of metabolism through enzymatic conversions can be achieved non-
invasively.  Most major diseases are linked to metabolic alterations, so by being able to 
visualise the flux of metabolic pathways enables a greater understanding of these diseases. 
It also provides essential information on the biodistribution, uptake and local environment 
of specific metabolites.  Hyperpolarised MR works well for studying processes that are 
fast, short-lived and dynamic since their study is difficult under thermal equilibrium 
conditions.   
 
The most well studied hyperpolarised metabolite is [1 – 13C]pyruvate, as it lies on an 
intersection of important metabolic pathways.  By hyperpolarising [1 – 13C]pyruvate, its 
conversion to [1 – 13C]lactate, [1 – 13C]alanine, and [13C]bicarbonate can be monitored 
(Figure 12).  The ratio of the converted metabolites will vary depending on the status of 
the cell, for instance tumours rely more heavily on the pyruvate-to-lactate pathway than 
normal cells which rely more on the pyruvate-to-alanine pathway.  Therefore 
hyperpolarised [1 – 13C]pyruvate can be used a diagnostic tool or to monitor the change 
in tumour metabolism after treatment with anti-tumour agents.  [1 – 13C]pyruvate is not 
the only metabolite that is studied, others include the isomers [2 – 13C]pyruvate and [1,2 
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– 13C2]pyruvate,  [1 – 
13C]lactate, [1 – 13C]alanine, [1,4-13C2]fumarate, [5 – 
13C]glutamine, 
[1 – 13C]urea and [2 – 13C]fructose.59 
 
 
Figure 12: Metabolic pathway of [1 - 13C]-pyruvate where LDH = lactate dehydrogenase, ALT 
aminotransferase = and CA = carbonic anhydrase. 
 
MR experiments with hyperpolarised [1 – 13C]pyruvate can show whether the tumour is 
responding to treatment by showing there is a metabolic change in the tumour.  However 
it does not show whether the treatment has destroyed any tumour cells.  For instance a 
decrease in [1 – 13C]-lactate can indicate a loss of cells within the tumour but could also 
be the result of metabolic change caused by a decrease in LDH activity or change in 
substrate concentration.  A method that directly detects cell death is highly sort after since 
cell death after treatment is a good prognostic indicator to treatment.  The formation of 
[1,4 – 13C2]malate from [1,4 – 
13C2]fumarate has been shown to be a sensitive marker of 
tumour cell death in vivo.60  Fumarate is an intracellular metabolite, and there is no 
detectable update of hyperpolarised [1,4 – 13C2]fumarate when administered extracellular 
in viable cells.  However in dying cells the plasma membrane permeability barrier has 
been damaged allowing for the uptake of [1,4 – 13C]fumarate into the cell and subsequent 
hydration to [1,4 – 13C]malate.  Therefore the detection of [1,4 – 13C]malate indicates cell 
necrosis.  
 
The microenvironment of tumours have a huge influence on the tumour aggressiveness, 
treatment response and metastatic spread.  Most tumours are associated with an acidic 
extracellular pH compared with normal tissue, so monitoring the extracellular pH can 
provide information on prognosis and response to treatment.  The extracellular pH of 
tumour can be imaged using the ratio of the signal intensities of hyperpolarised H13CO3
- 
and hyperpolarised 13CO2 using the Henderson-Hasselbalch equation (Equation 2).
61  
Hyperpolarised H13CO3
- can also be used as a generic biomarker for detecting the 
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presence of disease since the majority of pathological states (such as tumours, ischaemia, 
infection, hypoxia, and inflammation) are accompanied by low extracellular tissue pH or 
changes in the acid-base balance in the tissue. 
 
pH = pKa + log([H
13CO3
-]/[13CO2]) 
Equation 2: The Henderson-Hasselbalch equation. 
 
 
The use of hyperpolarised [1 – 13C]pyruvate in a clinical setting has been achieved in 
2010 with a clinical trial looking to detect tumour response to treatment of prostate 
cancer.62  The initial results from this trial confirmed the safety of [1 – 13C]pyruvate and 
also saw elevated [1 – 13C]lactate/[1 – 13C]pyruvate ratio in the tumours. Subsequent trials 
will guide the way for [1 – 13C]pyruvate to be used as a non-invasive cancer diagnostic 
and for the monitoring of cancer treatments.  
 
1.10. Hyperpolarisation – Imaging considerations and techniques 
 
Hyperpolarised magnetisation is in non-equilibrium and therefore is not renewable.  The 
polarisation decays to thermal equilibrium at rate T1.  So after each excited pulse, 
longitudinal magnetisation will recover to the thermal equilibrium value, not the 
hyperpolarised value.  Therefore the main disadvantage of hyperpolarisation techniques 
is that the polarisation is relatively short-lived, typically 10 – 30 s for hyperpolarised 13C-
compounds in vivo.  For all hyperpolarisation techniques that will be used in vivo the 
polarised compound has to be brought rapidly to body temperature and field strength, 
then injected, absorbed and distributed into the biological system without significant loss 
in polarisation.  This restricts the time window for clinical imaging diagnostic imaging to 
2 or 3 times the T1 relaxation time, therefore having a long T1 relaxation time is essential 
in order for the lifetime of the polarisation to be sufficiently long to be detected in 
subsequent imaging experiments.  In order to gain any information on metabolism, the 
hyperpolarised 13C-labelled substrate must also be metabolised quickly.  There are four 
main hyperpolarisation techniques; brute force, optical pumping, parahydrogen induced 






1.10.1. Brute force 
The thermal equilibrium polarisation, P, of a nuclei increases with increasing magnetic 
strength B0, and decreasing temperature T (Equation 3). Therefore hyperpolarisation can 
occur simply through “brute force” by subjecting the sample to a very high magnetic field 
and very low temperatures.  For example, if a sample is cooled to 4 K (using liquid helium) 
with a field strength of 20 T, the polarisation can be increased by a factor of 1000.58  
However, in order to obtain polarisation levels high enough to see a significantly 
increased signal in vivo, impractically low temperatures in the mK range is required and 
very high magnetic fields.  These conditions require very high costs therefore the brute 




















Equation 3: Definition of the thermal polarisation Pth where tanh refers to the hyperbolic tangens, B0 is 
the external magnetic field strength,  is the gyromagnetic ratio for nucleus, ħ is Planck’s constant over 
2, kB is the Boltzmann constant and T is the temperature. 
 
1.10.2. Optical pumping 
Another technique for hyperpolarisation is optical pumping and is used to hyperpolarise 
noble gases usually 3He or 129Xe.  Optical pumping allows the polarisation to be increased 
considerably, typically ~ 10% for 129Xe and ~ 50% for 3He.63  There are two methods 
used; spin-exchange optical pumping (SEOP) and metastable-exchange optical pumping 
(MEOP).  The most common method, SEOP, uses circularly polarised light to polarise 
the valence electron of a vapourised alkali metal.  The polarisation generated is then 
transferred to the nuclear spin of a noble gas by collision of the gas molecule with the 
alkali metal.  Rubidium is commonly used as it has only one valence electron, is in high 
abundance, and is readily vaporised.  In contrast to SEOP, MEOP does not require an 
alkali metal intermediate and the noble gas is polarised directly by a metastable noble gas 
state.  Despite being quicker than SEOP, MEOP is less efficient method for 
hyperpolarising noble gases.  Optical pumping is frequently used to hyperpolarise 3He or 
129Xe for medical imaging of the lung when used with 3He MRI.  129Xe has the advantage 
of being soluble in blood so hyperpolarised 129Xe can be used to image the circulatory 
system and organs.  The T1 relaxation times of noble gases are relatively long compared 
to other nuclei so will have longer polarisation lifetimes resulting molecules being 
34 
 
polarised for very long periods.  This technique however is only applicable to noble gases 
so has limited applications 
 
1.10.3. Parahydrogen-induced polarisation 
Parahydrogen-induced polarisation (PHIP) is a hyperpolarisation technique that is 
achieved via a chemical reaction using parahydrogen.64  Molecular hydrogen can exist in 
two possible states; orthohydrogen where the two proton spins are aligned parallel 
forming three triplet states or parahydrogen where the two spins are aligned anti-parallel 
which forms a singlet state.  At room temperature the ratio of ortho-H2: para-H2 is 3:1.  
Parahydrogen can be prepared by mixing hydrogen gas with a highly inhomogeneous, 
locally paramagnetic species (e.g. metal oxides or activated carbon) at a temperature of 4 
K, this results in 99.9% parahydrogen.65,66  This nuclear ordering or polarisation is 
achieved at much higher temperatures than by using the brute force method thus making 
parahydrogen an ideal source of spin order for hyperpolarisation experiments.  Once 
parahydrogen is produced, it is inserted into a carbon-carbon double or triple bond of an 
asymmetrical precursor molecule through catalytic hydrogenation (Figure 13).66  Once 
the C=C double bond is saturated with parahydrogen, its inherent spin order is transferred 
to a vicinal heteronucleus, typically a 13C nucleus via asymmetric coupling.  A 13C 
labelled carbonyl group is common among substrates studied using PHIP because it has 
a relatively long T1 relaxation time and helps with coordination with the hydrogenation 
catalyst.  Typically a -unsaturated carbonyl substrate is used as the PHIP- precursor.  
Parahydrogen-induced polarisation yields signal-to-noise enhancements of up to 105.   
 
 
Figure 13: Catalytic hydrogenation of a double bond in a precursor molecule using parahydrogen. 
 
 
A limitation on this technique is the availability of a corresponding unsaturated 
asymmetric precursor of the substrate of interest, thus can only be used on a limited class 
of molecules.  Another issue that limits the substrate scope is precursors that undergo 
keto-enol tautomerism where the more stable equilibrium form of the precursor is the 
keto form which cannot be hydrogenated (Figure 14a).65  These series of compounds 
cannot be used unless the enol tautomer is stabilised.  An ester is commonly used to 
stabilise the enol form, as the ester can be hydrogenated with parahydrogen then undergo 
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saponification with sodium hydroxide to produce a carboxylic acid and the desired 
polarised molecule (Figure 14).   
 
 
Figure 14: a) Keto-enol tautomerism b) Stabilisation of enol tautomer through formation of an ester, 
followed by para-hydrogenation and ester hydrolysis. 
 
1.10.4. Dynamic nuclear polarisation 
The final hyperpolarisation technique is dynamic nuclear polarisation (DNP) and has 
emerged as the frontrunner for hyperpolarisation techniques due to high polarisation, 
large substrate range and wide range of biomedical applications.  DNP involves the high 
spin polarisation of free electrons being transferred to a nuclear spin by microwave 
irradiation.  This enhances the differences between the nuclear energy levels resulting in 
a dramatically enhanced MR signal by up to 105.  Dynamic nuclear polarisation was first 
predicted by Overhauser in 1953,67 and was later observed experimentally in metals by 
Slichter.  Over the years DNP has played an important role in producing solid targets for 
high-energy physics research, structural biology determination,68 and accessing in vivo 
metabolism.69,70 The latter process is possible due to the key development from Golman 
and co-workers where they showed the polarised nuclear spins can be warmed rapidly to 
room temperature with substantial retention of the polarisation that was present in the 
frozen solid state therefore producing a hyperpolarised liquid-state.71  This is achieved by 
rapidly dissolving the frozen sample in pressurised superheated water ~ 180 °C.  Electrons 
are inherently highly polarised (>90%) due to their large gyromagnetic ratio.  
 
1.11. Dissolution-DNP experiment 
 
DNP works by transferring the polarisation of an electron to the nuclei of interest using 
microwave irradiation at low temperature and high magnetic field.  This is achieved using 
specialised equipment, a DNP polariser.  During a dissolution-DNP experiment there are 




1. Sample preparation: The DNP sample consists of the substrate to be 
hyperpolarised enriched with a MR-active nucleus (e.g. 13C), a source of unpaired 
electron and a solvent.  For some substrates a glassing agent, such as glycerol, is 
used and/or Gd-chelates added to enhance polarisation. Organic free radicals are 
usually the source of unpaired electron used in DNP experiments.  The electron 
resonance needs to have a linewidth of the same order or lower than the nuclear 
Larmor frequency, therefore a trityl radical e.g. OX063 is commonly used as the 
free electron source when polarising protons.  However when using a trityl radical 
and 13C, thermal mixing is often the source of polarisation due to the electron 
resonance being wider than the 13C Larmor frequency.  Therefore nitroxide 
radicals such as TEMPO, BDPA, DPPH or galvinoxyl are often used.  The solvent 
used in DNP experiments is chosen to maximise the concentration of the 13C 
substrate in the sample to enhance 13C-13C spin diffusion during polarisation and 
allowing a more concentrated solution after dissolution.  To ensure the 
homogeneous distribution of the radical, the sample must form an amorphous 
solid or become “glassy” upon freezing.  To achieve this, a co-solvent such as 
DMSO or glycerol can be added to the aqueous sample.  It has been showed that 
the addition of Gd3+-chelates can increase the polarisation of a sample.72  In a 
recent study, the gadolinium complex 10-(2-hydroxy-propyl)-1,4,7,10-
tetraazacyclododecane-1-4-7-triacetic acid (gadoteridol) was added to sample of 
[1 – 13C]pyruvate with different radicals; OX063, 4-oxo TEMPO and BDPA. 
They showed a 300% increase in solid state polarisation with pyruvate and OX063 
when adding Gd3+-chelate.  This increase has been attributed to the shortening of 
the electronic spin-lattice relaxation time T1e.  However since the Gd-chelates are 
paramagnetic, they may also shorten the T1 of the 
13C nucleus in the molecule of 
interest, thus reducing the observable window available.  
 
2. Hyperpolarisation: The sample cup is inserted in the polariser and rapidly frozen 
to ~1.2 K (which is achieved by boiling off helium under vacuum at ~100 Pa) and 
is placed in a magnetic field.  The electron spin polarisation can then be transferred 
to the nuclear spins by microwave irradiation at or close to the Larmor frequency, 





3. Dissolution: The dissolution process involves transferring the solid 
hyperpolarised sample from the polariser to in vitro or in vivo models in either a 
MRI or NMR machine whilst retaining the polarisation.71  It first needs to be 
rapidly warmed to room temperature which is achieved by rapidly dissolving the 
frozen sample in pressurised superheated water (180 °C).  Several solvents can be 
employed for dissolution but for biological applications an aqueous buffer is used.  
A chelating agent (typically ethylene-dinitrotetraacetic acid, or ETDA) is often 
used to bind paramagnetic ions that might increase the relaxation rate. The 
solution is then ready for in vitro or in vivo applications, which usually performed 
with 1-2 minutes following dissolution to minimise T1-dependent loss of signal.  
 
1.12. Hyperpolarisation substrates 
 
There are a number of different techniques used to induce hyperpolarisation, but the 
hyperpolarisation of substrates for in vivo studies has been dominated by a technique 
called dynamic nuclear polarisation (DNP).  In principle any nucleus can be polarised, 
although attention has largely been focussed on 13C.  This is due to its relatively long T1 
times and commercial availability of 13C-labelled cell metabolites.  In 1H-MRS the 
chemical shift range of metabolites of interest is limited (≈0 ppm), which results in 
crowded spectra resulting in difficult deconvolution of the data.  Also, a large number of 
water and lipid protons relative to the metabolites can overwhelm the spectrum.  However, 
the chemical shift range of 13C metabolites is much larger than 1H ( ≈ 200 ppm), which 
allows for improved resolution of metabolites that would otherwise not be resolved.  Also, 
because the natural abundance of 13C in the body is very low, the background noise 
created by these nuclei is kept to a minimum since non-enriched metabolites are not 
generally observable in biological applications.  The 13C nucleus has a gyromagnetic ratio 
that is 25% that of 1H and its natural abundance is much lower at 1.1%, making it very 
insensitive, so the MR imaging of endogenous 13C compounds is not possible within 
reasonable imaging times.  However, using hyperpolarised 13C-enriched metabolites, the 
sensitivity can be increase dramatically.  Despite the fact that the vast majority of 
hyperpolarised experiments (certainly for biological applications) use the 13C nucleus 









1 1H 99.98 1 H2O 
2 13C 1.11 0.2515 Pyruvate, fructose, urea 
3 15N 0.37 0.1013 Choline73 
4 29Si 4.70 0.1987 Nanoparticles74 
5 89Y 100 0.1761 DOTA chelates75 
Table 3: Nuclei and example substrates that have been hyperpolarised using dissolution-DNP. 
 
1.12.1. 13C DNP probe development 
 
At present hyperpolarised 13C agents can be divided into three categories according to 
their uses: 
1. Endogenous molecules modified by 13C enrichment:  These molecules are often key 
biochemicals in metabolic pathways.  Not only can these metabolites be imaged but 
their metabolic products can also be detected in real-time.  This provides 
information that will help better understand and treat metabolic diseases such as 
cancer and diabetes e.g. [1 – 13C]pyruvate or [1 – 13C]lactate 
2. Environmental sensors: These agents can be endogenous or non-endogenous and 
are used to detect chemical environment e.g. H13CO3
- used to detect pH.  
3. Molecules to advance and understand DNP-NMR techniques and technology e.g. 
[2,3 – 13C2] diacetyl is used to study spin polarisation in the singlet state. 
 
There are many considerations for developing 13C DNP substrates used for in vitro and 
in vivo studies.  They are generally small molecules (<200 Da) and contain a 13C nucleus 
with a long T1 time.  In hyperpolarisation studies the T1 relaxation time determines how 
long the hyperpolarisation lasts, and therefore the length of useful imaging time.  After 
dissolution, ~37% of the hyperpolarised MR signal remains after 1 × T1 and ~ 5% after 3 
× T1.  Therefore, the imaging window after dissolution is usually only 3 – 5 × T1.  For this 
reason, the placement of the 13C nucleus in a DNP probe usually means that it does not 
have a neighbouring spin ½ nucleus, for example, carboxylate carbons.  Therefore, 13C 
nuclei attached directly to protons are not feasible candidates for DNP probes due to 
having small T1 times, however, this can be overcome by substitution of 
1H with 2H.  The 
majority of 13C DNP substrates usually contain carbonyl groups: carboxylic acids, 
ketones, amides and esters have all been studied.  Of these, carboxylic acids are most 
popular due to their abundance in endogenous metabolites, water solubility, longer T1 
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times, relative ease of 13C-enrichment and because they are often the active functional 
group in metabolic conversion.  Non-carbonyl substrates can also be used in DNP studies, 
providing they have a sufficient T1 time.  
 
The placement of a 13C in a carboxyl or carbonyl group, which removes the 13C-1H 
intramolecular dipolar relaxation, is not always possible, especially for aliphatic 
compounds.  However, the polarisation lifetime can still be increased by deuterium 
enrichment but the 2H enrichment needs to occur at non-exchangeable sites.  Deuterium 
is a quadrupole nucleus with a spin of 1 therefore it exhibits scalar coupling (J-coupling) 
with other spin ½ nuclei e.g. 13C nuclei where J(13C-2H) ~ 30 Hz.  Using 
13C probes with 
deuterium enrichment has been used on multiple occasions and has been shown to 
dramatically increase T1 times (Table 4).  The size of the effect is proportional to the 
strength of the 1H coupling (with 13C) of the replaced nucleus, the stronger the coupling, 
the greater the effect.  However, 2H substitution also leads to splitting which can decrease 
the overall SNR when moving to field strengths where J is large relative to .  2H 
Substitution can also have an impact on the metabolism in biological systems, due to 
kinetic isotope effects and may impact the ability to observe certain deuterated 13C 
metabolites in DNP-NMR by slowing down the rate of metabolic conversion.   
 
Entry Probe Non 
deuterated T1 
time 
Deuterated T1 time 
1 [2 – 13C, U – 2H] fructose 16 s (@11.7 
T) 
34 s (@11.7 T) 
2 [U – 13C, U – 2H] glucose - T1 reported are 
13C1-5 ~ 12 s 
and 13C6 ~10 s. 
3 [5 – 13C, 4 – 2H2] glutamine - Results in ~ two-fold 
increase in the T1 time for 
C5. 
Table 4: Comparison of T1 from deuterated and non-deuterated substrates. 
 
Generally DNP probes are small in molecular size (<200 Da). This is due to their ease of 
synthesis, high aqueous solubility and relevance in fast metabolism.  Also the T1 rate 
decreases as a function of the increasing correlation time (c) seen with increasing 
molecular size. The highest reported DNP enhancements are seen with small molecules 
(<200 Da).  13C DNP probes that are to be used in biological systems (in vitro or in vivo) 
are usually limited to those that are water-soluble.  The probe also has to be highly soluble 
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in the solvent as it needs to be polarised at high concentrations in order for effective 
polarisation to occur.  High concentrations are also needed because of the inevitable 
dilution caused by the dissolution process. The high concentration of the hyperpolarised 
DNP agents in in vitro and in vivo experiments means the toxicity of the agents also has 
to be considered. Therefore, the DNP probe is usually an endogenous metabolite, 
chemically similar to one, or chemically inert (e.g. Gd-chelates).  Another limitation of 
the type of probe that can be used in DNP experiments is the synthetic feasibility of 13C 
enrichment of a probe that meets the above requirements and is met at reasonable costs.  
 
1.13. Project aims 
 
The aim of this project is to investigate the ortho-quinone metabolism of CA1P 9 by 
synthesising then hyperpolarising a 13C-labelled combretastatin A1P.  At first, the 
location of the 13C label needs to be determined which can be done by finding the carbon 
atom with the longest T1 time.  Next, a route needs to be developed that incorporates a 
13C label into one of the already established syntheses of combretastatins. 
 
 





Chapter 2: Synthesis of [13C]-Combretastatin 
A1P 
 
2.1. T1 relaxation times of Combretastatin A1P 
 
The synthesis of a hyperpolarised [13C]-labelled CA1P substrate first requires the 
optimum 13C labelling site to be determined.  The site of the 13C nucleus needs to be 
chosen so it induces the largest hyperpolarisation as well as being synthetically viable.  
The T1 value of the 
13C nucleus dictates the length of hyperpolarisation and therefore the 
imaging window (3 – 5 × T1) in which to observe the metabolism of CA1P.  This means 
a long T1 value is crucial.  The T1 relaxation times of the carbon atoms in CA1P 9 were 





















Figure 16: The T1 values for the 13C atoms in  
CA1P 9 (34 mM in D2O). 
Table 5: 13C chemical shifts values of CA1P 9 with 
measured T1 relaxation values for a 34 mM sample 
in D2O. 
 
                                                          






1 133.75 2.7 
2 106.8 0.33 
3 152.09 5.2 
4 135.68 9.0 
5 152.09 5.2 
6 106.8 0.33 
7 125.8 0.46 
8 130.0 0.4 
9 124.06 2.3 
10 125.0 0.42 
11 108.3 0.36 
12 151.9 3.2 
13 143.56 8 
14 134.44 6.4 
15 56.1 1.6 
16 56.0 1.2 
17 60.9 0.8 
18 56.0 1.2 
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The longest relaxation time was found to be the carbon in the 4-position in ring A with a 
value of 9.0 seconds (Figure 15, Table 5, Entry 4).  However C4 is on the opposite side 
of the molecule to where the oxidative changes occur on the phosphorylated ring during 
metabolism, therefore any chemical change that occurs during metabolism would produce 
a small-to-negligible chemical shift change for the signal of the 13C label.  With the 
second highest T1 relaxation time of 8.0 seconds, C13 could be another candidate for 
13C 
labelling.  Not only does it have a high relaxation time T1, it is also located on the 
metabolically active ring, so was chosen as the site for the 13C label (Figure 17). 
 
Figure 17: Target 13C-labelled molecule. 
 
2.2. Synthesis of core aromatic species 
 
The synthesis of [13C]-combretastatin A1P [13C]-71 presented several significant 
challenges, the first of which is the regioselective insertion of the carbon-13 label into an 
aromatic species.  Since there are no suitable commercially available sources of 13C-
labelled aromatic compounds, a route needed to be developed to synthesise a 1,2,3-
trioxybenzene species 72, where a 13C label is installed in the C2  position (Scheme 19). 
 
 
Scheme 19: Retrosynthesis analysis of CA1P 71. 
 
A common route for the synthesis of 1,2,3-trihydroxybenzene 73 comes from the 
decarboxylation of gallic acid either using a copper autoclave or by microbes.76,77  
Pyrogallol 73 can also be synthesised from phenol,78 or the deoxygenation of 
polyhydrobenzenes.79  However these routes all require an aromatic precursor which is 
commonly derived from the enzymatic reactions of glucose.  There are a limited number 
of routes for the synthesis of pyrogallol 73 which involve a non-aromatic simple precursor, 
one of which is to start from 2,2,6,6-tetrahalocyclohexanone 74 that can be treated with 
butyrolactone and potassium hydroxide to give pyrogallol 73 (Scheme 20).80  2,2,6,6-
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Tetrahalocyclohexanone 74 can be synthesised through chlorination of cyclohexanone 75 
which can be synthesised by the double Grignard addition of 1,5-dibromopentane to 
carbon dioxide.  For the 13C-synthesis of the carbon dioxide can be replaced with 
commercially available [13C]-carbon dioxide.   
 
 
Scheme 20: Retrosynthetic analysis of pyrogallol 73 via 2,2,6,6-tetrachlorocyclohexanone 74. 
 
The first synthesis of pyrogallol 73 from an aliphatic source was developed by 
Shipchandler (Scheme 21).81  It was achieved by the condensation of dimethyl 
dimethoxymalonate 76 with dimethyl glutarate 77 followed by aromatisation and 
decarboxylation.  However for this synthesis to be viable the 13C label needs to be in the 
central carbon of the dimethyl dimethoxymalonate 76 which itself is not trivial and would 
add a number of steps to the synthesis. 
 
 
Scheme 21:  Formation of pyrogallol 73 from aliphatic precursors 76 and 77. 
 
Another route involves oxidation of the enol form of 1,3-cyclohexanedione using singlet 
oxygen in the presence of fluoride ions and polymer bound Rose Bengal which was 
developed by Wasserman and Picket (Scheme 22).82  13C-Labelled 1,3-cyclohexanedione 
[13C]-78 can be prepared following the method by Botting and co-workers by the reaction 
of [13C]-methyllithium with glutaric acid monomethyl ester chloride 79 which forms 
ketone [13C]-80 which is then cyclised to [13C]-cyclohexanedione [13C]-78 with 
potassium tert-butoxide.83,84  This route has the advantage of using [13C]-methyl iodide 
as the [13C]-label source which is a liquid, commercially available, and easily converted 
into Grignard reagents or lithiated species.  The proposed route also has strong literature 
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precedence and has only 3 steps, so was chosen as a basis for the synthesis of [13C]-
combretastatin A1 [13C]-71.  
 
 
Scheme 22: Proposed route for the synthesis of [13C]pyrogallol. 
 
The first step of the synthesis involves the insertion of a 13CH3 unit into glutaric acid 
monomethyl ether 80.  The transformation of acid chloride 79 to labelled ketone [13C]-80 
has already been achieved in the literature.85  Boyce and co-workers first converted 
monomethyl ester acid chloride 79 to the mixed anhydride 81 which was then reacted 
with [13C]-methylmagnesium iodide to form [13C]-methyl-5-oxohexanoate [13C]-80 but 
in a low 30% yield (Scheme 23).  Botting then modified the procedure and reacted acid 
chloride 79 directly with a cuprate formed from the reaction of [13C]-methyl iodide, 
lithium metal and copper iodide.83  This gave methyl-5-oxohexanoate [13C]-80 in an 
improved yield of 57%.  At a later date, the same group repeated the reaction on a larger 
scale (294 mmol) under identical reaction conditions with a yield of 43%.84  The drop in 
yield highlights a potential problem when scaling up the reaction under these conditions.  
Finally Yamamoto et. al. treated glutaric acid monomethyl ester chloride 79 with di-[13C]-
methylcadmium which was synthesised from the reaction between cadmium chloride and 
[13C]-methyl magnesium iodide.96  The resulting methyl-5-oxohexanoate [13C]-80 was 
formed in a 72% yield.  Even though this method produced high yields the drawbacks are 
the hygroscopic, pyrophoric and highly toxic nature of dimethylcadmium. 
 
 
Scheme 23: Literature results for the synthesis of methyl-5-oxohexanoate [13C]-80 from glutaric acid 




The work in this project began using non-labelled (12C) material to establish and optimise 
a strategy before using 13C substrates.ii  The glutaric acid monomethyl ester chloride 79 
starting material was prepared by methanolysis of glutaric anhydride 82 and gave 
monomethyl glutarate 83 in quantitative yields and was used without further purification.  
The dropwise addition of thionyl chloride to monomethyl glutarate 83 yielded the acid 
chloride 79 in an 88% yield after isolation through distillation (Scheme 24).86  The acid 
chloride 79 was then freshly distilled before each experiment. 
 
 
Scheme 24: Formation of glutaric acid monomethyl ester chloride 79. 
 
Next, the glutaric acid monomethyl ester chloride 79 was added to the lithium 
dimethylcuprate formed from the treatment of methyl lithium and copper(I) iodide and 
this gave methyl-5-oxohexanoate 84 in a 47% yield, which is comparable to the results 
observed by Botting (Table 6, Entry 1).83,84  The reaction was optimised by using 
commercially available methyl magnesium bromide, but unfortunately this resulted in a 
lower yield of methyl-5-oxohexanoate 84 (Table 6, Entry 2).  For the eventual 13C 
synthesis the Grignard reagent will need to be synthesised from commercially available 
sources of 13C (13CH3I).  Therefore, methyl magnesium iodide was made from magnesium 
turnings and methyl iodide in diethyl ether, and when the resulting Grignard reagent was 
treated with acid chloride 79 and copper(I) iodide, the resulting methyl-5-oxohexanoate 
84 was formed in a higher yield of 55% (Table 6, Entry 3).  Next, the copper source was 
changed to copper(I) bromide dimethyl sulfide complex as it was expected to form a more 
stable organocopper reagent.  When treated with the three different methyl 
organometallics an improved yield was observed in each case (Table 6, Entry 4 – 6).  The 
best result was observed when treating glutaric acid monomethyl ester chloride 79 with 
methyl magnesium iodide and copper(I) bromide dimethyl sulfide complex which gave 
the desired ketone 84 in a 69% yield (Table 6, Entry 6).  It was noticed that when the 
copper(I) bromide dimethyl sulfide complex was freshly recrystallised from dimethyl 
sulfide, higher and more consistent yields were observed.   
                                                          





Scheme 25: Transformation of glutaric acid monomethyl ester chloride 79 to methyl-5-oxohexanoate 84. 
 
 
Entry Methyl source Copper source Crude mass of methyl-5-
oxohexanoate 
1 MeLi CuI 47% 
2 MeMgBr CuI 22% 
3 MeMgIa CuI 55% 
4 MeLi CuBr.DMSb 50% 
5 MeMgBr CuBr.DMSb 62% 
6 MeMgIa CuBr.DMSb 69% 
a Synthesised from magnesium turnings and iodomethane; b Freshly recrystallised from DMS 
 
Table 6: Optimisation of the transformation of glutaric acid monomethyl ester chloride 79 to methyl-5-
oxohexanoate 84. 
 
Previous cyclisations of methyl-5-oxohexanoate 84 to 1,3-cyclohexanedione 75 have 
been carried out using either potassium tert-butoxide or sodium methoxide.83–85  Botting 
and co-workers showed that cyclisation using potassium tert-butoxide on a 5.22 mmol 
scale gave an 86% yield, however scaling the reaction up to 14.5 mmol and adding a 
purification step decreased the yield to 69%.83,84  Boyce and co-workers also observed a 
lower yield of 61% when using sodium methoxide at a larger scale of 41 mmol.85  
Following the procedure described by Botting, the intramolecular Claisen condensation 
was carried out on methyl-5-oxohexanoate 84 in dry tetrahydrofuran using potassium 
tert-butoxide as a base (Scheme 26).  On a 12.5 mmol scale 1,3-cyclohexanedione 75 was 
formed in an 68% yield after purification by flash column chromatography.  The 1H NMR 








Previously in the Jones group, two attempts were made at the oxidative aromatisation of 
1,3-cyclohexanedione 75 to pyrogallol 73, the first reproducing the work by Wasserman 
and Pickett.82  This process involved oxidising the enol form of 1,3-cyclohexanedione 85 
using singlet oxygen in the presence of fluoride ions and polymer bound Rose Bengal, 
but this failed to give the desired product, just returning starting material.  The other 
method explored used hydrogen peroxide and sodium hypochlorite in the presence of 
fluoride ions; however this again returned starting material.   
 
It is known that resorcinol 86 can be synthesised from the aromatisation of 1,3-
cyclohexanedione 75 by catalytic dehydrogenation using a palladium on charcoal catalyst 
in refluxing xylene or toluene.83,84  However attempts to reproduce these results were 
unsuccessful; despite loss of starting material and formation of aromatic signals in the 
crude 1H NMR spectrum, formation of the desired resorcinol 86 was not observed 
(Scheme 27).  Another oxidising agent which is known to promote dehydration and 
aromatisation reactions is 2,3-dichloro-5,6-dicyanobenzoquinone (DDQ) however when 
1,3-cyclohexanedione 75 was treated with DDQ in refluxing toluene, a complex mixture 
was obtained and no resorcinol 86 was observed.  
 
 
Scheme 27: Attempts at aromatisation of 1,3-cyclohexandione 75. 
   
Molecular iodine is another oxidising agent used for the aromatisation of cyclohexenone 
derivatives and was first used in 1980 by Tamura and Yoshimoto.87  The addition of 
iodine to methanol heated at reflux afforded a variety of anisole derivatives.  Later these 
conditions were applied to 1,3-cyclohexanedione derivatives which were transformed 
into substituted resorcinols.88,89  When these conditions were applied to 1,3-
cyclohexanedione 75, both aromatisation and O-methylation were observed and the 





Scheme 28: Formation of dimethoxy resorcinol 87. 
 
With a high yielding step into an aromatic species, the next step is to insert a phenol 
substituent onto carbon-2.  This can be achieved by selective formylation in the C-2 
position followed by a Baeyer-Villiger oxidation.  Initial attempts at selective formylation 
involved treating 2,6-dimethoxybenzene 87 with paraformaldehyde, magnesium 
dichloride and triethylamine.90  Usually in this reaction the treatment of a phenol and 
MgCl2-NEt3 results in the formation of magnesium phenoxide, which coordinates with 
the oxygen of the paraformaldehyde and directs the carbon-carbon bond formation to the 
ortho-position.91  However using these conditions on 2,6-dimethoxybenzene 87 returned 
only starting material, perhaps due to the methoxy group being unable to coordinate 
effectively to the magnesium metal.  Other known ortho-formylation methods include 
using Reimer-Tiemann conditions of chloroform and sodium hydroxide.  Here the 
chloroform and sodium hydroxide react to form a dichlorocarbene and undergoes attack 
at the ortho-position of the phenol ring.  When applying these Reimer-Tiemann 
conditions to 2,6-dimethoxybenzene 87 no reaction was observed, likely to be due to the 
absence of a negatively charged phenolate species which increases the nucleophilicity of 
the aromatic ring. 
 
Vilsmeier-Haack conditions use phosphoryl chloride and dimethylformamide which react 
to form an electrophilic chloroiminium ion, which goes on to react with arenes to produce 
an iminium ion intermediate which can be hydrolysed to a benzaldehyde.  Despite this 
being a generic formylation method, it was thought that when applied to 2,6-
dimethoxybenzene 87 the two methoxy groups could direct the formylation into the C-2 
position.  Unfortunately the desired product was not seen when these conditions were 
used with 2,6-dimethoxybenzene 87.  However, the successful formylation of 2,6-
dimethoxybenzene 87 was achieved through the regioselective lithiation with n-
butyllithium at 0 °C in tetrahydrofuran in the presence of N,N,N′,N′-
tetramethylethylenediamine (TMEDA) followed by treatment with dimethylformamide 





Scheme 29:  Formylation of 2,6-dimethoxybenzene 87. 
 
The regioselectivity of the resulting benzaldehyde 88 was confirmed by the splitting 
pattern in the 1H NMR spectrum; two aromatic protons signals were observed, a doublet 
with an integral of two protons and a triplet with an integral of one proton.  Haight and 
co-workers state that although the TMEDA was not essential for metalation it is thought 
to stabilise the DMF adduct.92  The group also found that the addition of aqueous 
hydrochloric acid in the workup procedure was required to prevent the formation of 
Cannizzaro reaction by-products, the reduced alcohol and oxidised carboxylic acid, 
neither of which were observed during the formylation of 2,6-dimethoxybenzene 87. 
 
The conversion of a benzaldehyde into a phenol can be achieved by a Baeyer-Villiger 
oxidation reaction using a peroxy acid or hydrogen peroxide species.  Therefore, 2,6-
dimethoxybenzaldehyde 88 was initially treated with hydrogen peroxide in methanol, but 
unfortunately this failed to yield the desired phenol 89 and instead gave unreacted starting 
material and the carboxylic acid 90 in a 2:1 ratio (Scheme 30).93  
 
 
Scheme 30: Baeyer-Villiger reaction on 2,6-dimethoxybenzaldyde 88. 
 
The carboxylic acid 90 was formed through hydride-migration in the rearrangement step 
of the Baeyer-Villiger reaction (Scheme 31, Route A).  In order for the desired phenol 89 
to form, aryl group migration is required (Scheme 31, Route B).  This was observed after 
treatment of 2,6-dimethoxybenzaldehyde 88 with meta-chloroperoxybenzoic acid in 
dichloromethane, which gave the formate ester 91 (Scheme 31).  Subsequent cleavage of 





Scheme 31: Baeyer-Villiger oxidation mechanism. 
 
2.3. Synthesis of CA1P via selective reduction of diarylalkyne 
 
With a route towards a tri-oxygenated benzene species 89 in hand, the synthesis towards 
CA1 8 could continue.  The selective alkyne reduction strategy seen previously in the 
synthesis of CA1 8 and CA4 7,34,38,39,41 was chosen as it is 100% Z-selective, therefore 
reducing the need for isomer separation and giving potentially higher yields than other 
reported strategies.  It was envisioned that the alkyne 91 needed for the selective reduction 
could be synthesised by a Sonogashira reaction (Scheme 32). 
 
  
Scheme 32: Retrosynthesis of CA1 8 via selective hydrogenation and the Sonogashira reaction. 
 
The selective reduction strategy also has the added advantage that it could be applied to 
a different hyperpolarisation technique called para-hydrogen induced polarisation 
(PHIP).64  This technique uses the addition of the naturally polarised para-hydrogen to 
unsaturated precursors through a hydrogenation reaction and this results in a highly 
hyperpolarised species.  Since one of the proposed steps in the synthesis of CA1P 9 is a 
hydrogenation there is potential to use PHIP to enhance the polarisation (Scheme 33).  
This could be useful if the hyperpolarisation created by dynamic nuclear polarisation is 
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insufficient to see a signal, as the hyperpolarisation from para-hydrogen could be 
transferred to the 13C nucleus when used in conjunction with dynamic nuclear polarisation.  
 
 
Scheme 33: Theoretical hydrogenation with para-hydrogen to generate hyperpolarised [13C]-CA1P 71. 
 
The synthesis of the terminal alkyne component 36 of the Sonogashira reaction was 
achieved using a Corey-Fuchs reaction (Scheme 34).  The aldehyde 17 was treated with 
carbon tetrabromide and triphenylphosphine, and formed the dibromoalkene 92 in a 95% 
yield.  Subsequent treatment of the dibromoalkene 92 with n-butyllithium gave the alkyne 
36 in an 81% yield upon work up and purification. 
 
 
Scheme 34: Formation of the terminal alkyne 36 component of the Sonogashira reaction. 
 
The synthesis of the iodo-component 93 of the Sonogashira reaction began by attempting 
to demethylate 2,6-dimethoxyphenol 89 which then can be iodinated (Scheme 35, Table 
7).  2,6-Dimethoxyphenol 89 was treated with the demethylating agent boron trichloride 
but this unfortunately returned starting material (Table 7, Entry 1).  Starting material was 
also recovered when the demethylating reagent was changed to aluminium trichloride 
(Table 7, Entry 2).  The hard acid/soft nucleophile reagent pair of thiourea/aluminium 
trichloride has been shown to dealkylate alkyl aryl ethers where it is suspected the sulfur 
atom acts as a weak nucleophile and is capable of cleaving a methoxy group.94  Treatment 
of 2,6-dimethoxyphenol 89 with 1.2 equivalents of both thiourea and aluminium chloride 
did produce the desired mono-demethylated compound 94 but only with a 46% 
conversion (Table 7, Entry 3).  When the number of equivalents were increased to 2.5 the 
conversion increased slightly to 60% (Table 7, Entry 4).  However no improvement was 




Scheme 35: Strategy 1: Demethylation followed by iodination. 
 
 
Entry Conditions Conversion (%)a 
1 BCl3 (1.2 eq.) 0 
2 AlCl3 (1.2 eq.) 0 
3 AlCl3 (1.2 eq.), thiourea (1.2 eq.) 46 
4 AlCl3 (2.5 eq.), thiourea (2.5 eq.) 60 
5 AlCl3 (4.0 eq.), thiourea (4.0 eq.) 59 
a From analysis of crude 1H NMR spectrum 
Table 7: Attempts at demethylation of 2,6-dimethoxyphenol 89. 
 
Since the selective demethylation of 2,6-dimethoxyphenol 89 was problematic it was 
envisioned that demethylation could be performed on the aldehyde 88.  The carbonyl 
group can aid and direct the demethylation and the remaining aldehyde 95 functionality 
can then be converted to the phenol 94 via Baeyer-Villiger oxidation (Scheme 36).  Boron 
trichloride was chosen as the demethylating agent as it has previously been shown to 
effectively cleave methyl ethers in the ortho position,24 and when treated with 2,6-
dimethoxybenzaldehyde 88 mono-demethylation successfully occurred giving the phenol 
95 in an 88% yield after purification.  Next, the Baeyer-Villiger reaction of the 
benzaldehyde 95 was attempted using meta-chloroperoxybenzoic acid followed by 
sodium hydroxide as this was successful in the benzaldehyde to phenol transformation 
previously observed in the formation of 2,6-dimethoxyphenol 89 (Scheme 31).  
Unfortunately no conversion to the phenol 94 was observed and instead, 21% conversion 
to the carboxylic acid was seen which was due to hydride-migration rather than the 
desired aryl-migration in the rearrangement step of the Baeyer-Villiger reaction (Table 8, 
Entry 2).  Therefore the oxidising agent was changed to hydrogen peroxide under basic 
conditions, as this has been known to convert similar benzaldehydes to phenols that have 
methoxy- and hydroxyl-substituents.95  Unfortunately this only gave the desired diphenol 
94 with 19% conversion (Scheme 36, Table 8, Entry 2).  Matsumoto and co-workers 
reported the acid-catalysed oxidation of a number of benzaldehydes to phenols.93  These 
conditions, hydrogen peroxide in methanol with catalytic sulfuric acid, were used on 





Scheme 36: Strategy 2: Demethylation, Baeyer-Villiger oxidation then iodination. 
 
Entry Conditions Conversion (%)a 
1 mCPBA, DCM then KOH, MeOH 0b 
2 H2O2, NaOH 19 
3 H2O2, H2SO4 (cat.) then NaOH 100 
a From analysis of crude 1H NMR spectrum b 21% conversion to carboxylic acid 
Table 8: Attempts at conversion of benzaldehyde 95 to phenol 94. 
 
With the diphenol 94 in hand, the iodo coupling partner for the Sonogashira reaction 
needed to be made with the correct regioselectivity by adding an iodine atom in the 6-
position.  Iodination of diphenol 94 was proposed by firstly deprotonating with n-
butyllithium then treatment with iodine.  Due to the two free phenols being susceptible to 
deprotonation, the diphenol 94 was protected by treatment with MOMCl and sodium 
hydride in tetrahydrofuran, which afforded the protected diphenol 96 in a 62% yield 
(Scheme 37).  The MOM protecting group was chosen because it is not only easy to 
remove but could also potentially direct the lithiation to the 6-position.  Unfortunately, 
after treatment of protected diphenol 96 with n-butyllithium followed by addition of 
iodide, no iodine was incorporated into the molecule, with only starting material being 
recovered.  The deprotonation/lithiation step was repeated but instead of the addition of 
iodine, the reaction was quenched with deuterium oxide.  No deuterium incorporation 
was observed in the crude 1H NMR spectrum indicating that deprotonation did not occur.   
 
 
Scheme 37: Attempts at the iodination of protected iodide 96. 
 
Rather than trying to optimise the deprotonation step, different iodination conditions were 
looked at for the direct treatment of the substrate 94 with an electrophilic source of iodine 
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(Scheme 38, Table 9).  This strategy would also eliminate the need to use protecting 
groups.  The iodination of methoxy-substituted aromatic compounds has been achieved 
in the literature using N-iodosuccinimide, an electrophilic source of iodine.110  However 
iodination with N-iodosuccinimide in acetonitrile at room temperature did not yield the 
desired iodo compound 93 neither did increasing the reaction temperature to reflux (Table 
9, Entries 1 – 2).96  Iodine(I) chloride is another source of electrophilic iodine which can 
be generated in situ from N-chlorosuccinimide and sodium iodide in acetic acid and has 
been shown to iodinate electron-rich aromatics.97  However when 3-methoxy-benzene-
1,2-diol 94 was treated with N-chlorosuccinimide and sodium iodide, iodination did not 
occur (Table 9, Entry 3).  The regioselective iodination of a different methoxy-substituted 
phenol, 2-methoxy-benzene-1,3-diol, has been achieved using iodine and cerium(IV) 
ammonium nitrate (10 mol%) and when these conditions were applied to the diol 94, the 
iodo species 93 was formed but only with 16% conversion of the starting material.98  Even 
though the desired iodoarene 93 was produced, the unsatisfactory yield meant that other 
iodination conditions were investigated. 
 
The iodination of aromatics has been demonstrated using a superelectrophilic species 
generated in situ from N-iodosuccinimide and a variety of catalysts.  These include 




103  The diphenol 94 was treated with N-iodosuccinimide with catalytic 
trifluoroacetic acid and the desired iodinated species 93 was formed with 10% conversion 
(Table 9, Entry 5).99  Iodination under conditions by Romo was attempted on 3-methoxy-
benzene-1,2-diol 94, using the mild Lewis acid indium(III) trifluoromethanesulfonate as 
a catalyst (10 mol%) in addition to a stoichiometric amount of N-iodosuccinimide.103  
Under these conditions an improved conversion of 31% to the iodo-compound 93 was 
observed by 1H NMR spectroscopy (Table 9, Entry 6).  Leaving the reaction for an 
extended time or increasing the temperature by heating at reflux failed to give the desired 
iodo compound in a satisfactory yield (Table 9, Entries 7 – 10).   
 
 









1 NIS - MeCN rt 18 0b 96 
2 NIS - MeCN reflux 18 0b - 
3 NCS, NaI - AcOH rt 18 0 97 
4 I2, CAN - MeCN rt 18 16 
98 
5 NIS TFAc MeCN rt 18 10 99 
6 NIS In(OTf)3
d MeCN rt 18 31 103 
7 NIS In(OTf)3
d MeCN rt 24 35 - 
8 NIS In(OTf)3
d MeCN rt 48 45 - 
9 NIS In(OTf)3
d MeCN rt 84 49 - 
10 NIS In(OTf)3
d MeCN reflux 18 0 - 
a Determined from analysis of crude 1H NMR spectrum b degradation of starting material c 30 mol% d 10 
mol% 
 
Table 9: Optimisation for the iodination of 3-methoxy,1,2-benzenediol 94. 
 
As the consistently low conversion for the iodination reactions were surprising, the 
NIS/In(OTf)3 system was applied to an original substrate used in the paper, phenol 97 
(Scheme 39).  Under identical conditions the reaction proceeded to complete conversion 
which suggests that the diphenol substrate 94 is incompatible with this reaction.   
 
 
Scheme 39: Iodination of phenol 97. 
 
It was thought that the diphenol 94 could be deactivating the catalyst through coordination 
of the metal and the two phenolic oxygens.  To test this hypothesis 0.5 equivalents of the 
diphenol 94 and 0.5 equivalents of phenol 97 were put into the same reaction vessel with 
N-iodosuccinimide and In(OTf)3 at room temperature under the conditions reported.  No 
iodination occurred on either substrate suggesting that catalyst inhibition was occurring.  
1,2-Diols are known to be oxidised to ortho-quinone species in the presence of an 
oxidising reagent (Scheme 40).104,105  Therefore it is possible that the N-
iodosuccinimide/In(OTf)3 system could also be acting as an oxidising agent converting 





Scheme 40: Formation of ortho-quinone 98. 
 
As it was found that iodination of the unprotected diphenol 94 under these conditions 
cannot occur directly, iodination of a protected diphenol was investigated.  At first the 
MOM protected diphenol 96, which has been synthesised previously (Scheme 37), was 
treated with N-iodosuccinimide and In(OTf)3 (Scheme 41a).  The crude 
1H NMR 
spectrum showed that all the starting material had disappeared and that multiple products 
had formed.  The desired protected iodo species 99 was not seen since no MOM peaks 
were detected, however the diphenol 94 was observed.  It was thought the acid sensitive 
MOM groups were cleaved under these conditions resulting in a reactive aldehyde species 
which could go on and react to form by-products.  As the MOM protecting group was 
unsuitable, the diphenol 94 was protected as a methylenedioxy group 100 using 
dibromomethane and caesium fluoride in DMF.120  The resulting 1,3-benzodioxole 100 
was subjected to the N-iodosuccinimide and In(OTf)3 conditions and three products were 
formed: the two regioisomers of mono-iodinated product and the di-iodinated product in 
a 1:1:2 ratio (Scheme 41b).  The lack of convincing regioselectivity for the two 
regioisomers for the mono-iodinated compound is likely due to the fact that the sites of 
iodination are electronically and sterically very similar. 
 
 




Rather than pursuing different protecting groups that required both an additional 
protection and deprotection step, iodination on previously synthesised intermediates was 
examined.  Firstly, 2-hydroxy-4-methoxybenzaldehye 95 was treated with N-
iodosuccinimide and In(OTf)3 (Scheme 42).  Three products were formed believed to be 
two mono-substituted products 101 and 102 and a di-substituted product 103 in a 
69:21:10 ratio.  The major mono-iodinated product 101 was isolated through flash column 
chromatography with an overall yield of 45%.   
 
 
Scheme 42: Iodination of 2-hydroxy-4-methoxybenzaldehyde 95. 
 
The regioselectivity of the major mono-substituted isomer 101 was confirmed through 
nOe experiments (Figure 18).  When the sample was irradiated at a frequency 
corresponding to the aromatic proton Ha, an enhancement was observed at the signal for 
the aromatic proton Hb.  When the proton Hb was irradiated the signals of both the 
aromatic proton Ha and the methyl proton Hc were enhanced.  Finally when the methyl 
proton Hc was irradiated, a signal enhancement was observed for the aromatic proton Hb 
and small enhancement was observed for the aldehyde proton Hd.   
 
 
Figure 18: nOe – NMR study confirming the regioselectivity of the iodination to iodobenzaldehyde 101. 
 
The low overall yield for the iodination of 2-hydroxy-4-methoxybenzaldehyde 95 and the 
difficulties with both over-iodination and regioselectivity (Scheme 42) led to looking at 
the iodination on a symmetrical species followed by subsequent desymmetrisation by 
demethylation. 2,6-Dimethoxybenzaldehyde 88, which is another previously made 
intermediate, was subjected to the NIS/In(OTf)3 iodination conditions (Scheme 43).  
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Initially after 18 h, starting material 88 and a mono-substituted product 104 was seen in 
a 2:1 ratio.  When the reaction was repeated but the reaction time left for 72 hours, the 
ratio of the two products was 1:1.  When the number of equivalents of N-iodosuccinimide 
was increased from 1.1 to 2.2 and the number of equivalent of In(OTf)3 was increased 
from 0.1 to 0.2, 100% conversion was observed.  The mono-substituted product 104 was 
isolated through flash column chromatography with a yield of 51%.   
 
 
Scheme 43: Iodination of 2,6-dimethoxybenaldehyde 88 followed by selective demethylation. 
 
 
Entry Number of equivalents  
of NIS 
Number of equivalents 
of In(OTf)3 
Time (h) SM:P ratioa 
1 1.1 0.1 18 2:1 
2 1.1 0.1 72 1:1 
3 2.2 0.2 18 0:100 
a Determined from analysis of crude 1H NMR spectrum 
Table 10: Optimisation of the iodination of 2,6-dimethoxybenzaldehyde 88. 
 
There are only a handful of examples in the literature where the more sterically hindered 
methoxy group is selectively cleaved on a 1,3-dimethoxycarbonyl compound where 
either magnesium iodide etherate or boron tribromide was used.106  Yamahuchi and co-
workers were successful in selectively demethylating 2,6-dimethoxybenzaldehydes to 
their corresponding phenols with magnesium iodide etherate; their examples include the 
formation of 3-chloro-2-hydroxy-6-methoxybenzaldehyde from 3-chloro-2,6-
dimethyoxybenzaldehyde.106  Therefore the selective demethylation of 5-iodo-2,6-
dimethoxybenzaldehyde 104 is thought to occur under the same conditions.  The 
magnesium iodide etherate was made in situ by treating magnesium turnings with iodine 
in dry diethyl ether at reflux then leaving the reaction until the brown iodine colour had 
disappeared.  The solution was then added to 5-iodo-2,6-dimethoxybenzaldehyde 104 in 
toluene and heated at reflux.  Analysis of the crude 1H NMR spectrum showed two 
products in a 1:3 ratio (Scheme 44).  The minor product was the desired 2-hydroxy-4-
methoxybenzaldehyde 101, but unfortunately the major product was the de-iodinated 






Scheme 44: Demethylation of 5-iodo-2,6-dimethoxybenzaldehyde 104. 
 
The weak C-I bond had broken, possibly through a radical process caused by magnesium 
metal, so the reaction was repeated where the excess magnesium used in the formation of 
the magnesium iodide etherate was allowed to settle before decanting the solution to 
prevent any excess magnesium from being present in the reaction.  The reaction 
temperature was also lowered from reflux to room temperature, but the ratio of the 
products did not improve. 
 
 
Scheme 45: Possible explanation for the regioselectivity of demethylation observed by Yamauchi and co-
workers. 
 
Even though the reaction did not go to completion, the correct regioisomer was formed 
since the NMR data corresponded to the phenol 101 which was previously formed and its 
regiochemistry was confirmed by nOe studies (Figure 18).  The exact reasons behind the 
regioselectivity are unknown, however Yamaguchi and co-workers suggest that the 5-
halo-2,6-dimethoxybenzaldehyde can form an equilibrium of two chelation isomers 105 
and 106 with the magnesium iodide etherate (Scheme 45).  This chelation causes the 
methyl group in adduct 105 to have unfavourable steric interactions with the R group 
making it less stable than adduct 106.  However in order for the regioisomer 101 to be 
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formed the next step, the elimination of methyl iodide, must be kinetically more favoured 
for the unstable isomer 105 than the more stable isomer 106 by having a lower activation 
barrier. 
 
Since the correct regioselectivity was observed for the demethylation using magnesium 
iodide etherate, the low overall yield meant that other demethylation conditions were tried.  
The more traditional demethylating reagent, boron trichloride, was used and successful 
demethylation iodophenol 104 was formed with 100% conversion to the desired 
regioisomer which was determined by analysis of the crude 1H NMR spectrum (Scheme 
44).  The iodinated product 101 was purified by flash column chromatography but 
unfortunately the majority of the product degraded on the column and only 18% of the 
crude product was recovered. 
 
The final step towards synthesising the desired iodo-component 93 for the Sonogashira 
reaction involved the conversion of the aldehyde 101 to the phenol 93 via a Baeyer-
Villiger oxidation (Scheme 46, Table 11).  At first the aldehyde 101 was treated with 
meta-chloroperoxybenzoic acid, and this resulted in a 47% conversion of aldehyde 101 
to the desired diphenol 93 (Table 11, Entry 1).  When the peroxide was changed to 
hydrogen peroxide there was a slight increase in conversion to 50%.  As the reaction with 
meta-chloroperoxybenzoic acid showed a larger amount of unknown by-products in the 
crude 1H NMR spectrum, optimisation was carried out using hydrogen peroxide as the 
oxidant (Table 11, Entries 1 and 2).  To try and increase the conversion, the temperature 
of the reaction was increased from room temperature to 60 °C; however this resulted in 
decomposition of the starting material (Table 11, Entry 3).  The number of equivalents of 
hydrogen peroxide was also investigated; when increased to 2.5 equivalents the 
conversion increased to 64% (Table 11, Entry 4).  When the number of equivalents was 
increased further to 5.0 equivalents. no further increase in conversion was observed, 
therefore the number of equivalents of hydrogen peroxide was kept at 2.5 (Table 11, Entry 
5).  Next the reaction time was investigated; when the reaction time was decreased from 
18 hours to 1 hour a dramatic drop in conversion was observed, and when increased to 90 
hours no significant change in conversion was observed, suggesting a reaction time of 18 
hours was optimal (Table 11, Entry 6 and 7).  A change in solvent from methanol to 
ethanol saw a large decrease in conversion meaning that methanol was kept as the solvent 
(Table 11, Entry 8).  The reaction conditions were then changed from acid-catalysed to 
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base-catalysed but the treatment of aldehyde 101 with hydrogen peroxide and sodium 
hydroxide resulted in return of starting material.  When the reaction temperature for base 
catalysis was increased to 60 °C, the conversion increased slightly to <5% (Table 11, 
Entries 9 and 10).  Since acid was needed for the reaction to proceed, different types of 
acidic additives were investigated (Table 11, Entries 11-14).  The addition of 
trifluoroacetic acid to the reaction resulted in a small conversion of 6% (Table 11, Entry 
12), the addition of acetic acid gave a comparable conversion to that seen with sulfuric 
acid (Table 11, Entry 13), and the addition of selenium dioxide gave a conversion of 31% 
(Table 11, Entry 14).  A possibility for the low conversion could be due to the oxidation 
of the 1,2-diphenol product 93 to its corresponding ortho-quinone (Scheme 40).  
Therefore oxygen was eliminated from the reaction by carrying it out under nitrogen and 




Scheme 46: Attempts at the Baeyer-Villiger oxidation on benzaldehyde 101. 
 
 
Entry Peroxide Eq. of 
peroxide 




1c mCPBA 2.0 - DCM rt 18 47 
2d H2O2 1.3 H2SO4 MeOH rt 18 50 
3d H2O2 1.3 H2SO4 MeOH 60 °C 18 0
f 
4d H2O2 2.5 H2SO4 MeOH rt 18 64 
5 d H2O2 5.0 H2SO4 MeOH rt 18 65 
6 d H2O2 2.5 H2SO4 MeOH rt 1 7 
7 d H2O2 2.5 H2SO4 MeOH rt 90 63 
8 d H2O2 2.5 H2SO4 EtOH rt 18 24 
9  H2O2 2.5 NaOH
h MeOH rt 18 0g 
10  H2O2 2.5 NaOH
h MeOH 60 °C 18 <5 
11 d H2O2 2.5 - MeOH rt 18 0
g 
12 d H2O2 2.5 TFA MeOH rt 18 6 
13 d H2O2 2.5 AcOH MeOH rt 18 60 
14 d H2O2 5.0 SeO2 MeOH 60 °C 18 31 
15 d,e H2O2 5.0 H2SO4 MeOH rt 18 53 
a 0.2% b Determined by the ratio of starting material and product peaks in crude 1H NMR spectra,  c then 
treated with KOH d then treated with NaOH e under N2, f decomposed g unreacted starting material h 3.0 
eq. 
 





In summary, the best reaction conditions for the Baeyer-Villiger reaction of aldehyde 101 
to diphenol 93 were using 2.5 equivalents of hydrogen peroxide with 0.2% sulfuric acid 
in methanol at room temperature and leaving the reaction for 18 hours (Table 11, Entry 
4).  This resulted in a reasonable conversion from the aldehyde 101 to diphenol 93 at 64% 
but unfortunately attempts at purifying the crude material via flash column 
chromatography showed degradation of the product on the silica meaning no product 
could be isolated.  In order to determine the yield of the reaction, one molar equivalent of 
N-methylmalemimide was added as a NMR reference to the crude material.  The ratio 
between the reference peak and the product peaks in the 1H NMR spectra was 18% 
showing that significant material was lost through work up.  The reaction was repeated 
ensuring an acidic environment and doubling the number of extractions but unfortunately 
failed to improve either the conversion or the yield.  
 
As a result of the poor conversion and failure to isolate 1-iodo-2,3-dihydroxy-4-
methoxybenzene 93 from 3-iodo-2-hydroxy-6-methoxybenzaldehyde 101, it was decided 
to instead use the iodo-benzaldehyde 101 as the iodo-component for the Sonogashira 
reaction.  The reaction conditions followed those used by Lawrence and co-workers for 
the synthesis of CA4.107  Firstly the iodo-benzaldehyde 101 and 5-ethynyl-1,2,3-
trimethoxybenzene 36 [made previously (Scheme 34)] were treated with 
tetrakis(triphenylphosphine)palladium(0) and copper (I) iodide in triethylamine but 
unfortunately this returned starting material.  It was noticed during the reaction that there 
was significant amount of undissolved starting material, therefore the base, which also 
acts as the solvent was investigated.  The alkyne 36 dissolved in triethylamine but the 
iodoarene 101 did not.  However the iodoarene 101 did partially dissolve in diethylamine 
and pyrrolidine, and fully dissolved in piperidine.  Therefore the base was changed to 
piperidine, the reaction was also heated to reflux and all the starting material was 
consumed and a product was isolated in a 60% yield after column chromatography 





Scheme 47: Sonogashira reaction of aryl iodide 101 and alkyne 36. 
 
Unfortunately the isolated product was not the desired alkyne product 107.  The expected 
1H NMR spectrum should have 3 singlets in the methoxy region, an alcohol peak, an 
aldehyde peak and in the aromatic region a singlet with an integral of 2H, and two 
doublets with an integral of 1H each.  However the 1H NMR spectrum of the product had 
an additional singlet (1H) in the aromatic region and no OH peak.  The 13C J-MOD NMR 
spectrum for the expected product was expected to have 3 CH3 peaks, 1 deshielded CH1 
peak for the aldehyde, 3 aromatic CH1 peaks and 9 CH0 peaks in the aromatic region.  
However, the 13C J-MOD NMR spectrum for the product differs from the expected 
spectrum by having 4 CH1 peaks and 8 CH0 peaks in the aromatic region.  Sonogashira 
reactions using copper are prone to Glaser coupling, where the alkyne component 
undergoes homocoupling upon oxidation and leads to a symmetrical diyne.  In the system 
with 5-ethynyl-1,2,3-trimethoxybenzene 36 this would lead to the formation of 1,1'-(1,3-
butadiyne-1,4-diyl)-bis-(3,4,5-trimethoxybenzene) 108, however since the 1H NMR 
spectrum shows 8 different protons environments the dimerised product can be ruled out 
as this only has 3 different proton environments.  The 1H NMR spectrum of the product 
shows an additional aromatic proton and no alcohol proton when compared to the 
expected compound 107 therefore it was hypothesised that the expected ortho-
hydroxydiarylalkyne product 107 underwent a ring-closing reaction forming a 
benzofuran 109 (Scheme 48).  The expected 1H and 13C J-MOD NMR spectra for the 






Scheme 48: Formation of benzofuran 109 from aryl iodide 101 and alkyne 36. 
 
There are a number of reports in the literature of ortho-hydroxydiarylalkynes undergoing 
annulation under palladium catalysis.108,109  When investigating phenoxide-mediated 
Sonogashira coupling of trimethylsilylalkynes and aryliodides, Shigeta and Konishi 
found that when using ortho-hydroxy-iodoarenes they unexpectedly gave rise to 
benzofurans (Scheme 49a).108  This reaction has been utilised by Scammells and co-




Scheme 49: Examples of benzofuran formation from ortho-hydroxydiarylalkynes. 
 
As it was found that having an unprotected alcohol in the ortho-position on the iodoarene 
generates an undesired benzofuran, protection of the alcohol was required.  3-Iodo-2-
hydroxy-6-methoxybenzaldehyde 101 was initially protected with a tert-
butyldimethylsilyl ether protecting group using TBSCl, DMAP and triethylamine 
(Scheme 50).  The Sonogashira reaction with the resulting TBS-protected iodide 110 went 
to 100% completion but unfortunately no product was observed after purification by flash 
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column chromatography; however deprotected iodophenol 101 was seen.  In addition, no 
TBS-protected product 110 was seen when the silica was deactivated using 1% 
triethylamine.  Therefore the crude protected iodoarene 110 underwent the Sonogashira 
reaction under the same conditions as used on the unprotected system (Scheme 50).  
Unfortunately the formation of the desired diarylalkyne 111 did not occur, as the crude 
1H NMR spectrum showed loss of the TBS-protecting group suggesting that the TBS-
protecting group could be incompatible with these conditions.  Next, a methoxymethyl 
ether protecting group was used; unfortunately only a 16% conversion to the protected 
product 112 was observed when treating phenol 101 with sodium hydride and MOMCl. 
 
Scheme 50: Attempts at the Sonogashira reaction using protected iodoarenes. 
 
The next protecting group studied was the methyl ether protecting group.  This has the 
added advantage of being an intermediate already synthesised (Scheme 43) and therefore 
eliminating the need for both an additional protecting and deprotecting step.  The 
Sonogashira reaction between the methyl ether protected iodoarene 104 and the terminal 
alkyne 36 gave the diarylalkyne 113 in a 56% yield. 
 
 




Next, demethylation of the methoxy group in the ortho position relative to both the 
aldehyde and alkyne of the diarylalkyne 113 was required.  The reagent of choice was 
boron trichloride as it had already been shown as an effective ortho-demethylating agent.  
Since there is a hydroxyl group in both ortho positions to the benzaldehyde 113, 
theoretically demethylation could occur at either site.  However there is literature 
evidence that demethylation can occur on the more sterically hindered methyl ether, and 
this was also observed previously on the demethylation of 5-iodo-2,6-
dimethoxybenzaldehyde 104 (Scheme 44 and Scheme 45).  Unfortunately treatment of 
the diarylalkyne 113 with boron trichloride resulted in two products in a 1:1 ratio 
presumably the two demethylated products 107 and 114 ( Scheme 52). 
 
 
Scheme 52: Ortho-demethylation of diarylalkyne 113 
. 
 
The difficulties in achieving a suitable synthesis for the iodo-species for the Sonogashira 
reaction led to a different strategy being investigated where the iodo-component 115 
contained the trimethoxy A ring and the alkyne component 116 contained the 13C-labelled 
B ring (Scheme 53). 
 
 




For this new strategy, the iodo component 115 was synthesised from the commercially 
available 3,4,5-trimethoxyaniline 117 via a Sandmeyer reaction (Scheme 54).  The aniline 
117 was treated with nitrous acid which was prepared in situ from sodium nitrate and 
sulfuric acid, and this led to a diazonium salt intermediate which when treated with 
potassium iodide revealed the iodoarene 115 in an 81% yield.   
 
 
Scheme 54: Formation of 1-iodo-3,4,5-trimethoxybenzene 115. 
 
The alkyne component 116 can be derived from 2,3-dihydroxy-4-methoxybenzaldehyde 
118 via a Corey-Fuchs reaction and this aldehyde 118 needs to be derived from 2,6-
dimethoxyphenol 89 as this will contain the 13C label (Scheme 55).   
 
 
Scheme 55: Retrosynthesis of the alkyne component for the Sonogashira reaction. 
 
 
The synthesis towards the alkyne component 116 first began by methylating the phenol 
89 to 1,2,3-trimethoxybenzene 119 using sodium hydride and methyl iodide, and this was 
achieved in a 83% yield (Scheme 56).  Next, ortho-formylation on 1,2,3-
trimethoxybenzene 119 occurred using Rieche formylation conditions, and the resulting 
2,3,4-trimethoxybenzaldehyde 120 was isolated in a 90% yield (Scheme 56).  The 
regiochemistry of the benzaldehyde was confirmed by the multiplicities in the crude 1H 
NMR spectrum which had two distinct doublets (J =8.8 Hz) being observed for the two 
aromatic protons.  The regioselectivity is due to the coordination of the titanium atom to 
both the oxygen atom of the methoxy group in the substrate and the dichloromethyl 
methyl ether.  This forms a 6-membered titanium complex which influences the direction 
of the electrophilic substitution.  The C – formylation occurs exclusively in the 4 or 6 
position and since the starting substrate is a symmetrical species, formylation in both 
position will result in the same product 120.  The coordination of the titanium atom not 
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only provides the correct regioselectivity but it also increases the electrophilicity of the 
dichloromethyl methyl ether.110   
 
 
Scheme 56: Methylation of 1,3-dimethoxyphenol 89 followed by Rieche formylation and demethylation. 
 
The formation of benzaldehyde 118 has previously been achieved by two different 
strategies by Pettit and co-workers.  The first is the treatment of 2,3,4-
trihydroxybenzaldehyde with sodium borate which selectively forms a 2,3-borate ester 
121 allowing for the selective methylation of the 4-hydroxy group using dimethylsulfate 
(Scheme 57a).11  However, more recently Pettit established an alternative route towards 
2,3-dihydroxy-4-methoxybenzaldehyde 118 that was not only more atom economical but 
also more applicable on a larger scale.24  This route involved the demethylation of 2,3,4-
trimethoxybenzalydehyde 120 using 2 equivalents of boron trichloride which gave the 
desired mono-methylated product 118 in an 87% yield.111  Due to the latter method being 
both higher yielding and easier to synthesise from 2,6-dimethoxyphenol 89, it was 
proposed to be used as the demethylation method.  The selective demethylation of 2,3,4-
trimethoxybenzaldehyde 120 with boron trichloride gave 2,3-dihydroxy-4-
methoxybenzaldehyde 118 in an 86% yield.   
 
 
Scheme 57: Pettit’s formation of 2,3-hydroxy-4-methoxybenzaldehyde 118 a) via methylation of a 2,3 




To produce the desired alkyne component 116 needed for the Sonogashira reaction, the 
benzaldehyde 118 was subjected to Corey-Fuchs conditions (Scheme 58).  Treatment of 
the benzaldehyde 118 with triphenylphosphine and carbon tetrabromide gave the 
dibromoalkene 122 but unfortunately subsequent treatment with 5 equivalents of n-
butyllithium failed to give the dehydrohalogenated product 116. 
 
 
Scheme 58: Attempts at the Corey-Fuchs reaction on unprotected benzaldehyde 118. 
 
Therefore the diphenol moiety was protected as a tert-butyldimethylsilyl ether 22 and 1,3-
benzodioxole 123 which subsequently underwent the two-step Corey-Fuchs reaction 
(Scheme 59).  Protection with a TBS group, which was achieved by treating 2,3-
dihydroxy-4-methoxybenzaldehyde 118 with using TBSCl, DMAP and triethylamine, the 
TBS-protected aldehyde 22 was formed in a 57% yield after purification by 
recrystallisation.  This was then converted to the dibromoalkene 124 by treatment with 
triphenylphosphine and carbon tetrabromide in dichloromethane.  Subsequent treatment 
of the dibromoalkene 124 with n-butyllithium followed by purification gave the TBS-
protected alkyne 125 in a 72% yield (over 2 steps).  2,3-Dihydroxy-4-
methoxybenzaldehyde 118 was also protected as a 1,3-benzodioxole 123, which was 
achieved following treatment with potassium fluoride and dibromomethane.  The 
resulting protected-aldehyde 123 was isolated in a 65% yield and treated with carbon 
tetrabromide and triphenylphosphine and gave the dibromoalkene 126.  Then treatment 
of this dibromoalkene with n-butyllithium revealed the dioxole protected alkyne 127 in 




Scheme 59: Protection of aldehyde 118 and subsequent Corey-Fuchs reactions. 
 
The protected terminal alkynes 125 and 127 were then treated with 1-iodo-3,4,5-
trimethoxybenzene 115, tetrakis(triphenylphosphine)palladium(0), and copper (I) iodide 
in piperidine.  Unfortunately when using the TBS-protected alkyne 125, these 
Sonogashira conditions were unsuccessful in giving the desired diarylalkyne 128 as a 
large number of peaks were seen in the crude 1H NMR spectrum, including unreacted 
starting material and deprotected starting material.  As this was also seen before for the 
Sonogashira reaction between the TBS-protected iodoarene 110 and 5-ethynyl-1,2,3-
trimethoxybenzene 36 (Scheme 50) it was concluded that the TBS group is incompatible 
with these Sonogashira conditions.  However when these conditions were applied to the 
1,3-benzodioxole protected alkyne 127, the desired diarylalkyne 129 was formed in a 
31% yield (Scheme 60). 
 
 
Scheme 60: Sonogashira reactions between protected alkynes 125 and 127 with 5-iodo-1,2,3-
trimethoxybenzene 115. 
 
Next, the diarylalkyne 129 needed to be selectively reduced to the Z-alkene 130.  During 
their work to synthesise a different combretastatin, CA4 7, Lara-Ochoa and co-workers 
selectively reduced diarylalkyne 51 by generating a thermally stable Ti(II)-alkyne 
71 
 
complex 53 using n-butyllithium and Ti(OiPr)4 (Scheme 61).
39  The two aryl rings on the 
Ti(II)-alkyne complex are in a cis configuration and after hydrolysis the Z-CA4 7 is 
produced in high yields. 
 
 
Scheme 61: Formation and hydrolysis of a Ti(II)-alkyne complex 53 for the synthesis of CA4 7. 
 
 
Unfortunately when these conditions were applied to the protected diarylalkyne 129 the 
isolation of the protected-CA1 species 130 as a single Z-isomer was unsuccessful.  
Attempts at purification of the crude reaction material by flash column chromatography 
isolated two products with the same Rf value.  Analysis of the 
1H NMR spectrum 
suggested these products could be the Z and E-isomers of the desired alkene.  During 
Eisch’s investigations into the reactions of dialkyltitanium (IV) compounds with 
unsaturated substrates, they observed the unexpected isomerisation of cis-stilbene to its 
trans-isomer along with over-reduction to the alkane.112  Therefore it is possible that the 
desired Z-alkene 130 produced from reduction of diarylalkyne 129 can isomerise to the 
E-alkene under these conditions.  To check the quality of reagents and procedure, two 
other diarylalkynes 51 and 131 were reduced using the Ti(OiPr)4/nBuLi conditions.  The 
diarylalkynes 51 and 131 were first synthesised by Sonogashira reactions of 5-iodo-1,2,3-
trimethoxybenzene 115 and the corresponding iodoarene.  The diarylalkynes were then 
treated with Ti(OiPr)4 and nBuLi  and were both reduced with 100% conversion to the Z-
alkenes 7 and 132 respectively suggesting that the diarylalkyne 129 is incompatible with 





Scheme 62: Attempts at selective reduction of diarylalkyne 129 using nBuLi and Ti(OiPr)4. 
 
 
The reduction of diarylalkyne 129 was therefore attempted using the H-cube®, a 
continuous-flow hydrogenation flow reactor.  This time the reduction to the Z-alkene 130 
occurred, without the formation of the E-isomer, but unfortunately despite using a Lindlar 




Scheme 63: Hydrogenation of diarylalkyne 129 using H-cube® conditions. 
 
 
Rather than optimising the H-cube® hydrogenation conditions at this stage, the 
deprotection of the acetonide protecting group was looked at (Scheme 64).  Unfortunately 
a number of different deprotection conditions were attempted including, hydrochloric 
acid, boron trichloride113 and n-butyllithium,114 and these all failed in deprotecting either 





Scheme 64: Attempts at deprotection of alkene 130 and diarylalkyne 129. 
 
It was at this point that the whole synthesis via the Sonogashira reaction, up to this point, 
was examined and it was found that this already comprised of 12 steps with an overall 
yield of 1.9%.  Due to the cost of the 13C starting material and the fact that the remaining 
steps require a large amount of optimisation, another route towards the synthesis of CA1P 
9 was investigated.  
 
2.4. Synthesis of CA1P via the Wittig reaction 
 
In parallel to synthesising CA1 8 through the Sonogashira strategy, a Wittig strategy was 
examined.  It was envisioned that CA1 8 could be synthesised by the Wittig reaction of 
the commercially available 3,4,5-trimethoxybenzaldehyde 17 and the phosphonium salt 
134 (Scheme 65). 
 
Scheme 65: Wittig reaction strategy for the synthesis of CA1 8. 
 
The protected phosphonium salt 134, which needs to eventually contain the 13C label, can 
be derived from the aldehyde 118.  A route towards the aldehyde 118 has already been 
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established previously (Scheme 57).  At the start of the synthesis of the phosphonium salt 
134, the diphenol functionality of the aldehyde 118 needed to be protected.  A tert-
butyldimethylsilyl ether protecting group was chosen because it is simple to attach and 
remove, and has been shown to be stable under Wittig reaction conditions.11  Treatment 
of 2,3-dihydroxy-4-methoxybenzaldehyde 118 with triethylamine and 4-
dimethylaminopyridine followed by addition of tert-butyldimethylsilyl chloride gave the 
TBS-protected aldehyde 22 in a 57% yield (Scheme 66).  The protected aldehyde 22 was 
then reduced to the corresponding alcohol 135 using sodium borohydride in a 99% yield 
and then converted to the bromide 136 using phosphorus tribromide in a 92% yield.  Next, 
the bromide 136 was transformed to the phosphonium salt 137 using triphenylphosphine 
in refluxing dichloromethane in a 84% yield.  
 
Scheme 66: Synthesis of the Wittig precursor, phosphonium salt 137. 
 
The aldehyde component of the Wittig reaction, 2,3,4-trimethoxybenzaldehyde 17 is 
commercially available.  The ylide component was formed from the treatment of the 
phosphonium salt 137 with n-butyllithium, and then reacted with the aldehyde 17 to form 
the protected-CA1 24 with an E/Z ratio of 2.3:1 (determined by 1H NMR spectroscopy) 
(Scheme 67).  However the separation of the two isomers 23 and 24 by flash column 
chromatography was problematic due to the isomers having very close Rf values. 
 
 
Scheme 67: Wittig reaction between aldehyde 17 and phosphonium salt 137. 
 
The two E- and Z-TBS protected CA1 isomers 23 and 24 have previously been separated 
by recrystallization in ethanol, however when applied to the above system this failed to 
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separate the desired Z-isomer 24 in an acceptable yield.11  This is presumably due to the 
low proportion of Z-isomer 24 in the mixture and the large amount of triphenylphosphine 
oxide.  Therefore a pure mixture of E- and Z- isomers 23 and 24 was isolated through 
flash column chromatography before recrystallisation and this lead to the Z-isomer 24 
being isolated in a 21% yield.  This low yield of the isolation the desired Z-CA1 24 was 
due to the unfavourable selectivity of the Wittig reaction.  
 
There have been a number of modifications aimed at altering the E/Z stereoselectivity for 
the Wittig reaction, the majority of which occur on the phosphonium ylide, for example 
the Horner-Wadsworth-Emmons, Still-Gennari and Ando modifications.  A common 
modification of semi-stabilised triphenylphosphonium ylides is to replace the phenyl 
groups with heteroaryl groups or substituted aryl groups.  There are fewer modifications 
on the carbonyl component of the Wittig reaction; however Tian and co-workers recently 
reported the highly stereoselective olefination of semi-stabilised triphenylphosphonium 
ylides with N-sulfonyl imines.115  It is proposed that the olefination occurs through a 
Wittig-type reaction pathway involving the cycloaddition to a 1,2,-azaphosphetane 
intermediate, which collapses yielding an alkene and iminophosphorane.  The authors 
employed a sulfonyl electron-withdrawing group to activate the imine and to influence 
the selectivity.  They found that treating p-toluenesulfonyl- activated aromatic imines 
with a variety of benzylidenetriphenylphosphoranes yielded Z-alkenes with greater than 
99:1 selectivity and in good yields.  
 
 
Scheme 68: Olefination with N-sulfonyl imine 138 and phosphonium salt 137. 
 
It was therefore expected that a higher Z-selectivity would occur by converting the 3,4,5-
trimethoxybenzaldehyde 17 into the p-toluenesulfonyl-activated aromatic imine 138 
which would then undergo a Wittig-like reaction with the phosphonium salt 137.  The N-
76 
 
sulfonyl imine 138 was prepared by treating benzaldehyde 17 with p-toluenesulfonamide 
and tetraethyl orthosilicate and heating to 120 °C (Scheme 68).  Unfortunately when the 
N-sulfonyl imine 138 was treated with the phosphonium salt 137 under the conditions 
used by Tian and co-workers, low Z-selectivity was observed; instead of the 
expected >99:1 Z-selectivity, a ratio of 44:56 (Z:E) was found. 
 
As the synthetic route would later be repeated using [13C] material, it was important to 
reduce the number of steps that the label is involved in as much as possible.  This could 
be achieved by switching the components of the Wittig reaction, which also might see an 
improvement of the E:Z ratio of the product and allow better separation of the isomers 
(Scheme 69).   
 
 
Scheme 69: Second Wittig strategy for the synthesis of CA1 8. 
 
The aldehyde component, 2,3-bis-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-4-
methoxybenzaldehyde 22 had already been synthesised (Scheme 66).  The phosphonium 
salt for ylide component 139 was synthesised from the commercially available 3,4,5-
trimethoxybenzaldehyde 17 which was first reduced by sodium borohydride to give the 
alcohol 140 in a 97% yield after recrystallisation.  Next the alcohol 140 was brominated 
using phosphorus tribromide which gave the bromide 141 in a 72% yield after 
recrystallisation.  Finally the bromide 141 was treated with triphenylphosphine which 






Scheme 70: Synthesis of phosphonium salt 139 from the commercially available benzaldehyde 17. 
 
Treatment of the phosphonium salt 139 with n-butyllithium at -15 °C formed the ylide in 
situ which was warmed to room temperature then treated with the aldehyde 22 (Scheme 
71).  Analysis of the crude 1H NMR spectrum showed the Z:E ratio of the two isomers 
23 and 24 was 2.9:1.  Pettit and co-workers observed that the Z:E ratio is affected by the 
number of equivalents of nBuLi used: when decreasing the number of equivalents from 
1.5 to 1.0 they observed an increase in the Z:E from 3.5:1 to 9:1.11  However, these results 
could not be reproduced, with the Z:E ratio remaining the same when only 1.0 equivalent 
of n-butyllithium was used, even when the reaction was repeated under argon and using 
molecular sieves.  However, the temperature of the reaction was shown to affect the Z:E 
ratio.  The addition of n-butyllithium to the phosphonium salt 139 at -15 °C then allowing 
the mixture to warm to room temperature for 30 minutes, followed by the addition of the 
aldehyde 22, gave a Z:E ratio of 2.9:1.  But when the in situ generated phosphonium ylide 
was left at -15 °C (rather than being warmed to room temperature) and the temperature 
then lowered to -78 °C before the addition of the aldehyde 22, and then the mixture was 
warmed to 0 °C, this gave an increase in the Z:E ratio to 5.1:1.  The crude material was 
first purified using flash column chromatography to remove the triphenylphosphine oxide 
by-product and gave a clean mixture of the E- and Z-isomers 23 and 24.  The Z- and E-
isomers 23 and 24 were able to be separated by recrystallisation from ethanol, giving the 
Z-isomer in a 58% yield.   
 
 




The Wittig reaction between 3,4,5-trimethoxybenzaldehyde 17 and [[2,3-bis[[(1,1-
dimethylethyl)dimethylsilyl]oxy]-4-methoxyphenyl]methyl]triphenyl phosphonium 
bromide 137 gave predominately the E-alkene whereas the Wittig reaction where the 
components have been reversed, between 2,3-bis[[(1,1-
dimethylethyl)dimethylsilyl]oxy]-4-methoxybenzaldehyde 22 and triphenyl[(3,4,5-
trimethoxyphenyl)methyl]phosphonium bromide 139, predominantly gave the Z alkene 
(Table 12).  Literature shows that the Wittig reaction between the non-substituted 
benzylidenetriphenylphosphorane 142 and non-substituted benzaldehyde 143 shows no 
selectivity giving a 1:1 mixture of the E and Z-isomers.116  This highlights that the 
substitution on both the aryl aldehyde and benzylide can dramatically shift the selectivity.  
 
 
Entry Aldehyde Ylide or 
phosphonium salt 













a Obtained from reference 116 
Table 12: Ratios of Z and E isomers of the Wittig reaction between different semi-stabilised ylides. 
 
The generally accepted mechanism for the Wittig reaction is based on the cycloaddition 
mechanism proposed by Vedejs.117  The Li salt-free Wittig reactions of non-stabilised, 
semi-stabilised and stabilised ylides with carbonyls occur under kinetic control where the 
first step is the irreversible and stereoselective [2+2] cycloaddition between the ylide and 
aldehyde to give an oxaphosphetane intermediate 144 which then undergoes rapid 
irreversible and stereospecific cycloreversion to give an alkene 145 and phosphine oxide 
146 (Scheme 72).  The rate determining step is the oxaphosphetane formation and the E/Z 





Scheme 72: Vedejs' [2+2] cycloaddition mechanism for the Wittig reaction. 
 
Vedejs argued that the reaction of an unstabilised ylide occurs via an early transition state 
which is therefore reactant-like and non-planar (Scheme 73a), whereas the reaction with 
a stabilised ylide occurs through a late-stage transition state which is more planar and 
product-like (Scheme 73b). It is thought that semi-stabilised ylides (e.g. benzylides) react 
similarly to the unstabilised system.  The Wittig reaction in the synthesis towards CA1P 
9 requires Z-selectivity, and in order to enhance Z-selectivity, the transition state leading 
to the Z-oxaphosphetane needs to be stabilised or the transition state leading to the E-
oxaphosphetane should be destabilised. 
 
 
Scheme 73: a) Z-selectivity of unstabilised ylides via an early transition state b) E-selectivity of stabilised 
ylides via a late transition state. 
 
It has been shown that ortho-substitution of benzaldehydes with methoxy or halo groups 
give predominately Z-alkenes.116  Yamataka and co-workers proposed that the selectivity 
was due to the chelating interaction between the ortho-heteroatom and the ylide 
phosphorus atom.  In the initial stage of the Wittig reaction, the aldehyde and ylide are 
likely to form a -complex through a weak interaction between the carbonyl oxygen and 
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the electron deficient phosphorus atom on the ylide.  The stereochemistry of the resulting 
oxaphosphetane depends on the approach going into the transition state, either through 
pathway A or B (Scheme 74a).  When the benzylide and benzaldehyde have no 
substituents (Table 12, Entry 3) the C-P-O-C dihedral angle has relatively free rotation 
and results in a near equal ratio of the two isomers.116  However if there is an o-methoxy 
substituent (or heteroatom) on the benzaldehyde, it is believed the -complex adopts a 
different conformation.  The phosphorus atom forms a hypervalent octahedral structure 
where it accepts electrons from both the carbonyl oxygen and the heteroatom in the ortho-
position of the benzaldehyde (Scheme 74b and c).  In the favoured conformation, the aryl 
group of the ylide is on the same side as the aryl group of benzaldehyde in order to 
minimise the steric repulsion from the equatorial phenyl groups on the phosphorus; this 




Scheme 74: Initial -complex formed in the Wittig reaction when there is a) no ortho effect b) a favoured 
octahedral -complex formed due to the ortho-effect and c) an unfavoured octahedral -complex due to 
steric interactions. 
 
This ortho-effect was also observed by Gilheany and Byrne where they observed that 
having an ortho substituent that bears a lone pair considerably increases the proportion of 
the Z-alkene product.118  They also observed that ortho-substituted benzylides react with 
benzaldehydes with moderate E-selectivity.  No explanation was given for this selectivity 
but it is likely due to a different geometry of the transition state that favours the E-isomer.  
The observations and explanation by both Yamataka and Gilheany, support the E/Z 
selectivity shown during the Wittig reactions for the synthesis of CA1P (Table 12); the 
reaction with the highest Z:E ratio occurred with a benzaldehyde that has a heteroatom in 
the ortho position and when the benzylide component does not contain a substituent in 
the ortho position (Table 12, Entry 2).   
 
E-selectivity of the Wittig reaction can be increased by the introduction of lithium salts 
and is commonly employed in the Schlosser-Wittig modification when using unstabilised 
ylides.119  This lithium salt effect or ‘stereochemical drift’ was first observed by 
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Maryanoff and co-workers,120 and suggests the use of different non-lithium bases could 
also increase the amount of Z-isomer in the product. 
 
The separation of the E- and Z-isomers 23 and 24 was achieved by recrystallisation from 
ethanol.  On a 3.4 mmol scale the Z-isomer 24 was isolated in a 58% yield, however on a 
smaller 0.25 mmol scale only a 31% yield was obtained.  As the latter scale will be used 
when using [13C]-labelled material recovery of the remaining Z-isomer from the E/Z 
mixture was considered important.  Separation of the CA1-TBS isomers 23 and 24 
through flash column chromatography was prevented by their close Rf values.  Therefore 
separation of the two isomers at later stages of the synthesis was looked into.  An E/Z 
mixture of the TBS-protected alkenes 23 and 24 was treated with tetrabutylammonium 
fluoride in THF and gave E- and Z-CA1 144 and 8 (Scheme 75).  Unfortunately, the Rf 
values for these isomers remained too close to separate by flash column chromatography.  
Therefore E-CA1 144 and Z-CA1 8 were benzylated with dibenzyl phosphite, carbon 
tetrachloride, DIPEA and DMAP to give the E- and Z-benzylated isomers 145 and 56.  
However, again these isomers were inseparable by flash column chromatography. 
 
 
Scheme 75: Deprotection and benzylation of E- and Z- isomers 23 and 24. 
 
The isolation of the CA1-TBS E/Z isomers 23 and 24 by flash column 
chromatography was achieved using 10% ethyl acetate: petroleum ether.  This was 
changed to ethyl acetate: toluene as toluene can sometimes improve separation of 
aromatic species.  Unfortunately separation of the E and Z –CA1-TBS alkenes 23 and 
24 was no cleaner, likewise for the E/Z mixture of CA1 144 and 8, or the E/Z mixture 
of benzylated-CA1 145 and 56.  Next, the TLC plates were coated with silver nitrate, 
which is another methodology that can separate non-polar compounds of similar 
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polarities.  Unfortunately the separation for all three sets of E/Z isomers (23/24, 144/8 
and 145/56) was not improved.   
 
Since separating the E/Z isomers effectively was proving difficult, investigations 
began into converting the undesired E-isomer 23 into the desired Z-isomer 24.  
Photochemical isomerisation using UV irradiation is an attractive method for 
converting E-stilbenes to Z-stilbenes and has been used to convert the E-isomer of a 
different combretastatin, CA4, to its Z-isomer.30  The E to Z photochemical 
isomerisation of E-TBS-CA4 20 was observed in ethanol with UV light (254 nm) by 
Pettit and co-workers in a 64% yield after column chromatography (Scheme 76).30  
However when Lupattelli and co-workers tried to replicate these conditions, they 
observed significant quantities of a cyclised by-product phenanthrene 146.121  They 
therefore varied the polarities of the solvents used; in low-polarity solvents (n-hexane 
and benzene) the phenanthrene 146 was observed after 5-11 hours.  In methanol, 15 
mol% of phenanthrene 146 was observed after 4 hours and in other solvents (acetone 
and acetonitrile) phenanthrene 146 was detected after 16 hours (17 mol%).  They also 
looked at the E/Z ratio, and found that this decreased with increasing polarity of the 
solvent; n-hexanes had a E/Z ratio of 40:60, whereas methanol had a E/Z ratio of 11:89.  
They therefore used an intermediate solvent, acetone in their isomerisation of E-TBS-
CA4 20 to the desired Z-isomer 19 (Scheme 76). 
 
 
Scheme 76: E to Z isomerisation of E-TBS-CA4 20 observed by both Pettit and Lupattelli. 
 
Therefore investigations into converting E-CA1-TBS 23 to Z-CA1-TBS 24 using UV 
light began.  An E/Z mixture (55:45) of CA1-TBS 23 and 24 was irradiated with varying 
wavelengths of light/UV radiation, in hexane (Table 13, Entries 1-3).  However, no 
significant change in the Z:E ratio was observed, and no phenanthrene product was 
observed.  For the isomerisation of E-CA4-TBS 23 Lupattelli and co-workers found 
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higher E to Z isomerisation occurred with polar solvents, therefore the solvent in the E-
CA1-TBS 23 system was changed from hexanes to methanol.  Unfortunately, no 
significant increase in the Z:E ratio was observed (Table 13, Entries 4-6).  Iodine is known 
to catalyse the Z to E isomerisation of alkenes, therefore catalytic iodine was added to the 
reaction (Table 13, Entries 7-9).122,123  As it is thought that the iodide-catalysed 
isomerisation occurs through a radical mechanism, it is not surprising that the E-isomer 
was the major product from these reactions.   
 
Entry Wavelength Solvent Additive Z:E ratioa 
1 vis hexane - 45:55 
2 254 nm hexane - 49:51 











6 365 nm methanol - 43:57 














a Z:E ratio of the starting material was 45:55. b 0.2 mol%. 
Table 13: Attempts at isomerisation of E-alkene 23 to Z-alkene 24. 
 
 
Scheme 77: E/Z isomerisation of E-CA1-TBS 23 
 
Photoisomerisation of the E/Z mixture of CA1-TBS 23 and 24 failed to decrease the E/Z 
ratio, however it did reveal a method to access pure E-isomer 23.  Another way to 
isomerise alkenes is to first epoxidise, with retention of stereochemistry, then 
deoxygenate with inversion of stereochemistry, which will lead to overall isomerisation 
(Scheme 78).  The epoxidation is stereospecific, so pure E-alkene will react with retention 
of the alkene configuration and will give pure trans-epoxide.  It is then thought that this 
trans-epoxide can be opened by a nucleophile, such as triphenylphosphine, and this 
happens with inversion of stereochemistry to form the Z-isomer.   
 
 




Pure E-CA1-TBS 23 was first treated with meta-chloroperoxybenzoic acid in 
dichloromethane.  However this returned a complex mixture with multiple products and 
the desired trans-stilbene oxide 148 was not observed in the crude 1H NMR spectrum.  
Therefore another oxidising reagent was tried, dimethyldioxirane 147 (DMDO), which 
was freshly prepared from acetone and Oxone®.  This reagent has the advantage that the 
only by-product is acetone which can be removed by evaporation under reduced pressure.  
But, unfortunately no reaction occurred when E-TBS-CA1 23 was treated with DMDO 
147 in acetone at room temperature for 16 hours.  
 
 
Scheme 79: Attempts at epoxidation of E-CA1-TBS 23 with DMDO 147. 
 
As it was surprising that the epoxidation of E-CA1-TBS 23 did not occur when using 
DMDO 147, the quality of the DMDO 147 was investigated.  Unfortunately DMDO 147 
was synthesised at a low concentration in acetone solution and needed to be kept under 
argon in the freezer, therefore could not be characterised by conventional methods.  
Consequently, the DMDO solution 147 was treated with trans-stilbene 149, a substrate 
that is known to react with DMDO (Scheme 80).124  The reaction proceeded with 100% 
conversion to the trans-stilbene oxide 150 which was isolated in a 98% yield, thus 
confirming the quality of the DMDO solution.  
 
 




It therefore appears that the E-CA1-TBS 23 substrate is incompatible with the DMDO 
conditions.  To confirm this, a competition reaction was undertaken, where a 50:50 
mixture of E-CA1-TBS 23 and trans-stilbene 149 were treated with DMDO 147.  
Analysis of the crude 1H NMR spectrum showed 100% conversion of trans-stilbene 149 
to trans-stilbene oxide 150 and also showed some loss of E-CA1-TBS 23, and the 
appearance of new peaks.  As some E-CA1-TBS 23 had reacted with DMDO, the reaction 
was repeated but this time heated to 50 °C.  The reaction went to completion but 
unfortunately a number of products were observed, similar to those observed for the 
reaction using meta-chloroperoxybenzoic acid (Scheme 79). 
 
As the attempts at converting the unwanted E-CA1-TBS isomer 23 were unsuccessful, 
either through photoisomerisation (Scheme 77, Table 13), or via a trans-epoxide (Scheme 
79), the synthesis continued with the Z-CA1-TBS 24 isolated through recrystallisation 
from the Wittig reaction (Scheme 71).  The Z-isomer 24 was deprotected using 
tetrabutylammonium fluoride in tetrahydrofuran which yielded CA1 8 in a 97% yield 
after flash column chromatography (Scheme 81).   
 
 
Scheme 81: Deprotection of TBS-protected CA1 24 to Combretastatin A1 8. 
 
CA1 8 proved to be unstable over long periods of time, with degradation being observed 
if CA1 8 was left at room temperature, in air for longer than 72 hours.  For both stability 
and pharmacokinetic reasons, CA1 8 needs to be converted into its tetrasodium phosphate 
prodrug CA1P 9.  The prodrug 9 can be synthesised following the route established in the 
US patent by Pettit and Lippert, where CA1 8 is first converted to the tetrabenzyl-
protected phosphate 56, and then debenzylated and converted to the tetrasodium 
phosphate 9.24  During their investigations, Pettit and Lippert also attempted numerous 
debenzylation conditions including; Raney nickel, ferric chloride, 
trimethylphenylthiosilane, chromium trioxide, DDQ, triphenylcarbenium, tin(IV) 
chloride, and lithium hydroxide, all of which resulted in either incomplete benzylation, 
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E/Z isomerisation or reduction of the alkene.  However, they found success with treatment 
with chlorotrimethylsilane and sodium iodide followed by treatment with sodium 
methoxide.  Pettit and Lippert observed that a new bottle of sodium iodide and dilute 
concentrations were needed for the debenzylation step otherwise they experienced nearly 
a 1:1 ratio of Z- and E- isomers, presumably arising from the electrophilic addition of 
iodine to the Z- isomer to form an iodonium ion, and its subsequent elimination to the E-
isomer. 
 
Therefore CA1 8 was first treated with dibenzyl chlorophosphate, which was generated 
in situ from dibenzyl phosphite and carbon tetrachloride, and gave the tetrabenzyl 
protected phosphate 56 in a 60% yield after flash column chromatography (Scheme 82).  
Next, the benzylated phosphate 56 was treated with trimethylsilyl iodide generated in situ 
from chlorotrimethylsilane and sodium iodide.  The subsequent acid was treated with 
sodium methoxide in anhydrous methanol to yield the tetrasodium CA1P 9.  The reaction 
was performed ensuring a dilute concentration to prevent any Z-E isomerisation as 





Scheme 82: Synthesis of CA1P 9 from CA1 8. 
 
Unfortunately the tetrasodium salt 9 was found to be unstable over a short time (24 hours) 
despite the sample being kept at 4 °C and covered in foil to exclude light.  The tetrasodium 
salt 9 also degraded when attempts were made to purify the sample under HPLC 
conditions.  Consequently other salts of CA1P were examined.  Oxigene Inc., the 
company responsible for the clinical development of CA1P, uses the dipotassium salt 151 
in their clinical trials as they observed it to be more stable and therefore was of interest 




The formation of the dipotassium salt 151 has been reported by Brown and co-workers 
during their work on the carbon-14 radiosynthesis of CA1P.126  Like Pettit, they 
debenzylated the tetrabenzyl-protected CA1 8 to the tetra-TMS-phosphate ester but 
instead of quenching with sodium methoxide, Brown used potassium methoxide and 
carefully adjusted the pH.  Therefore the tetrabenzyl phosphate 56 was treated with 
trimethylsilyl bromide in acetonitrile at -10 °C.  This solution was then added dropwise 
to a solution of excess potassium methoxide in methanol at -10 °C and formed the 
tetrapotassium salt 152.  To determine the pH where the dipotassium salt is formed, a pH 
titration curve was generated (Figure 19).  The tetrapotassium salt 152 was dissolved in 
water and 10 mL of 0.1 M HCl acid was added in 0.2 mL increments and the pH measured 




Scheme 83: Synthesis of dipotassium phosphate salt of CA1P 151. 
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The pH was therefore adjusted to pH 7.8, the pH of the second equivalence point, then 
ethanol was added but only a small amount of precipitate was formed.  However when 
the pH was adjusted to pH 4.8, the pH reported in the literature, a greater quantity 
precipitate was formed and was isolated in a 45% yield.  The 1H NMR spectrum of the 
precipitated solid showed the presence desired dipotassium salt 151 but also showed the 
presence of another product which contained aromatic protons.  It was thought this could 
have arisen from the reaction between benzyl bromide (the by-product from the 
debenzylation reaction) and the acetonitrile solvent in a Ritter-like reaction.  Therefore 
the reaction was repeated but the acetonitrile solvent was removed immediately after the 
first step.  This time, the 1H NMR spectrum showed just the desired dipotassium salt 151, 
and was isolated in a 58% yield.  However, when the reaction was repeated on a smaller 
scale to replicate the scale that this will later be carried out on 13C material, the precipitate 
was only formed in a 32% yield.   
 
In order to try and increase the yield of CA1P 151 when synthesised on a small scale, the 
CA1P solution in ethanol was left to precipitate for longer and the temperature reduced 
to -20 °C, but unfortunately this failed to increase the yield.  Furthermore, all the solvent 
was removed and the resulting residue was re-dissolved in the minimum amount of water 
then ethanol was added, but unfortunately the resulting precipitate was formed in the same 
yield as before.  And finally, isopropanol was used as a solvent, but this failed to produce 
any more dipotassium CA1P 151. 
 
Despite a low yield observed for the debenzylation of phosphate 56 to CA1P 151 on a 
small scale at this point, an effective route had been established for the synthesis of CA1P 
151.  Therefore, there was confidence that the route established on 12C material can be 
translated to 13C material for the synthesis of 13C-labelled CA1P [13C]-153. 
 
2.5. Synthesis of [13C]-CA1P 
 
Now that a route for the synthesis of CA1P 151 had been established using unlabelled, 
12C material the synthesis was repeated on 13C-labelled material.  The dipotassium salt 
[13C]-153 can be synthesised from 13C-labelled CA1 [13C]-154.  The route utilised the 
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Scheme 84: Retrosynthesis of 13C-labelled CA1P [13C]-153. 
 
For the first step, the [13C]-labelled Grignard reagent was made by treating commercially 
available [13C]-methyl iodide with magnesium turnings in diethyl ether.  The resulting 
[13C]-methyl magnesium iodide was added to the acid chloride 79 and formed the ketone 
[13C]-80.  The presence of a by-product was also observed in the crude 1H NMR spectrum.  
This by-product was also seen, in smaller amounts, in the 12C-synthesis but by using a 
13C label the identity was deduced to be diester [1 – 13C]-5-dimethylester pentanedioic 
acid [13C]-156.  This deduction was achieved through analysis of the crude 1H NMR 
spectrum where a doublet peak was seen in the methoxy region with a large JC-H value of 
146.8, which is caused by the coupling of the three methyl protons with the 13C label. 
 
 
Scheme 85: Synthesis of [13C]-labelled ketone [13C]-80. 
 
This by-product may have arisen from the hydrolysis of the acid chloride 79 to the acid 
83, followed by methylation from the Grignard reaction or unreacted methyl iodide.  An 
alternative theory is the oxidation of the Grignard reagent to an iodomethoxymagnesium 
species, which can then react with the acid chloride 79 to form the ester [13C]-156.  
Therefore, the reaction was repeated ensuring anhydrous and deoxygenated conditions, 
but the percentage of unwanted by-product remained the same.  However [13C]-methyl-
5-oxohexanoate [13C]-80 was the major product of the reaction and was isolated in a 55% 
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yield after column chromatography.  The lower yield observed when using the [13C]-
labelled material highlights the potential problem of scaling the reaction up; on the 7.4 
mmol scale used for 12C-material the ketone 84 was synthesised in a 69% yield, whereas 
using a 39 mmol scale for the 13C-material gave a 55% yield.   
 
Methyl 5-oxo-[6-13C]-hexanoate [13C]-80 was then cyclised to the [2-13C]-cyclohexane-
1,3-dione [13C]-78 using potassium tert-butoxide and was isolated after column 
chromatography in a 61% yield (Scheme 86).  The diketone [13C]-78 was then aromatised 
and methylated using iodine in methanol which gave the dimethoxybenzene [13C]-157 in 
a 67% yield.  Next, an ortho-formylation reaction occurred on the dimethoxy benzene 
[13C]-157 and this was achieved through selective lithiation with n-butyllithium followed 
by quenching with dimethylformamide.  After purification, the benzaldehyde [13C]-158 
was isolated in an 89% yield. 
 
 
Scheme 86: Synthesis of [13C]-labelled benzaldehyde [13C]-158 from ketone [13C]-80. 
 
The benzaldehyde [13C]-158 then underwent a Baeyer-Villiger oxidation using meta-
chloroperoxybenzoic acid to form a formate ester which was cleaved under basic 
conditions to reveal the dimethoxy phenol [13C]-159 in an 80% yield.  The phenol [13C]-
159 was then methylated using methyl iodide, and after flash column chromatography the 
trimethoxybenzene [13C]-160 was isolated in an 80% yield.  The trimethoxybenzene 
[13C]-160 then underwent an ortho-formylation reaction using titanium tetrachloride and 
dichloromethyl methyl ether, and this gave the benzaldehyde [13C]-161 in a 71% yield.  
 
 




In order to convert the benzaldehyde [13C]-161 into the Wittig-aldehyde component for 
the Wittig reaction, the benzaldehyde [13C]-161 underwent selective double 
demethylation with boron trichloride, which gave the diphenol [13C]-162 in an 84% yield 
(Scheme 88).  The two phenol moieties were then protected as tert-butyldimethylsilyl 




Scheme 88: Synthesis of [13C]-labelled Wittig reagent [13C]-163 from benzaldehyde [13C]-161. 
 
The phosphonium ylide component of the Wittig reaction was derived from the 
phosphonium salt 139, and this was synthesised in three steps from the corresponding, 
commercially available, aldehyde 17 (Scheme 70).  The Wittig reaction between the 
protected aldehyde [13C]-163 and the phosphonium salt 139 occurred forming the E and 
Z-isomers [13C]-164 and [13C]-165 in a 1:4.5 ratio (Scheme 89).  The mixture of E- and 
Z-isomers [13C]-164 and [13C]-165 was purified by flash column chromatography, then 
the Z-isomer [13C]-165 isolated by recrystallisation from ethanol in a 31% yield.   
 
 
Scheme 89: Wittig reaction between aldehyde [13C]-163 and phosphonium salt 139. 
 
The TBS-protected CA1 [13C]-165 was then deprotected using tetra-n-butylammonium 
fluoride which revealed the [13C]-labelled combretastatin A1 [13C]-154 in a 92% yield 
(Scheme 90).  Next, [13C]-CA1 [13C]-154 was converted to its prodrug [13C]-153.  This 
was achieved by first forming the tetrabenzyl protected phosphate [13C]-166 by treatment 
of CA1 [13C]-154 with dibenzyl phosphite and carbon tetrachloride.  After purification 
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Scheme 90: Synthesis of [13C]-labelled dibenzyl phosphate [13C]-166 from (Z)-CA1-TBS [13C]-165. 
 
The final step for the synthesis of [13C]-CA1P [13C]-153 involves the debenzylation of 
the tetrabenzyl phosphate [13C]-166 using bromotrimethylsilane followed by treatment 
with potassium methoxide and partial acidification.  Subsequent addition of ethanol and 
filtration of the precipitate revealed an off-white solid.  The 1H NMR spectrum 
corresponds to the dipotassium salt [13C]-153, however multiple peaks were observed in 
the 31P NMR spectrum.  Initially this was thought to be due to the presence of other 
potassium salts.  However when the sample was re-dissolved in water and the pH 
checked, multiple peaks still remained in the 31P NMR.  
 
 
Scheme 91: Synthesis of [13C]-labelled CA1P [13C]-153. 
 
Another theory is that incomplete benzylation occurred on some of the phosphate [13C]-
166.  However, this was ruled out due to the absence of any benzyl peaks in the 1H NMR 
spectrum.  Therefore it was hypothesised that the bromotrimethylsilane or a degraded 
product thereof could be acting as a nucleophile and attacking the phosphorus centre 
(Scheme 92).  This would account for the lack of benzyl groups in the 1H NMR spectrum 





Scheme 92: Possible nucleophilic attack at the phosphorus centre on tetrabenzyl phosphate [13C]-166. 
 
Therefore the debenzylation step was repeated using a new bottle of bromotrimethylsilane 
which was also freshly distilled over calcium hydride.  Unfortunately, no improvement 
in the yield was observed and multiple peaks were still seen in the 31P NMR spectrum.  
The range of the peaks in the 31P NMR spectrum for CA1P [13C]-153 were -4.18 to -2.36.  
As the peaks assigned in the 31P NMR spectrum for unlabelled CA1P 151 are -3.0 and -
3.7, it is possible that the dipotassium CA1P salt [13C]-153 was formed.  The additional 
peaks could have arisen due to the presence of other potassium CA1P salts or the presence 
of inorganic phosphates.   
 
2.6. Synthesis of [13CD3]-CA1P 
 
Another 13C-labelled CA1 analogue [13CD3]-167 was synthesised involving a shorter 
synthesis.  A methoxy group would be the easiest target as it can be inserted at a later 
stage in the synthesis and will be more economical in regards to the label.  Brown and co-
workers have successfully achieved the radiosynthesis of combretastatin A1 with a 14-
carbon label in the methoxy group in the 6-position of Ring A.126  However this synthesis 
cannot be applied to a hyperpolarised 13C synthesis as the location of the label is thought 
to be too far away from the expected site of metabolism in Ring B.  Therefore the methoxy 
group on Ring B was chosen.  The T1 relaxation time for this position of the unlabelled 
material is 1.6 s (Figure 15, Table 5, Entry 15) and this would only allow for a very small 
imaging window (3 – 5 × T1).  However deuterium enrichment is known to increase the 
T1 times of 
13C substrates dramatically.  This was recently shown by Sando and co-
workers when they used a deuterated 13C methoxy group (13CD3O) in the development of 
hyperpolarised 13C probes.127  The hyperpolarised substrate used was [13C, 2H3]-p-
anisidine (Figure 20b), where the carbon-13 atom in the methoxy group was found to 
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have a T1 value of 44.4 s which is significantly higher than a T1 time of 6.3 s for the 
corresponding carbon atom in the non-deuterated p-anisidine (Figure 20b).   
 
 
Figure 20: a) p-anisidine b) [13C, 2H3]-p-anisidine. 
 
It was therefore envisioned that deuterium enrichment would sufficiently increase the T1 
time of the target CA1P molecule.  The synthesis of [13CD3]-CA1P [13CD3]-167 can 
follow the previously established Wittig route where triphenyl-[(3,4,5-
trimethoxyphenyl)methyl]phosphonium bromide 139 is treated with a TBS-protected 
aldehyde [13CD3]-168.  Unlike the previous synthesis of [13C]-combretastatin [13C]-153 
where the 13C – label was embedded in the aromatic ring of the benzaldehyde, this new 
synthesis targeted the 13C label at the methoxy group in Ring B.  
 
 
Scheme 93: Retrosynthesis of [13CD3]-CA1P [13CD3]-167. 
 
The synthesis of the 13CD3-labelled aldehyde [13CD3]-168 component of the Wittig 
reaction requires insertion of the label using a methylation step with methyl iodide, due 
to [13C, d3]-labelled methyl iodide being the most accessible commercially available 
source of the 13CD3 unit.  This method for synthesising the 
13CD3-labelled aldehyde was 
developed and synthesised by Dr. Ed Cochrane (from the Jones group).  Like the 
development of the route for the synthesis of [13C]-CA1P [13C]-153, the route was first 
established on unlabelled 12C material. His synthesis started with attempts at selective 
methylation of 2,3,4-trihydroxybenzaldehyde 169 to 2,3-dihydroxy-4-methoxy-
benzaldehyde 118 (Scheme 94).  The benzaldehyde 169 was first treated with potassium 
carbonate followed by addition of methyl iodide; unfortunately this resulted in a mixture 
of mono-, di- and tri-methylated products.  Next the potassium carbonate was replaced 
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with sodium hydride, but this again failed to yield the desired mono-methylated species, 
instead primarily giving the di-methylated species.  Pettit and co-workers have shown the 
selective methylation of 2,3,4-trihydroxybenzaldehyde 169 via a 2,3-borate; the 
benzaldehyde 169 was treated with borate to selectively form the 2,3-borate ester which 
allows the specific methylation by dimethylsulfate.  However when these conditions were 
attempted using methyl iodide instead of dimethylsulfate, which was used due to the 
commercial availability of [13C,d3]-methyl iodide, no methylation occurred.  
 
 
Scheme 94: Attempted methylation of 2,3,4-trihydroxybenzaldehyde 169 to 2,3-dihydroxy-4-
methoxybenzaldehyde 118. 
 
Due to the difficult nature of selectively methylating 2,3,4-trihydroxybenzaldehyde 169 
the next approach looked at demethylating the TBS-protected aldehyde 22  (Scheme 95).  
The first demethylating reagent attempted was boron tribromide, which is known to 
cleave aryl methyl ethers.  However, when one equivalent of boron tribromide was treated 
with the TBS-protected aldehyde 22, one of the TBS groups was removed and the 
methoxy group was left intact.  Next, the less reactive boron trichloride was used as the 
demethylating reagent however this again removed one of the TBS protecting groups 
rather than cleaving the methyl ether.  Other demethylating conditions were tried 
including; diphenyl phosphide with n-butyllithium, titanium isopropoxide with tetra-n-
butylammonium bromide, and titanium isopropoxide with boron trichloride; 
unfortunately these all failed to cause demethylation. 
 
 




As both the selective methylation route and the demethylation route were unsuccessful it 
was decided to first do a non-selective tri-methylation on the 2,3,4-
trihydroxybenzaldhyde 169 followed by selective demethylation (Scheme 96).  First 
2,3,4-trihydroxybenzaldehyde 169 was treated with caesium carbonate and [13C,d3]-
methyl iodide in dry acetone which gave the trimethylated-labelled aldehyde [13CD3]-170 
in a 74% yield after flash column chromatography.  Demethylation of the methylated 
aldehyde [13CD3]-170 with boron trichloride selectively removed the methoxide groups 
from the ortho and meta positions in a 96% yield after recrystallisation.  The resulting 
free phenols in aldehyde [13CD3]-171 were protected using tert-butyldimethylsilyl 
chloride with triethylamine and 4-dimethylaminopyridine, after purification by flash 
column chromatography the TBS-protected aldehyde [13CD3]-168 was formed in an 80% 
yield. 
 
Scheme 96: Synthesis of [13CD3]-labelled aldehyde [13CD3]-172. 
 
Now with the 13CD3-labelled aldehyde [13CD3]-168 (which was synthesised by Dr. Ed 
Cochrane) in hand, this aldehyde [13CD3]-168 was then employed in the Wittig strategy 
which was already established for the synthesis for 13C-CA1P [13C]-153.  The aldehyde 
[13CD3]-168 was treated with the ylide formed in situ by the reaction of 3,4,5-
trimethyoxybenzyl phosphonium bromide 139 and n-butyllithium and gave the E and Z 
isomers in a 85% yield after flash column chromatography (Scheme 97).  The E/Z mixture 
was recrystallised with ethanol to reveal pure Z-isomer [13CD3]-172 in a 58% yield.  The 
Z-isomer [13CD3]-172 was then deprotected using tetrabutylammonium fluoride in THF, 
revealing [13CD3]-CA1 [13CD3]-173 in a 98% yield after flash column chromatography.  
[13CD3]-Combretastatin A1 [13CD3]-173 was then treated with dibenzyl chlorophosphate, 
which was generated in situ from dibenzyl phosphite and carbon tetrachloride, and gave 
the tetrabenzyl protected phosphate [13CD3]-174 in a 63% yield after flash column 





Scheme 97: Synthesis of phosphate [13CD3]-174 from protected benzaldehyde 168. 
 
The protected phosphate [13CD3]-174 was then converted to the tetrasodium salt [13CD3]-
167.  Unfortunately over a few days the sample of CA1P [13CD3]-167, which was left in 
the fridge and wrapped in foil to exclude light, decomposed.  The sample also degraded 
when it was put immediately on to a HPLC reverse phase column. 
 
 







A method had been established for the synthesis of [13C]-labelled combretastatin A1P 
[13C]-153.  The method was first carried out using unlabelled 12C-material and then 
applied using 13C starting material.  The site of the 13C-labelled was chosen to be carbon-
13 on Ring B as it has a long T1 time and is on the metabolically active ring.  A route was 
then developed for the synthesis of a 1,2,3-trioxygenated species with the regioselective 
placement of the 13C label (Scheme 102).  This was achieved by developing the work 
initially done by Botting and co-workers.84  The addition of a methylcuprate to the acid 
chloride 79, resulted in a ketone 84 which was then cyclised and aromatised.  To insert 
an oxygen on to the 2-position of 2,6-dimethoxybenzene 87 a formylation first occurred, 
which underwent a Baeyer-Villiger oxidation to reveal a 1,2,3-trioxygenation species 
with the correct placement of the 13C label.   
 
 
Scheme 99: The two Sonogashira strategies for the synthesis of CA1P 9. 
 
There have been a number of syntheses in the literature of combretastatins. The selective 
reduction of a diarylalkyne, synthesised via a Sonogashira reaction, was initially chosen 
as it was believed to be the most economic route with a high Z-selectivity.  One of the 
components of the Sonogashira reaction needed to be derived from the 1,2,3-
trioxygenated aromatic species which will contain the 13C label.  Unfortunately the 
synthesis of the iodoarene 93 for the Sonogashira reaction proved problematic (Scheme 
100).  Since the iodoarene 93 was unable to be isolated, the Sonogashira reaction between 
other iodoarenes was investigated.  The Sonogashira reactions using iodoarenes 101 and 
110 resulted in unexpected benzofuran formation and deprotection respectively.  
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However the Sonogashira reaction using iodoarene 104 which formed diarylalkyne 113 
was successful but unfortunately the subsequent deprotection was non-selective.  
 
 
Scheme 100: Attempts at synthesising iodoarene 93 from benzaldehyde 88. 
 
As this route (Scheme 99a) proved not to be viable, the components of the Sonogashira 
were reversed so that the alkyne was located on ring B, which contains the site for the 13C 
label.  The Sonogashira reaction was successful when using a methylene acetal protecting 
group of the 1,2-diol.  Unfortunately initial attempts at the selective reduction of the 
resulting diarylalkyne 129 using H-cube® conditions was low-yielding as well as over-
reduction being observed.  Also attempts at the methylene acetal deprotection were 
unsuccessful.  Excluding these last two steps (selective reduction and deprotection) this 
Sonogashira route (Scheme 99b) already involved 12 steps with an overall yield of 1.9%.  
As the subsequent two steps showed initial difficulties, a different strategy was 
investigated (Scheme 101). 
 
 
Scheme 101: The two Wittig strategies for the synthesis of CA1P 9 
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Two different Wittig routes were successfully employed for the synthesis of CA1P 9 
(Scheme 101).  The first has the site of the 13C label on the phosphonium ylide component 
of the reaction whereas the second had it on the aldehyde component.  The E/Z selectivity 
of the two Wittig reactions differed dramatically; one being E-selective and the other 
being Z-selective.  Therefore the second Wittig reaction was the chosen route.  Even 
though the E:Z ratio was in favour of the desired Z-isomer 24, separating the isomers was 
problematic on a small scale.  Attempts were made to separate them through different 
chromatographic and recrystallisation techniques but on a small scale the Z-isomer was 
isolated in only a 31% yield.  Attempts were also made to convert the unwanted E-isomer 
23 into the Z-isomer 24 through photoisomerisation or via a trans-oxide 148 but this again 
was fruitless.  Nevertheless, the route continued and the Z-isomer 24 was deprotected to 
reveal CA1 8.  Attempts were made to convert CA1 8 to CA1P 9, unfortunately the 
tetrasodium salt 9 was found to be unstable, degrading over a short period of time and 
unable to be purified by HPLC.  Therefore the CA1 8 was converted to the dipotassium 
CA1P salt 151.  
 
 





With a route for the synthesis of CA1P 151 in hand using 12C material, the synthesis was 
repeated using 13C starting material.  The yields for the 13C route broadly matched that of 
the 12C route apart that of the Wittig reaction.  This was due to different scales of the 
reactions, the 13C route was performed on a smaller scale, hence the difficulties in the 
recrystallisation step.  Also due to the small scale of the final debenzylation step, the 
[13C]-CA1P [13C]-153 was unable to be isolated cleanly. 
 
Future work includes the isolation then hyperpolarisation of [13C]-CA1P [13C]-153 
(Figure 21).  This can be achieved using a HyperSense™ DNP polariser.  After finding 
the optimal conditions for maximum polarisation, the hyperpolarised sample can be 
transferred to an NMR spectrometer using the dissolution process.  An enhanced 13C 
signal is expected to be seen when compared with a non-hyperpolarised sample. 
 
 
Figure 21: Future hyperpolarisation and MR experiments on [13C]-CA1P [13C]-153. 
 
This can be taken on to in vitro or in vivo studies (Figure 21).  Hopefully, not only will a 
hyperpolarised signal of [13C]-CA1P [13C]-153 be observed but also that of its metabolites 
particularly the ortho-quinone [13C]-175.  The concentration and location of these 
reactive metabolites can be determined giving valuable information on the metabolism 
and reactivity of CA1 8.   
 
 




Chapter 4: Experimental 
4.1. General 
 
All reactions were performed under nitrogen at room temperature unless otherwise stated, 
using glassware, flame-dried under vacuum, with magnetic stirring and if required heated 
using Dry Syn® blocks.  All reagents were obtained from commercial suppliers and were 
used without further purification unless otherwise stated.  4Å Molecular sieves were 
activated by flame-drying under vacuum.  Reactions that were performed at 0 °C used 
water/ice baths, -78 °C used acetone/dry ice bath, -10 °C used salt/ice/water bath and -20 
°C used acetone/dry ice bath. 
 
Tetrahydrofuran, dichloromethane, acetonitrile, dimethylformamide and diethyl ether 
solvents used in reactions were obtained from the departmental Grubbs solvent system 
and stored under a positive pressure of nitrogen.  All other solvents were obtained from 
commercial suppliers and used without prior drying unless otherwise stated.  
Commercially available Grignard reagents were titrated against a standard solution of (-
)-menthol using phenanthroline as an indicator.  n-Butyllithium was titrated before use 
against a standard solution of benzophenone tosylhydrazone. 
 
Analytical thin layer chromatography (TLC) was carried out utilising aluminium backed 
Merck TLC plates (silica gel 60 F254) and visualised with UV light (254 nm) followed 
by either a potassium permanganate, phosphomolybdic acid or dinitrophenylhydrazine 
dip then exposed to heat.  AgNO3-coated TLC plates were made by dipping TLC plates 
in aqueous AgNO3 solution (12.5% w/v), wrapping in aluminium foil and put in the oven 
(120 °C) for 2 hours.  Flash column chromatography was performed using Flurochem 
Limited Silica Gel 40 – 60 60Å as the stationary phase.  The eluent for each purification 
is noted within the individual experimental procedures. 
 
All 1H, 13C and 31P spectra were obtained using either a Bruker AC 250 or AC 400 
spectrometer.  13C NMR spectra were recorded using the JMOD method.  The NMR 
solvent used is noted within the individual experimental procedures.  Chemical shifts are 




High resolution mass spectrometry was performed by the University of Sheffield Mass 
Spec department on either a MicroMass LCT spectrometer operating in electrospray 
mode or a MicroMass Prospec system operating in electron impact mode.  Infrared 
spectra were recorded on a Perkin-Elmer 1600 FT-IR using a Universal diamond ATR 
top-plate.  Melting points were measuring on a Gallenkamp melting point apparatus and 
are uncorrected.  Elemental analysis was performed on a Perkin-Elmer 2400 CHNS/O 
Series II apparatus.  The pH was measured using pH indicator paper except for the 
synthesis of CA1P 151 or [13C]-153 were a pH meter was used which had previously 
been calibrated with calibration buffers.  UV radiation was achieved through exposure of 
sample to a UV lamp used for visualising TLC plates equipped with both short-wave (254 
nm) and long-wave (366 nm) lamps.  H-cube® reactions were conducted using a 
ThalesNano H-cube® continuous-flow hydrogenation reactor with a pre-packed CatCart® 





4.2 Synthesis towards [12C]-CA1P 
 




Glutaric anhydride (20.0 g, 175 mmol) and methanol (7.1 mL, 175 mmol) was added to 
chloroform (200 mL) and heated at reflux for 5 hours.  The solvent was removed under 
reduced pressure affording the title compound 83 (25.6 g, 100%) as a colourless oil which 
was used without further purification; 1H NMR (400 MHz, CDCl3) δ 1.99 (pent., 2H, J 
7.3, CH2CH2CH2), 2.43 (t, 2H, J 7.3, COCH2), 2.47 (t, 2H, J 7.3, COCH2), 3.68 (s, 3H, 
OCH3); 
13C NMR (101 MHz, CDCl3) δ 19.8 (CH2), 32.9 (2 × CH2), 51.7 (OCH3), 173.3 









Thionyl chloride (25.6 mL, 350 mmol) was added dropwise to neat pentandioic acid 
monomethyl ester 83 (25.6 g, 175 mmol) and left for 10 minutes.  Purification by 
distillation at atmospheric pressure (110 °C) gave the title compound 79 (25.3 g, 88%) as 
a colourless oil;  1H NMR (400 MHz, CDCl3) δ 2.02 (pent, 2H, J 7.2, CH2CH2CH2), 2.41 
(t, 2H, J 7.1, CH2CO2CH3), 3.01 (t, 2H, J 7.1, CH2COCl), 3.69 (s, 3H, OCH3); 
13C NMR 
(101 MHz, CDCl3) δ 20.2 (CH2), 32.1 (CH2), 46.0 (CH2), 51.8 (OCH3), 172.8 (C=O), 









Magnesium turnings (0.18 g, 7.40 mmol) were dry stirred for 5 min and diethyl ether (8 
mL) was then added.  Methyl iodide (0.44 mL, 7.05 mmol) was added drop-wise to the 
reaction mixture at a rate to induce heating at a steady reflux.  The resulting methyl 
magnesium iodide was added dropwise to a solution of freshly recrystallised copper 
bromide dimethyl sulphide complex (1.52 g, 7.40 mmol) in diethyl ether (12 mL) at -10 
°C and left for 30 minutes. The resulting solution was added dropwise to a solution of 
glutaric acid monomethyl ester chloride 79 (0.97 mL, 7.0 mmol) in diethyl ether (12 mL) 
and the reaction mixture and left stirring overnight.  The reaction was quenched with a 
saturated solution of ammonium chloride (20 mL).  The precipitate was filtered under 
suction and the filtrate was extracted with diethyl ether (3 × 15 mL).  The combined 
organic layers were washed with brine (50 mL) and dried over magnesium sulfate.  After 
filtration and removal of the solvent under reduced pressure, the crude material was 
purified by flash column chromatography on silica gel using an eluent of 20% ethyl 
acetate: 40 – 60 °C petroleum ether to afford the title compound 84 as pale yellow oil 
(0.696 g, 69%); 1H NMR (400 MHz, CDCl3) δ 1.89 (pent, 2H, J 7.2, CH2CH2CH2), 2.14 
(s, 3H, CH3), 2.35 (t, 2H, J 7.2, CH2), 2.51 (t, 2H, J 7.2, CH2), 3.67 (s, 3H, OCH3); 
13C 
NMR (101 MHz, CDCl3) δ 18.8 (CH2), 29.9 (CH3), 33.0 (CH2), 42.5 (CH2), 51.6 (OCH3), 










Potassium tert-butoxide (1.40 g, 12.5 mmol) was dissolved in tetrahydrofuran (15 mL) to 
which methyl 5-oxohexanoate 84 (0.36 g, 2.5 mmol) was added.  The reaction was heated 
at reflux for 7 hours.  The organic solvents were removed under reduced pressure and the 
residue was dissolved in water (15 mL) and acidified to pH 1 with concentrated 
hydrochloric acid.  The aqueous layer was extracted with ethyl acetate (10 × 15 mL) and 
the combined organic layers dried over magnesium sulfate.  After filtration the solvent 
was removed under reduced pressure and yielded the crude product which was purified 
by flash column chromatography on silica gel using an eluent of 100% ethyl acetate 
giving the title compound 75 (0.967 g, 68%) as a yellow solid; mp 106 – 108 °C; 1H NMR 
(400 MHz, CDCl3) δ 1.97 [pent, 2H, J 6.4, CH2 (keto) and CH2 (enol)], 2.38 [t, 2.5H, J 
6.4, 2 × CH2 (keto) and CH2 (enol)], 2.59 [t, 1.5H, J 6.4, CH2 (enol)], 3.41 [s, 0.5H, CH2 
(keto)], 5.48 [s, 0.75H, =CH (enol)], 10.51 [s, 0.75H, OH (enol)]; 13C NMR (101 MHz, 
CDCl3) δ 18.2 [CH2 (keto)], 21.0 [CH2 (enol)], 32.3 [CH2 (enol)], 39.8 [CH2 (enol) and 2 
× CH2 (keto)], 58.4 [CH2 (keto)], 104.2 [=CH (enol)], 192.8 [C=O and C-O (enol)], 204.4 










1,3-Cyclohexandione 75 (5.00  g, 44.6  mmol) was dissolved in methanol (100 mL).  
Iodine (22.6 g, 89.2 mmol) was added and the reaction mixture was heated at reflux for 
1.5 hours.  The methanol was removed under reduced pressure and the residue dissolved 
in dichloromethane (60 mL).  The organic layer was washed with sodium hydrogen 
carbonate (20 mL), 10% aq. sodium thiosulfate (20 mL) and 5% sodium hydroxide (20 
mL).  The combined aqueous layers were then extracted with dichloromethane (3 × 30 
mL) and the resulting combined organic layers were dried over magnesium sulfate, 
filtered and the solvent was removed under reduced pressure.  Purification of the crude 
material by flash column chromatography using an eluent of 5% ethyl acetate: 40 – 60 °C 
petroleum ether afforded the title compound 87 as a colourless oil (4.88 g, 79%); 1H NMR 
(400 MHz, CDCl3) δ 3.80 (s, 6H, 2 × OCH3), 6.48 (t, 1H, J 2.4, ArH), 6.52 (dd, 2H, J 8.2, 
2.4, 2 × ArH), 7.19 (t, J 8.2, ArH); 13C NMR (101 MHz, CDCl3) δ 55.3 (2 × OCH3), 100.5 
(ArCH), 106.2 (2 × ArCH), 129.9 (ArCH), 160.9 (2 × ArC).  NMR data in accordance 









1,3-Dimethoxybenzene 87 (4.94 g, 35.7 mmol) and N,N,N`,N`- tetramethylethylene 
diamine (6.0 mL, 40.3 mmol) was dissolved in tetrahydrofuran (60 mL).  The reaction 
mixture was cooled to 0 °C and n-butyllithium (21 mL, 2.0 M in hexanes, 42.8 mmol) 
was added and the reaction left stirring for 30 minutes.  Dimethylformamide (4.1 mL, 
53.5 mmol) was added dropwise and the solution stirred for a further 1 hour.  The reaction 
was quenched with hydrochloric acid (1 M, 40 mL) whilst maintaining the temperature 
below 25 °C.  The organic solvent was removed under reduced pressure.  The aqueous 
layer was then extracted with diethyl ether (3 × 20 mL) and the combined organic layers 
were washed with brine (40 mL), dried over magnesium sulfate, filtered and the solvent 
removed under reduced pressure.  The crude material was purified by flash column 
chromatography on silica using an eluent of 20% ethyl acetate:  40 – 60 °C petroleum 
ether to afford the title compound 88 (4.34 g, 73%) as a white solid; mp 95 – 98 °C (lit.132 
96 – 98 °C); 1H NMR (400 MHz, CDCl3) δ 3.89 (s, 6H, 2 × OCH3), 6.57 (d, J 8.4, 2H, 2 
× ArH), 7.44 (t, J 8.4, 1H, ArH), 10.50 (s, 1H, CHO); 13C NMR (101 MHz, CDCl3) δ 
56.1 (2 × OCH3), 103.9 (2 × ArCH), 114.3 (ArC), 135.9 (ArCH), 162.2 (2 × ArC), 189.5 









2,6-Dimethoxy-benzaldehyde 88 (0.250 g, 1.50 mmol) was dissolved in dichloromethane 
(5 mL) and cooled to 0 °C.  meta-Chloroperbenzoic acid (≤77%, 0.674 g, 3.00 mmol) was 
added dropwise as a dichloromethane solution (3 mL) and the reaction was left at 0 °C 
for 3 hours.  The organic layer was washed with sodium sulfite solution (5 ml) then 
sodium hydrogen carbonate (5 mL).  The combined aqueous layers were extracted with 
dichloromethane (3 × 10 mL) then the combined organic layers were washed with brine 
(20 mL), dried over magnesium sulfate, filtered, and the solvent removed under reduced 
pressure.  The resulting formate ester was dissolved in methanol (5 mL) and cooled to 0 
°C.  Potassium hydroxide (0.295 g, 5.23 mmol) in methanol (10 mL) was added dropwise 
and the reaction left for 45 minutes.  Water (10 mL) was added and the solution was 
acidified to pH 2 using concentrated hydrochloric acid.  The aqueous layer was extracted 
with diethyl ether (6 ×10 mL) and the combined organic layers were washed with brine, 
dried over magnesium sulfate, filtered and the solvent removed under reduced pressure.  
The crude reaction material was purified by flash column chromatography using an eluent 
of 20% ethyl acetate: 40 – 60 °C petroleum ether and afforded the title compound 89 as 
a white solid (0.135 g, 58%); mp 52 – 53 °C (lit.134 52 – 56 °C); 1H NMR (400 MHz, 
CDCl3) δ 3.89 (s, 6H, 2 × OCH3), 5.52 (s, 1H OH), 6.59 (d, J 8.4, 2H, 2 × ArH), 6.80 – 
6.83 (m, 1H, ArH); 13C NMR (101 MHz, CDCl3) δ 56.3 (2 × OCH3), 104.9 (2 × ArCH), 










Carbon tetrabromide (2.54 g, 7.65 mmol) was dissolved in dichloromethane (20 mL) and 
cooled to 0 °C.  Triphenylphosphine (4.01 g, 15.3 mmol) was added at 0 °C and the 
reaction was stirred for 15 minutes.  3,4,5-Trimethoxybenzaldehyde (1.00 g, 5.10 mmol) 
was dissolved in dichloromethane (6 mL) and added dropwise to the reaction vessel.  The 
reaction was stirred at 0 °C for 5 minutes, then the solvent was removed under reduced 
pressure to yield a brown oil.  Purification of the crude material by flash column 
chromatography on silica gel using an eluent of 15% ethyl acetate: 40 – 60 ºC petroleum 
ether afforded the title compound 92 as a pale yellow oil (1.71 g, 95%).  1H NMR (400 
MHz; CDCl3)  3.86 (s, 6H, 2 × OCH3), 3.87 (s, 3H, OCH3), 6.80 (s, 2H, 2 × ArH), 7.41 
(s, 1 H, CH); 13C NMR (101 MHz, CDCl3)  56.2 (2 × OCH3), 60.9 (OCH3), 88.8 (Br2C=), 
105.8 (2 × ArCH), 130.6 (ArC), 136.6 (=CH), 138.3 (ArCOCH3), 153.0 (2 × ArCOCH3); 
1H NMR data in accordance with the literature apart from peaks at 3.86 and 3.87 were 









1,1-Dibromo-2-(3,4,5-trimethoxyphenyl)-ethylene 92 (1.25 g, 3.54 mmol) was dissolved 
in tetrahydrofuran (25 mL) and cooled to -78 °C.  n-Butyllithium (6.5 mL, 1.9 M in 
hexanes, 12.4 mmol) was added dropwise to the reaction mixture and left stirring at -78 
ºC for 30 minutes.  Ammonium chloride (25 mL) was added to the reaction mixture and 
warmed to room temperature.  The organic layer was removed under reduced pressure 
and the aqueous layer was extracted with ethyl acetate (3 × 20 mL).  The combined 
organic layers were washed with brine (50 mL), dried over magnesium sulfate, filtered 
and the solvent removed under reduced pressure.  Purification of the crude material by 
flash column chromatography on silica gel using an eluent of 10% ethyl acetate: 40 – 60 
ºC petroleum ether afforded the title compound 36 as a white crystalline solid (0.551 g, 
81%); mp 56 – 59 °C; 1H NMR (400 MHz, CDCl3) δ 3.03 (s, 1H, ≡CH), 3.85 (s, 9H, 3 × 
OCH3), 6.73 (s, 2H, 2 × ArH); 
13C NMR (101 MHz, CDCl3) δ  56.2 (2 × OCH3), 61.0 
(OCH3), 76.2 (C≡CH), 83.7 (ArC), 103.3 (C≡CH), 109.4 (2 × ArCH), 117.0 (2 × ArC), 
153.1 (ArC).  NMR data in accordance with the literature apart from in the 1H spectrum 
where only one singlet (9H) was observed at 3.85 whereas two singlets at 3.83 (6H) and 
3.84 (3H) and were reported.  Also in the 13C spectrum, only one singlet was observed at 
56.2 whereas two singlets were reported at 56.1 and 56.2.  In the literature the 1H and 13C 









2,6-Dimethoxybenzaldehyde 88 (4.34 g, 26.1 mmol) was dissolved in dichloromethane 
(50 mL).  Boron trichloride (26 mL, 1 M, 26.1 mmol) was added dropwise to the reaction 
mixture.  The reaction was left stirring at room temperature for 18 hours which was then 
quenched with the dropwise addition of sat. sodium bicarbonate solution (50 mL) at 0 °C.  
The mixture was then acidified to pH 2 concentrated hydrochloric acid.  The aqueous 
layer was separated and extracted with dichloromethane (3 × 40 mL).  The combined 
organic layers were washed with brine (100 mL), dried over magnesium sulphate, filtered 
and the solvent removed under reduced pressure.  The crude material was purified by 
flash column chromatography on silica gel using an eluent of 5% ethyl acetate: 40 – 60 
°C petroleum ether and afforded the title compound 95 as colourless crystals (3.09 g, 
78%); mp 75 – 76 °C (lit.137 73.5 – 74.5 °C); 1H NMR (400 MHz, CDCl3) δ 3.90 (s, 3H, 
OCH3), 6.37 (d, 1H, J 8.4, ArH), 6.52 (d, 1H, J 8.4, ArH), 7.41 (t, 1H, J 8.4, ArH), 10.34 
(s, 1H, HC=O), 11.98 (s, 1H, OH); 13C NMR (101 MHz, CDCl3) δ  55.8 (OCH3), 101.0 
(ArCH), 109.9 (ArCH), 110.8 (ArC), 138.4 (ArCH), 162.2 (ArC), 163.7 (ArC), 194.4 
(HC=O);  NMR data was in accordance with the literature apart from in the 1H NMR 










2-Hydroxy-6-methoxybenzaldehyde 95 (3.09 g, 20.3 mmol) was dissolved in methanol 
(50 mL).  Hydrogen peroxide (2.7 mL, 30%, 26.4 mmol) was added dropwise followed 
by a few drops of conc. sulfuric acid.  The reaction mixture was stirred at room 
temperature for 18 hours then quenched with 1M sodium hydroxide (30 mL).  The 
mixture was acidified to pH 2 with concentrated  hydrochloric acid and the aqueous layer 
separated then extracted with ethyl acetate (10 × 20 mL).  The combined organic layers 
were washed with brine (50 mL), dried over magnesium sulfate, filtered then the solvent 
removed under reduced pressure.  The crude sample was purified by flash column 
chromatography on silica gel using an eluent of 25% ethyl acetate: 40 – 60 °C petroleum 
ether to afford the title compound 94 (2.59 g, 75%) as a colourless oil. 1H NMR (400 
MHz, CDCl3) δ 3.87 (s, 3H, OCH3), 5.68 (s, 1H, OH), 5.71 (s, 1H, OH), 6.49 (dd, 1H, J 
8.3, 1.2, ArH), 6.63 (dd, 1H, J 8.3, 1.2, ArH), 6.77 (t, 1H, J 8.3, ArH); 13C NMR (101 
MHz, CDCl3) δ 56.2 (OCH3), 103.3 (ArCH), 109.0 (ArCH), 119.9 (ArCH), 132.6 (ArC), 
144.1 (ArC), 147.2 (ArC); 1H NMR data in accordance with the literature apart from the 
aromatic region was reported as multiplet at 6.77 – 6.49 ppm (m, 3H) and the phenols 









Sodium hydride (0.180 g, 4.50 mmol, 60% dispersed in mineral oil) was suspended in 
tetrahydrofuran (10 mL) and cooled to 0 °C.  3-Methoxy-1,2-benzenediol 94 (0.420g, 
3.00 mmol) was added dropwise (in 2 mL tetrahydrofuran) and the reaction stirred at 0 
°C for 15 minutes, warmed to room temperature and left stirring for 30 minutes.  The 
reaction was then cooled to 0 °C and chloromethyl methyl ether (0.41 mL, 5.39 mmol) 
was added dropwise and the reaction stirred for 3 hours.  The reaction mixture was 
washed saturated ammonium chloride solution (3 × 10 mL) and the combined aqueous 
layers extracted with ethyl acetate (3 × 10 mL).  The combined organic layers were 
washed with brine (30 mL), dried over magnesium sulfate, filtered and the solvent 
removed under reduced pressure.  The crude reaction material was purified by flash 
column chromatography on silica with an eluent of 10% ethyl acetate: 40 – 60 °C 
petroleum ether to afford the title compound 96 (0.424 g, 62%) as a white solid; mp 29 – 
30 °C; max (ATR)/ cm
-1 2904 (C-H), 1599 (aromatic); Found: C, 57.89; H 7.06; C11H16O5 
requires C, 57.89; H, 7.07; 1H NMR (400 MHz, CDCl3) δ  3.50 (s, 3H, OCH3), 3.62 (s, 
3H, OCH3), 3.85 (s, 3H, OCH3), 5.14 (s, 2H, CH2), 5.20 (s, 2H, CH2), 6.63 (dd, J 8.4, 1.2, 
1H, ArH), 6.79 (dd, J 8.4, 1.2, 1H, ArH), 6.99 (t, J 8.4, 1H, ArH); 13C NMR (101 MHz, 
CDCl3) δ 56.0 (OCH3), 56.2 (OCH3), 57.1 (OCH3), 95.3 (CH2), 98.4 (CH2), 106.3 
(ArCH), 109.3 (ArCH), 124.1 (ArCH), 135.6 (ArC), 151.1 (ArC), 153.6 (ArC); m/z (ESI) 
246 (38%, M+H2O), 229.1073 (59, MH











3-Methoxy-1,2-benzenediol 94 (0.250 g, 1.78 mmol) was dissolved in 
dimethylformamide (4 mL) under nitrogen.  Caesium fluoride (0.813 g, 5.35 mmol) was 
added followed by dibromomethane (0.13 mL, 1.78 mmol) and the reaction mixture 
heated to 120 – 130 °C with stirring and left for 6 hours.  Water (10 mL) was added and 
the aqueous layer extracted with diethyl ether (3 × 10 mL).  The combined organic layers 
were washed with water (20 mL), sodium hydroxide (1M, 20 mL) and brine (20 mL), 
then dried over magnesium sulfate and filtered.  The solvent was removed under reduced 
pressure and afforded the title compound 100 (0.209 g, 77%) as a yellow solid which was 
used without further purification; mp 41 – 42 °C (lit.141 39 – 41 °C); 1H NMR (400 MHz, 
CDCl3) δ 3.89 (s, 3H, OCH3), 5.94 (s, 2H, OCH2O), 6.51 – 6.53 (m, 2H, 2 × ArH), 6.77 
(t, J 8.2, 1H, ArH); 13C NMR (101 MHz, CDCl3) δ 56.5 (OCH3), 101.2 (CH2), 102.4 
(ArCH), 107.5 (ArCH), 122.1 (ArCH), 135.2 (ArC), 144.1 (ArC), 148.8 (ArC).  1H NMR 
data in accordance with the literature apart from the triplet at 6.77 was reported in the 









2,6-Dimethoxybenzaldehyde 88 (3.11 g, 18.7 mmol) was dissolved in acetonitrile (60 
mL).  Indium(III) trifluoromethanesulfonate (2.11 g, 3.74 mmol) and N-iodosuccinimide 
(9.29 g, 41.2 mmol) were added to the reaction mixture and left stirring at room 
temperature for 18 hours.  Water (60 mL) was added and the aqueous layer separated then 
extracted with ethyl acetate (3 × 40 mL).  The combined organic layers were washed with 
brine (80 mL), dried over magnesium sulfate, filtered and the solvent removed under 
reduced pressure.  The crude compound was purified by flash column chromatography 
on silica gel using an eluent of 10% ethyl acetate: 40 – 60 °C petroleum ether affording 
the title compound 104 (2.79 g, 51%) as a light orange solid; mp 45 – 47 °C; max 
(ATR)/cm-1 1682 (HC=O), 1461 (aromatic); Found: C, 37.31; H 3.15; C9H9IO3 requires 
C, 37.01; H, 3.11; 1H NMR (400 MHz, CDCl3) δ 3.87 (s, 3H, OCH3), 3.91 (s, 3H, OCH3), 
6.61 (d, 1H, J 8.9 ArH), 7.89 (d, 1H, J 8.9, ArH), 10.36 (s, 1H, CHO); 13C NMR (101 
MHz, CDCl3) δ 56.4 (OCH3), 63.0 (OCH3), 82.5 (ArCI), 109.9 (ArCH), 120.0 
(ArCCHO), 144.6 (ArCH), 161.5 (ArCO), 162.5 (ArCO), 188.6 (HC=O); m/z (ES+) 









3-Iodo-2,6-dimethoxybenzaldehyde 104 (0.50 g, 1.71 mmol) was dissolved in 
dichloromethane (25 mL) at room temperature.  Boron trichloride (1.70 mL, 1M, 1.71 
mmol) was added dropwise to the reaction mixture and left stirring for 12 hours.  The 
solution was acidified to pH 2 with concentrated hydrochloric acid.  Water (25 mL) was 
added and the aqueous layer was extracted with dichloromethane (3 × 20 mL).  The 
combined organic layers were washed with brine (60 mL), dried over magnesium sulfate, 
filtered and the solvent removed under reduced pressure to afford the crude product.  
Purification by flash column chromatography on silica gel using an eluent of 5% ethyl 
acetate: 40 – 60 ºC petroleum ether afforded the title compound 101 (0.094 g, 18%) as a 
yellow solid; mp 115 – 118 °C; max (ATR)/ cm
-1 3208 (OH), 2989 (C-H), 1650 (HC=O), 
1602 (aromatics), 1560 (aromatics), 1276 (C-OH); Found: C, 34.52; H 2.30; C8H7O3 
requires C, 34.56; H, 2.54; 1H NMR (400 MHz, CDCl3) δ 3.89 (s, 3H, OCH3), 6.27 (d, 
1H, J 8.8, ArH ), 7.82 (d, 1H, J  8.8, ArH), 10.18 (s, 1H, HC=O), 12.80 (s, 1H, ArOH); 
13C NMR (101 MHz, CDCl3) δ 56.1 (OCH3), 74.2 (ArCI), 103.8 (ArCH), 110.94 
(ArCCHO), 146.9 (ArCH), 162.0 (ArCO), 162.8 (ArCO), 193.7 (HC=O); m/z (ES-) 









Copper iodide (3.4 mg, 0.018 mmol) and tetrakis(triphenylphosphine)palladium(0) (83.1 
mg, 0.071 mmol) were dissolve in piperidine (2 mL).  3-Iodo-2-hydroxy-6-
methoxybenzaldehyde 101 (100 mg, 0.36 mmol) was added followed by the dropwise 
addition of 5-ethynyl-1,2,3-trimethoxybenzene 36 (69 mg, 0.36 mmol, in 0.5 mL 
piperidine).  The reaction was left stirred for 16 hours then saturated ammonium chloride 
solution (5 mL) was added.  The solution was acidified to pH 2 with concentrated 
hydrochloric acid.  The aqueous layer was extracted with diethyl ether (3 × 10 mL).  The 
combined organic layers were washed with brine (20 mL), dried over magnesium sulfate, 
filtered and the solvent removed under reduced pressure.  The crude material was purified 
by flash column chromatography on silica with an eluent of 30% ethyl acetate: 40 – 60 
°C petroleum ether to afford the title compound 109 (55 mg, 45%) as a light yellow solid; 
max (ATR)/ cm
-1 2517 [H-C(O)], 1571 (HC=O), 1502 (aromatic); 1H NMR (400 MHz, 
CDCl3) δ 3.92 (s, 3H, OCH3), 3.99 (s, 6H, 2 × OCH3), 4.02 (s, 3H, OCH3), 6.91 (s, 1H, 
HC=C-O), 6.95 (d, J 8.7, 1H, ArH), 7.13 (s, 2H, 2 × ArH), 7.73 (d, J 8.7, 1H, ArH ), 
10.71 (s, 1H, HC=O); 13C NMR (101 MHz, CDCl3) δ 56.3 (2 × OCH3), 56.7 (OCH3), 
61.0 (OCH3), 99.8 (ArCH), 102.2 (2 × ArCH), 107.6 (ArCH), 111.1 (ArC), 124.2 (ArC), 
125.5 (ArC), 127.4 (ArCH), 138.8 (ArC), 153.6 (ArC), 153.7 (ArC), 156.8 (ArC), 160.1 










Copper iodide (5 mg, 0.026 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.120 
g, 0.10 mmol) were dissolved in piperidine (1 mL) and acetonitrile (1 mL).  3-Iodo-2,6-
dimethoxybenzaldehyde 104 (0.145 g, 0.52 mmol) was added followed by the dropwise 
addition of 5-ethynyl-1,2,3-trimethoxybenzene 36 (0.100 g, 0.52 mmol) in piperidine (1 
mL).  The reaction heated to 50 °C was left stirred for 16 hours then saturated ammonium 
chloride solution (5 mL) was added.  The aqueous layer was extracted with diethyl ether 
(3 × 10 mL).  The combined organic layers were washed with brine (30 mL), dried over 
magnesium sulfate, filtered and the solvent removed under reduced pressure.  The crude 
material was purified by flash column chromatography on silica with an eluent of 30% 
ethyl acetate: 40 – 60 °C petroleum ether to afford the title compound 113 (0.104 g, 56%) 
as an orange solid; mp 112 – 113 °C; max (ATR)/ cm
-1 2932 (C-H), 1686, 1575 (HC=O), 
1507 (aromatic); 1H NMR (400 MHz, CDCl3) δ 3.87 (s, 3H, OCH3), 3.88 (s, 6H, 2 × 
OCH3), 3.93 (s, 3H, OCH3), 6.74 (d, J 9.2, 1H ArH), 6.76 (s, 2H, 2 × ArH), 7.65 (d, J 9.2, 
1H, ArH), 10.45 (s, 1H, HC=O); 13C NMR (101 MHz, CDCl3) δ 56.2 (2 × OCH3), 56.3 
(OCH3), 61.0 (OCH3), 62.6 (OCH3), 83.5 (C≡C), 93.5 (C≡C), 107.3 (ArCH), 108.6 (2 × 
ArCH), 110.2 (ArC), 118.2 (2 × ArC), 119.1 (ArC), 139.4 (ArCH), 153.2 (2 × ArCO), 










3,4,5-Trimethoxyaniline (1.00 g, 5.46 mmol) was suspended in water (12 mL) and 
sulfuric acid (conc, 0.8 mL) and cooled to 0 °C.  Sodium nitrate (3.77 g, 56.4 mmol) was 
dissolved in water (6 mL) and added dropwise to the reaction mixture whilst the 
temperature was maintained at 0 °C.  The reaction mixture was then added to a solution 
of potassium iodide (1.40 g, 8.43 mmol) in water (3 mL) at 50 °C and left for 30 minutes.  
The reaction was cooled to room temperature, aqueous sodium sulfite (20 mL) was added 
and the solution was extracted with diethyl ether (3 × 20 mL).  The combined organic 
layers were washed with brine (40 mL), dried over magnesium sulfate, filtered and the 
solvent removed under reduced pressure which yielded the title compound 115 (1.30 g, 
81%) as a yellow solid which was used without further purification; mp 85 – 86 °C (lit.143 
83 – 85 °C; 1H NMR (400 MHz, CDCl3) δ 3.81 (s, 3H, OCH3), 3.83 (s, 6H, 2 × OCH3), 
6.88 (s, 2H, 2 × ArH); 13C NMR (101 MHz, CDCl3) δ 56.4 (2 × OCH3), 60.8 (OCH3), 
86.0 (ArC), 115.1 (2 × ArCH), 138.4 (ArC), 154.0 (2 × ArC).  All data in accordance 









2,6-Dimethoxyphenol 89 (0.53 g, 3.4 mmol) was dissolved in acetone (10 mL) then 
potassium carbonate (0.71 g, 5.2 mmol) was added and the reaction mixture cooled to 0 
°C.  18-Crown-6 (0.1 mL, 0.14 mmol) and iodomethane (0.32 mL, 5.2 mmol) were added 
at 0 °C and the reaction was allowed to warm to room temperature and stirred overnight.  
The resulting mixture was poured onto diethyl ether (10 mL), filtered and the filtrate 
concentrated down under reduced pressure to yield the title compound 119 (0.48 g 83%) 
as a white solid which was used without further purification; mp 40 – 42 °C (lit.144 44 
°C); 1H NMR (400 MHz, CDCl3) δ 3.85 (s, 3H, OCH3), 3.86 (s, 6H, 2 × OCH3), 6.58 (d, 
J 8.3, 2H, 2 × ArH), 6.99 (t, J 8.3, 1H, ArH); 13C NMR (101 MHz, CDCl3) 56.1 (2 × 
OCH3), 60.8 (OCH3), 105.4 (2 × ArCH), 123.6 (ArCH), 138.3 (ArC), 153.6 (2 × ArC).  









1,2,3-Trimethoxybenzene 119 (6.10 g, 36.2 mmol) was dissolved in dichloromethane (70 
mL) and cooled to 0 °C.  Titanium (IV) chloride (8.0 mL, 72.5 mmol) was added dropwise 
followed by dichloromethyl methyl ether (6.60 mL, 72.5 mmol).  The reaction mixture 
was warmed to room temperature and left stirring for 3 hours.  Cold water (50 mL) was 
added to reaction mixture and the aqueous layer extracted with dichloromethane (3 × 50 
mL).  The combined organic layers were washed with hydrochloric acid (1M, 100 mL), 
saturated aqueous sodium bicarbonate (100 mL) and brine (100 mL), then dried over 
magnesium sulfate.  After filtration and removal of solvent under reduced pressure the 
title compound 120 (6.38 g, 90%) was obtained as a white solid which was used without 
further purification; mp 32 – 33 °C (lit.146 30 – 31 °C) 1H NMR (400 MHz, CDCl3) δ 3.88 
(s, 3H, OCH3), 3.93 (s, 3H, OCH3), 4.02 (s, 3H, OCH3), 6.75 (d, J 8.8, 1H, ArH), 7.60 (d, 
J  8.8, 1H, ArH), 10.24 (s, 1H, CHO); 13C NMR (101 MHz, CDCl3) δ  56.2 (OCH3), 61.0 
(OCH3), 62.3 (OCH3), 107.4 (ArCH), 123.3 (ArC), 124.2 (ArCH), 141.6 (ArC), 156.9 









2,3,4-Trimethoxybenzaldehyde 120 (0.25 g, 1.3 mmol) was dissolved in dichloromethane 
(7 mL) and boron trichloride (1M in dichloromethane, 1.3 mL, 1.3 mmol) was added 
dropwise.  The reaction was left stirring for 2 hours before another equivalent of boron 
trichloride (1M in dichloromethane, 1.3 mL, 1.3 mmol) was added dropwise and the 
reaction was left stirring for 24 hours.  The reaction was quenched with sat. sodium 
bicarbonate (10 mL) and acidified to pH 2 using concentrated hydrochloric acid  The 
aqueous layer was then extracted with dichloromethane (3 × 10 mL) and the combined 
organic layers washed with brine (20 mL), dried over magnesium sulfate and filtered.  
The solvent was removed under reduced pressure, and the crude material recrystallised 
with ethyl acetate/hexane to afford the title compound 118 (0.19 g, 86%) as a white solid; 
mp 113 – 114 °C (lit.111 115 – 116 °C); 1H NMR (400 MHz, CDCl3) δ 3.98 (s, 3H, OCH3), 
5.53 (s, 1H, OH), 6.61 (d, J 8.8, 1H, ArH), 7.14 (d, J 8.8, 1H, ArH), 9.74 (s, 1H, CHO), 
11.12 (s, 1H, OH); 13C NMR (101 MHz, CDCl3) δ 56.4 (OCH3), 103.6 (ArCH), 116.1 
(ArC), 126.1 (ArCH), 133.0 (ArC), 149.1 (ArC), 153.0 (ArC), 195.3 (CHO).  All data in 










2,3-Dihydroxy-4-methoxybenzaldehyde 118 (2.70 g, 16.1 mmol) was dissolved in 
dichloromethane (50 mL).  Triethylamine (6.7 mL, 48.3 mmol) and DMAP (0.49 g, 4.0 
mmol) were added and the mixture was stirred for 10 minutes.  tert-Butyldimethylsilyl 
chloride (5.82 g, 38.6 mmol) was added to the reaction mixture in portions and stirred for 
12 hours at room temperature.  After addition of water (40 mL), the aqueous layer was 
extracted with dichloromethane (3 × 30 mL) and the combined organic layers were 
washed with brine (50 mL) and dried over magnesium sulfate.  Filtration, followed by the 
removal of solvent under reduced pressure gave the crude material which was purified by 
recrystallisation from methanol to afford the title compound 22 (3.64 g, 57%) as pale 
yellow crystals; mp 72 – 73 °C (lit.147 74.5 – 76 °C); 1H NMR (400 MHz, CDCl3) δ 0.14 
[s, 12H, 2 × OSi(CH3)2C(CH3)3], 0.99 [s, 9H, OSi(CH3)2C(CH3)3], 1.04 [s, 9H, 
OSi(CH3)2C(CH3)3], 3.84 (s, 3H, OCH3), 6.62 (d, J 8.8, 1H, ArH), 7.48 (d, J 8.8, 1H, 
ArH), 10.22 (s, 1H, CHO); 13C NMR (101 MHz, CDCl3) δ -3.8 [2 × OSi(CH3)2C(CH3)3], 
18.6 [OSi(CH3)2C(CH3)3], 18.8 [OSi(CH3)2C(CH3)3], 26.0 [OSi(CH3)2C(CH3)3], 26.2 
[OSi(CH3)2C(CH3)3], 55.2 (OCH3), 105.4 (ArCH), 121.4 (ArCH), 123.4 (ArC), 136.8 









2,3-Dihydroxy-4-methoxybenzaldehyde 118 (0.387 g, 2.3 mmol) and caesium fluoride 
(1.05 g, 6.9 mmol) were dissolved in dimethylformamide (10 mL).  Dibromomethane 
(0.16 mL, 2.3 mmol) was added dropwise and the reaction heated to 125 °C under 
nitrogen for 6 hours.  Water (10 mL) was added aqueous layer was extracted with diethyl 
ether (3 × 10 mL).  The combined organic layers were washed with sodium hydroxide (1 
M, 20 mL) and brine (20 mL) then filtered through Celite®, dried over magnesium sulfate, 
filtered and the solvent removed under reduced pressure to afford the title compound 123 
(0.267 g, 65%) that was used without further purification; mp 84 – 86 °C (lit.141 82 – 85 
°C);  1H NMR (400 MHz, CDCl3) δ 3.98 (s, 3H, OCH3), 6.13 (s, 2H, CH2), 6.62 (d, J 9.0, 
1H, ArH), 7.30 (d, J 9.0, 1H, ArH), 9.98 (s, 1H, CHO); 13C NMR (101 MHz, CDCl3) δ 
56.8 (OCH3), 103.0 (CH2), 107.9 (ArCH), 114.5 (ArC), 123.8 (ArCH), 135.7 (ArC), 
148.4 (ArC), 150.3 (ArC), 187.1 (HC=O); m/z (ES+) 181.0498 (100%, MH+. C9H9O4 








Carbon tetrabromide (0.418 g, 1.26 mmol), triphenylphosphine (0.661 g, 2.52 mmol) and 
triethylamine (0.18 mL, 1.26 mmol) were dissolved in dichloromethane (3 mL) and 
stirred under nitrogen for 1 hour at room temperature.  The reaction mixture was cooled 
to 0 °C and 2,3-di[(tert-butyldimethylsilyl)oxy]-4-methoxybenzaldehyde 22 (0.250 g, 
0.63 mmol) was added.  The reaction mixture was allowed to warm to room temperature 
and left stirring for 16 hours.  The resulting precipitate was filtered off and the filtrate 
concentrated down under reduced pressure.  The residue was then stirred in petroleum 
ether (10 mL) for 10 minutes, filtered and the filtrate concentrated down under reduced 
pressure.  The resulting residue was dissolved in tetrahydrofuran (2 mL) and cooled to -
78 °C.  n-Butyllithium (1.3 mL, 1.8 M in hexanes, 2.21 mmol) was added dropwise to the 
reaction mixture and left stirring at -78 ºC for 30 minutes.  Ammonium chloride (5 mL) 
was added to the reaction mixture and warmed to room temperature.  The organic layer 
was removed under reduced pressure and the aqueous layer was extracted with ethyl 
acetate (3 × 5 mL).  The combined organic layers were washed with brine (15 mL), dried 
over magnesium sulfate, filtered and the solvent removed under reduced pressure.  
Purification of the crude material by flash column chromatography on silica gel using an 
eluent of 5% ethyl acetate: 40 – 60 ºC petroleum ether afforded the title compound 125 
as a colourless oil (0.178 g, 72%); 1H NMR (400 MHz, CDCl3) δ 0.11 [s, 6H, 
OSi(CH3)2C(CH3)3], 0.20 [s, 6H, OSi(CH3)2C(CH3)3], 1.00 [s, 9H, OSi(CH3)2C(CH3)3], 
1.05 [s, 9H, OSi(CH3)2C(CH3)3], 3.09 (s, 1H, ≡CH), 3.77 (s, 3H, OCH3), 6.46 (d, J 8.4, 
1H, ArH), 7.02 (d, J 8.4, 1H, ArH); 13C NMR (101 MHz, CDCl3) δ -3.9 [OSi(CH3)2C(CH-
3)3], -3.4 [OSi(CH3)2C(CH3)3], 18.5 [OSi(CH3)2C(CH3)3], 18.7 [OSi(CH3)2C(CH3)3], 26.1 
[OSi(CH3)2C(CH3)3], 26.3 [OSi(CH3)2C(CH3)3], 55.0 (OCH3), 79.7 (C≡C), 82.2 (C≡C), 
104.8 (ArCH), 109.1 (ArC), 126.3 (ArCH), 137.0 (ArCO), 149.2 (ArCO), 153.3 (ArCO).  








Carbon tetrabromide (0.368 g, 1.11 mmol) and triphenylphosphine (0.582 g, 2.22 mmol) 
were dissolved in dichloromethane (3 mL) and stirred under nitrogen for 1 hour at room 
temperature.  The reaction mixture was cooled to 0 °C and 4-methoxy-2,3-
(methylenedioxy)-benzaldehyde 123 (0.100 g, 0.55 mmol) was added.  The reaction 
mixture was allowed to warm to room temperature and left stirring for 16 hours.  The 
resulting precipitate was filtered off and the filtrate concentrated down under reduced 
pressure.  The residue was then stirred in petroleum ether (10 mL) for 10 minutes, filtered 
and the filtrate concentrated down under reduced pressure.  The resulting residue was 
dissolved in tetrahydrofuran (2 mL) and cooled to -78 °C.  n-Butyllithium (1.1 mL, 1.8 
M in hexanes, 1.96 mmol) was added dropwise to the reaction mixture and left stirring at 
-78 ºC for 30 minutes.  Ammonium chloride (5 mL) was added to the reaction mixture 
and warmed to room temperature.  The organic layer was removed under reduced pressure 
and the aqueous layer was extracted with ethyl acetate (3 × 5 mL).  The combined organic 
layers were washed with brine (15 mL), dried over magnesium sulfate, filtered and the 
solvent removed under reduced pressure.  Purification of the crude material by flash 
column chromatography on silica gel using an eluent of 10% ethyl acetate: 40 – 60 ºC 
petroleum ether afforded the title compound 127 (0.177 g, 89%) as a white solid; mp 50 
– 52 °C; max (ATR)/ cm
-1 3188 (C-H), 2917 (C-H), 2105 (≡CH), 1642; 1H NMR (400 
MHz, CDCl3) δ 3.21 (s, 1H, C≡CH), 3.91 (s, 3H, OCH3), 6.05 (s, 2H, CH2), 6.48 (d, J 
8.8, 1H, ArH), 6.92 (d, J 8.8, ArH); 13C NMR (101 MHz, CDCl3) δ 56.6 (OCH3), 68.2 
(C≡C), 80.0 (C≡C), 102.0 (CH2), 105.3 (ArC), 107.8 (ArCH), 126.1 (ArCH), 132.5 












Copper iodide (25 mg, 0.13 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.661 
g, 0.50 mmol) was added to a solution of 1-iodo-3,4,5-trimethoxybenzene 115 (0.661 g, 
2.50 mmol) in piperidine (5 mL).  1-Ethynyl-2,3-(methylenedioxy)-4-methoxybenzene 
127 (0.441 g, 2.50 mmol) in piperidine (2 mL) was added dropwise to the reaction mixture 
and left stirring for 18 hours.  Water (15 mL) was added and the aqueous layer separated 
and extracted with diethyl ether (3 × 15 mL).  The combined organic layers were washed 
with brine (20 mL), dried over magnesium sulfate, filtered and the solvent removed under 
reduced pressure.  The crude reaction material was purified by flash column 
chromatography on silica gel using an eluent of 20% ethyl acetate: 40 – 60 °C petroleum 
ether which gave the title compound 129 (0.265 g, 31%) as a yellow solid; mp 112 – 114 
°C; max (ATR)/ cm
-1 3005 (C-H), 2159 (C≡C), 1575, 1508 (aromatic); 1H NMR (400 
MHz, CDCl3) δ 3.86 (s, 3H, OCH3), 3.86 (s, 6H, 2 × OCH3), 3.92 (s, 3H, OCH3), 6.07 (s, 
2H, OCH2O), 6.52 (d, J 8.8, 1H, ArH), 6.76 (s, 2H, 2 × ArH), 6.96 (d, J 8.8, 1H, ArH); 
13C NMR (101 MHz, CDCl3) δ 56.2 (2 × OCH3), 56.6 (OCH3), 61.0 (OCH3), 82.4 (C≡C), 
92.2 (C≡C), 98.6 (ArC), 101.9 (CH2), 107.8 (ArCH), 108.8 (2 × ArCH), 118.2 (ArC), 
125.7 (ArCH), 135.0 (ArC), 138.8 (ArC), 144.3 (ArC), 149.4 (ArCO), 153.0 (2 × ArCO); 









Copper iodide (9 mg, 0.05 mmol) and tetrakis(triphenylphosphine)palladium(0) (0.22 g, 
0.19 mmol) was added to a solution of 1-iodo-2,4-dimethoxybenzene (0.25 g, 0.95 mmol) 
in piperidine (3 mL).  5-Ethynyl-1,2,3-trimethoxybenzene 36 (0.18 g, 0.95 mmol) in 
piperidine (2 mL) was added dropwise to the reaction mixture and left stirring for 18 
hours.  Water (10 mL) was added and the aqueous layer separated and extracted with 
diethyl ether (3 × 10 mL).  The combined organic layers were washed with brine (20 mL), 
dried over magnesium sulfate, filtered and the solvent removed under reduced pressure.  
The crude reaction material was purified by flash column chromatography on silica gel 
using an eluent of 20% ethyl acetate: 40 – 60 °C petroleum ether which gave the title 
compound 131 (0.212 g, 68%) as a yellow solid; mp 81 – 84 °C; max (ATR)/ cm
-1 3014 
(C-H), 2935 (C-H), 2840 (C-H), 1571, 1509 (aromatic), 1408 (CH2); 
1H NMR (400 MHz, 
CDCl3) δ 3.84 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.87 (s, 6H, 2 × OCH3), 3.90 (s, 3H, 
OCH3), 6.46 – 6.50 (m, 2H, 2 × ArH), 6.78 (s, 2H, 2 × ArH), 7.42 (d, J 8.4, 1H, ArH); 
13C NMR (101 MHz, CDCl3) δ 55.4 (OCH3), 55.9 (OCH3), 56.2 (2 × OCH3), 60.9 
(OCH3), 84.8 (C≡C), 92.0 (C≡C), 98.5 (ArCH), 105.0 (ArCH), 108.9 (2 × ArCH), 118.9 
(2 × ArC≡),  134.3 (ArCH), 153.0 (2 × COCH3), 161.2 (COCH3), 161.3 (2 × COCH3); 










2,3-Di[(tert-butyldimethylsilyl)oxy]-4-methoxybenzaldehyde 22 (2.00 g, 5.0 mmol) was 
dissolved in ethanol (20 mL) and cooled to 0 °C.  Sodium borohydride (0.19 g, 5.0 mmol) 
was added in portions over 5 minutes.  The reaction was left stirring at 0 °C for 30 minutes 
then was quenched with water (20 mL).  The organic solvent was removed under reduced 
pressure and the aqueous phase was extracted with ethyl acetate (3 × 15 mL).  The 
combined organic layers were washed with brine (25 mL), dried over magnesium sulfate 
and filtered.  The solvent was removed under reduced pressure and the crude material 
was recrystallised from ethanol to afford the title compound 135 (1.99 g, 99%) as off-
white solid; mp 73 – 74 °C; 1H NMR (400 MHz, CDCl3) δ 0.10 [s, 6H, 
OSi(CH3)2C(CH3)3], 0.14 [s, 6H, OSi(CH3)2C(CH3)3], 0.98 [s, 9H, OSi(CH3)2C(CH3)3], 
1.03 [s, 9H, OSi(CH3)2C(CH3)3], 1.82 (t, J 6.2, 2H, CH2OH), 3.76 (s, 3H, OCH3), 4.60 
(d, J 6.2, 2H, CH2OH), 6.51 (d, J 8.4, 1H, ArH), 6.88 (d, J 8.4, 1H, ArH); 
13C NMR (101 
MHz, CDCl3) δ  -3.8 [OSi(CH3)2C(CH3)3], -3.6 [OSi(CH3)2C(CH3)3], 18.4 
[OSi(CH3)2C(CH3)3], 18.8 [OSi(CH3)2C(CH3)3], 26.2 {2 × [OSi(CH3)2C(CH3)3]}, 54.9 
(OCH3), 61.6 (CH2OH), 104.9 (ArCH), 120.5 (ArCH), 126.3 (ArC), 136.9 (ArC), 145.3 
(ArC), 151.9 (ArC).  NMR data in accordance with the literature with the exception for 










2,3-bis[[(1,1-Dimethylethyl)dimethylsilyl]oxy]-4-methoxy-benzenemethanol 135 (1.00 
g, 2.51 mmol) was dissolved in dichloromethane (5 mL) and cooled to 0 °C.  Phosphorus 
tribromide (0.24 mL, 2.51 mmol) was added to the reaction mixture and stirred for 6 hours 
at 0 °C followed by addition of water (10 mL).  The aqueous layer was separated and 
extracted with dichloromethane (3 × 10 mL).  The combined organic layers were washed 
with brine (20 mL), dried over magnesium sulfate and filtered.  The solvent was removed 
under reduced pressure to reveal the title compound 136 (1.07 g, 92%) as a tan-coloured 
solid which was used without further purification; mp 99 – 100 °C; 1H NMR (400 MHz, 
CDCl3) δ 0.11 [s, 6H, OSi(CH3)2C(CH3)3], 0.14 [s, 6H, OSi(CH3)2C(CH3)3], 0.98 [s, 9H, 
OSi(CH3)2C(CH3)3], 1.07 [s, 9H, OSi(CH3)2C(CH3)3], 3.76 (s, 3H, OCH3), 4.53 (s, 2H, 
CH2), 6.50 (d, J 8.8, 1H, ArH), 6.94 (d, J 8.8, 1H, ArH); 
13C NMR (101 MHz, CDCl3) δ 
–3.8 [OSi(CH3)2C(CH3)3], -3.6 [OSi(CH3)2C(CH3)3], 18.6 [OSi(CH3)2C(CH3)3], 18.8 
[OSi(CH3)2C(CH3)3], 26.2 {2 × [OSi(CH3)2C(CH3)3]}, 30.8 (CH2), 55.0 (OCH3), 105.0 
(ArCH), 123.0 (ArC), 123.1 (ArCH), 137.0 (ArC), 145.8 (ArC), 152.7 (ArC).  All NMR 
data in accordance with the literature apart from in the 13C NMR spectrum, the peak at 











136 (0.697 g, 1.51 mmol) was dissolved in dichloromethane (10 mL).  
Triphenylphosphine (0.436 g, 1.66 mmol) was added to the reaction mixture and was 
heated at reflux for 24 hours.  The solvent was removed under reduced pressure and 
diethyl ether (20 mL) was added to the resulting residue forming a slurry which was 
stirred for 1 hour.  The solid was filtered was washed with diethyl ether (15 mL) to obtain 
the title compound 137 (0.918 g, 84%) as a white solid which was used without further 
purification; mp 190 – 192 °C; 1H NMR (400 MHz, CDCl3) δ -0.04 [s, 6H, 
OSi(CH3)2C(CH3)3], 0.13 [s, 6H, OSi(CH3)2C(CH3)3], 0.83 [s, 9H, OSi(CH3)2C(CH3)3], 
0.95 [s, 9H, OSi(CH3)2C(CH3)3], 3.67 (s, 3H, OCH3), 5.14 (d, JH-P 14.4, 2H, CH2), 6.31 
(d, J 8.7, 1H, ArCH), 6.64 (dd, JH-H 8.7, JH-P 3.0, 1H, ArCH), 7.60 – 7.78 (m, 15H, 3 × 
C6H5); 
13C NMR (101 MHz, CDCl3) δ -3.6 [OSi(CH3)2C(CH3)3], -3.4 
[OSi(CH3)2C(CH3)3], 18.4 [OSi(CH3)2C(CH3)3], 18.7 [OSi(CH3)2C(CH3)3], 24.7 (d, JC-P 
48.8, CH2),  26.1 [OSi(CH3)2C(CH3)3], 26.2  [OSi(CH3)2C(CH3)3], 54.9 (OCH3), 105.7 
(ArCH), 111.3 (d, JC-P 8.1, ArCCH2), 118.1 (ArCOSi), 118.9 (ArCOSi), 123.8 (d, JC-P 
4.9, ArCH), 130.2 (d, JC-P 12.5, 6 × ArCH), 134.1 (d, JC-P 9.7, 6 × ArCH), 134.9 (d, JC-P 
2.7, 3 × ArCH), 137.2 (3 × PCH2C), 152.5 (d, JC-P 3.4, ArCOCH3); 
31P NMR (162 MHz, 
CDCl3) δ 21.19.  
1H and 31P NMR data in accordance with the literature apart from in the 










3,4,5-Trimethoxybenzyltriphosphonium bromide 139 (1.79 g, 3.4 mmol) was dissolved 
in tetrahydrofuran (50 mL) at -10 °C.  n-Butyllithium (1.2 M in hexanes, 2.9 mL, 3.4 
mmol) was added dropwise and the reaction left for 30 minutes.  The reaction mixture 
was cooled to -78 °C and 2,3-di[(tert-butyldimethylsilyl)oxy]-4-methoxybenzaldehyde 
22 (1.36 g, 3.4 mmol) in tetrahydrofuran (7 mL) was added dropwise to the reaction 
mixture and was left to warm to 0 °C.  The reaction was quenched with water (30 mL) 
and the organic layer removed under reduced pressure.  The aqueous layer was extracted 
with diethyl ether (3 × 20 mL) and the combined organic layers were washed with brine 
(40 mL), dried over magnesium sulfate, filtered and the solvent removed under reduced 
pressure.  The crude reaction material was purified by flash column chromatography 
using an eluent of 10% ethyl acetate: 40 – 60 °C petroleum ether and recrystallised from 
ethanol to yield the Z-isomer 24 (1.11 g, 58%) as a white crystals; mp 118 – 120 °C (lit.11 
117 – 118 °C); 1H NMR (400 MHz, CDCl3) δ 0.10 [s, 6H, OSi(CH3)2C(CH3)3], 0.19 [s, 
6H, OSi(CH3)2C(CH3)3], 1.00 [s, 9H, OSi(CH3)2C(CH3)3], 1.04 [s, 9H, 
OSi(CH3)2C(CH3)3], 3.67 (s, 6H, OCH3), 3.74 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.36 
(d, J 12.2, 1H, HC=C), 6.36 (d, J 8.8, 1H, ArH), 6.59 (d, J 12.2, 1H, C=CH), 6.62 (s, 2H, 
2 × ArH), 6.92 (d, J 8.8, 1H, ArH); 13C NMR (101 MHz, CDCl3) δ -3.9 
[OSi(CH3)2C(CH3)3], -3.2 [OSi(CH3)2C(CH3)3], 18.6 [OSi(CH3)2C(CH3)3], 18.7 
[OSi(CH3)2C(CH3)3], 26.1 [OSi(CH3)2C(CH3)3], 26.4 [OSi(CH3)2C(CH3)3], 55.0 
(OCH3), 55.8 (2 × OCH3), 60.9 (OCH3), 104.2 (ArCH), 105.9 (2 × ArCH), 122.2 (ArCH), 
123.2 (ArC-C=C), 127.4 (C=), 127.7 (=C), 132.8 (ArC-C=), 136.8 (COSi), 136.9 (COSi), 










A E/Z mixture of 2`,3`-Bis-[(tert-butyldimethylsilyl)-oxy]-combretastatin A1 24 (64 mg, 
0.11 mmol, E/Z ratio: 55:45) was dissolved in hexanes (0.5 mL) then iodine (5.8 mg, 
0.023 mmol) was added and the reaction left stirring at room temperature for 16 hours.  
5% Aqueous sodium thiosulfate (2 mL) was added and the aqueous layer extracted with 
diethyl ether (3 × 2 mL).  The combined organic layers were washed with brine (5 mL), 
dried over magnesium sulfate and filtered.  The solvent removed under reduced pressure 
to afford the title compound 23 (64 mg, 100%) as a white solid which required no further 
purification; mp 138 – 139 °C (lit.11 139 – 140 °C); 1H NMR (400 MHz, CDCl3) δ 0.12 
[s, 6H, OSi(CH3)2C(CH3)3], 0.14 [s, 6H, OSi(CH3)2C(CH3)3], 1.00 [s, 9H, 
OSi(CH3)2C(CH3)3], 1.09 [s, 9H, OSi(CH3)2C(CH3)3], 3.79 (s, 3H, OCH3), 3.86 (s, 3H, 
OCH3), 3.88 (s, 6H, OCH3), 6.56 (d, J 8.8, 1H, ArH), 6.72 (s, 2H, 2 × ArH), 6.81 (d, J 
16.4, 1H, HC=C), 7.20 (d, J 8.8, 1H, ArH), 7.31 (d, J 16.4, 1H, C=CH); 13C NMR (101 
MHz, CDCl3) δ -3.8 [OSi(CH3)2C(CH3)3], -3.5 [OSi(CH3)2C(CH3)3], 18.7 
[OSi(CH3)2C(CH3)3], 18.8 [OSi(CH3)2C(CH3)3], 26.1 [OSi(CH3)2C(CH3)3], 26.5 
[OSi(CH3)2C(CH3)3], 55.0 (OCH3), 56.0 (2 × OCH3), 60.9 (OCH3), 103.3 (=CH), 105.3 
(=CH), 117.4 (2 × ArCH), 123.8 (ArC), 124.2 (ArCH), 126.1 (ArCH), 133.8 (ArC), 137.0 
(COSi), 137.5 (COSi), 145.6 (COCH3), 151.9 (COCH3), 153.4 (2 × COCH3).  1H NMR 









2,3,4-Trimethoxybenzaldehyde (0.50 g, 2.6 mmol), p-toluenesulfonamide (0.44 g, 2.6 
mmol) and tetraethoxysilane (0.6 mL, 2.68 mmol) was heated to 120 °C for 5 hours then 
cooled to room temperature.  The crude compound was recrystallised from ethyl acetate 
and  petroleum ether to afford the title compound 138 (0.58 g, 65%) as a yellow solid; 
mp 139 – 141 °C; 1H NMR (400 MHz, CDCl3) δ 2.44 (s, 3H, ArCH3), 3.89 (s, 6H, 2 × 
OCH3), 3.93 (s, 3H, OCH3), 7.16 (s, 2H, 2 × ArH), 7.35 (d, J 8.0, 2H, 2 × ArH), 7.88 (d, 
J 8.0, 2H, 2 × ArH), 8.91 (s, 1H, HC=N); 13C NMR (101 MHz, CDCl3) δ 21.7 (ArCH3), 
56.4 (2 × OCH3), 61.1 (OCH3), 108.5 (2 × ArCH), 127.4 (ArC), 128.1 (2 × ArCH), 129.8 
(2 × ArCH), 135.3 (ArC), 144.2 (ArC), 144.5 (ArC), 153.5 (2 × ArC), 169.8 (HC=N); 
m/z (ESI) 350.1055 (100%, MH+. C17H20NO5S requires 350.1057).  
1H NMR data in 










3,4,5-Trimethoxybenzaldehyde (5.00 g, 25.5 mmol) was dissolved in ethanol (100 mL) 
and cooled to 0°C.  Sodium borohydride (0.964 g, 25.5 mmol) was added in portions and 
the reaction left stirring for 30 minutes.  The reaction was quenched with water (100 mL) 
and the organic solvent removed under reduced pressure.  The remaining aqueous layer 
was extracted with ethyl acetate (3 × 50 mL).  The organic layers were combined and 
washed with brine (100 mL), dried over magnesium sulfate, filtered and the solvent 
removed under reduced pressure to afford the title compound 140 (4.89 g, 97%) as a 
colourless oil which was used without further purification; 1H NMR (400 MHz, CDCl3) 
δ 3.64 (s, 6H, 2 × OCH3), 3.65 (s, 3H, OCH3), 3.88 (s, 1H, OH), 4.41 (s, 2H, CH2), 6.41 
(s, 2H, 2 × ArH);  13C NMR (101 MHz, CDCl3) δ 56.1 (2 × OCH3), 60.9 (OCH3), 65.4 
(CH2), 103.8 (2 × ArCH), 136.7 (ArC), 137.2 (ArC), 153.3 (2 × ArC);  All data in 








3,4,5-Trimethoxybenzenemethanol 140 (4.89 g, 24.7 mmol) was dissolved in 
dichloromethane (50 mL) and cooled to 0 °C.  Phosphorus tribromide (2.3 mL, 24.7 
mmol) was added dropwise and the reaction left to stir at 0 °C for 6 hours.  Water (50 
mL) was added to the reaction mixture and then extracted with dichloromethane (3 × 30 
mL).  The combined organic layers were washed with brine (50 mL), dried over 
magnesium sulfate, filtered and the solvent removed under reduced pressure.  The crude 
material was recrystallised from 40 – 60 °C petroleum ether to afford the title compound 
141 (4.67 g, 72%) as a white solid; mp 74 – 75 °C (lit.152 74 – 75 °C); 1H NMR (400 
MHz, CDCl3) δ 3.83 (s, 3H, OCH3), 3.86 (s, 6H, 2 × OCH3), 4.46 (s, 2H, CH2), 6.61 (s, 
2H, 2 × ArH); 13C NMR (101 MHz, CDCl3) δ 34.3 (CH2), 56.1 (2 × OCH3), 60.9 (OCH3), 
106.1 (2 × ArCH), 133.2 (ArC), 138.1 (ArC), 153.3 (2 × ArC).  All data in accordance 









5-(Bromomethyl)-1,2,3-trimethoxybenzene 141 (0.40 g, 1.5 mmol) was dissolved in 
tetrahydrofuran (4.5 mL), triphenylphosphine (0.52 g, 1.9 mmol) was added, and the 
mixture was heated at reflux for 6 hours.  The resulting white solid was filtered and 
washed with diethyl ether (10 mL) and hexanes (10 mL) to give the title compound 139 
(0.64 g, 79%) as a white solid; mp 219 – 220 °C (lit.154 222 – 223 °C); 1H NMR (400 
MHz, CDCl3) δ 3.49 (s, 6H, 2 × OCH3), 3.74 (s, 3H, OCH3), 5.40 (d, JH-P 14.0, 2H, CH2), 
6.48 (d, J 2.4, 2H, 2 × ArH), 7.57 – 7.62 (m, 6H, 6 × ArH); 7.71 – 7.77 (m, 9H, 9 × ArH); 
13C NMR (101 MHz, CDCl3) δ 30.8 (d, JC-P 46.7 , CH2), 56.2 (2 × OCH3), 60.8 (d, JC-P 
2.2, OCH3), 108.9 (d, JC-P 5.7, 2 × ArCH), 117.9 (d, JC-P 86.0, 3 × ArCP), 122.5 (d, JC-P 
9.0, CCH2P), 130.0 (d, JC-P 12.6, 6 × ArCH), 134.7 (d, JC-P 9.8, 6 × ArCH), 134.8 (d, JC-
P 2.8, 3 × ArCH), 137.6 (d, JC-P 4.8, COCH3), 153.0 (d, JC-P 3.6, 2 × COCH3); 
31P NMR 
(162 MHz, CDCl3) 23.3.  All NMR data in accordance with the literature apart from in 










A 1 L two-necked round bottom flask was equipped with a U-tube and connected to a 
100 mL receiving flask which was also connected to a cold finger condenser filled with 
dry ice/acetone.  The reaction flask was cooled to 0 °C and the receiving flask cooled to 
-78 °C.  The reaction flask was charged with sodium bicarbonate (24 g, 0.29 mol), water 
(100 mL) and acetone (80 mL, 1.1 mol) and the resulting suspension stirred vigorously 
through magnetic stirring.  Oxone ® (50 g, 0.16 mol) was added to the reaction mixture 
in five portions at 3 minute intervals.  A 125 mbar vacuum was applied 3 minutes after 
the last addition.  The ice/water bath was removed from the reaction vessel and reaction 
left with vigorous stirring for 80 minutes.  The distilled DMDO solution (approx. 40 mL) 
was collected, dried over potassium carbonate, filtered, and then stored under argon at -
20 °C.  
 
Titration of DMDO solution 
The DMDO solution (0.5 mL) was added to a solution of water (5 mL), potassium iodide 
(20 mg) and a few drops of acetic acid.  The resulting iodine solution was titrated against 









trans-Stilbene (0.100 g, 0.55 mmol) was dissolved in acetone (1 mL) and a solution of 
DMDO in acetone (0.06 M, 9.2 mL, 0.55 mmol) was added at room temperature.  The 
reaction was left stirring for 18 hours after which the solvent was removed under reduced 
pressure.  The resulting residue was re-dissolved in dichloromethane (2 mL) then dried 
over magnesium sulfate, filtered and the solvent removed under reduced pressure which 
yielded the title compound 150 (0.106 g, 98%) as a white solid which required no further 
purification; mp 67 – 68 °C (lit.124 69 – 70 °C); 1H NMR (400 MHz, CDCl3) δ 3.89 (s, 
2H, 2 × CH), 7.35 – 7.42 (m, 10H, 10 × ArCH); 13C NMR (101 MHz, CDCl3) δ 62.8 (2 
× CH), 125. 6 (4 × ArCH), 128.4 (2 × ArCH), 128.6 (4 × ArCH), 137.2 (2 × ArC).  All 











2’,3’-Bis-[(tert-butyldimethylsilyl)-oxy]-(Z)-combretastatin A1 24 (0.150 g, 0.27 mmol) 
was dissolved in tetrahydrofuran (1 mL).  Tetrabutylammonium fluoride (1M in 
tetrahydrofuran, 1.1 mL, 1.1 mmol).  The mixture was left stirring for 30 minutes after 
which hydrochloric acid (1M, 5 mL) was added the mixture extracted with ethyl acetate 
(3 × 5 mL).  The combined organic layers were washed with brine (10 mL), dried over 
magnesium sulfate, filtered and the solvent removed under reduced pressure. The crude 
material was purified by flash column chromatography on silica with an eluent of 50% 
ethyl acetate: 40 – 60 °C petroleum ether to reveal the title compound 8 (0.088 g, 97%) 
as an off-white solid; mp 117 – 118 °C (lit.11 113 – 115 °C); 1H NMR (400 MHz, CDCl3) 
δ 3.66 (s, 6H, 2 × OCH3), 3.82 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 5.43 (s, 2H, 2 × OH), 
6.38 (d, J 8.5, 1H, ArH), 6.52 (s, 2H, 2 × ArH), 6.53 (d, J 12.0, 1H, HC=CH), 6.59 (d, J 
12.0, 1H, HC=CH), 6.76 (d, J 8.5, 1H, ArH); 13C NMR (101 MHz, CDCl3) δ 55.9 (2 × 
OCH3), 56.2 (OCH3), 60.9 (OCH3), 102.9 (ArCH), 105.9 (2 × ArCH), 117.8 (ArC), 120.4 
(ArCH), 124.1 (C=C), 130.3 (C=C), 132.5 (ArC), 132.6 (ArC), 137.2 (ArC), 141.6 (ArC), 












(0.104 g, 0.31 mmol) was dissolved in acetonitrile (1.5 mL) and cooled to -20 °C.  Carbon 
tetrachloride (0.6 mL, 6.26 mmol) was added followed by the addition of N,N-
diisopropylethylamine (0.09 mL, 0.50 mmol) and 4-dimethylaminopyridine (7.6 mg, 0.06 
mmol).  The reaction was stirred for 5 minutes then dibenzyl phosphite (0.36 mL, 1.31 
mmol) was added and the reaction warmed to 0 °C over 2 hours.  Monopotassium 
phosphate (5 mL, 0.5 M) was added and the aqueous layer extracted with ethyl acetate (3 
× 5 mL).  The organic layers were combined and washed with brine (10 mL), dried over 
magnesium sulfate, filtered and the solvent removed under reduced pressure.  The crude 
reaction material was purified by flash column chromatography on silica with an eluent 
of 50% ethyl acetate: 40 – 60 °C petroleum ether and afforded the title compound 56 
(0.158 g, 60%) as a light brown oil; 1H NMR (400 MHz, CDCl3) δ 3.64 (s, 6H, 2 × OCH3), 
3.79 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 5.09 (d, J 2.8, 2H, CH2), 5.11 (d, J 2.0, 2H, CH2), 
5.19 (d, J 7.2, 4H, 2 × CH2), 6.48 (s, 2H, 2 × ArH), 6.53 (d, J 12.0, 1H, HC=C), 6.66 (d, 
J 12.0, 1H, C=CH), 6.69 (d, J 9.0, 1H, ArH), 7.03 (d, J 9.0, 1H, ArH), 7.24 – 7.31 (m, 
10H, 2 × C6H5); 
13C NMR (101 MHz, CDCl3) δ 55.9 (2 × OCH3), 56.4 (OCH3), 60.4 
(OCH3), 69.7 [OP(O)(OCH2Ph)], 69.8 [OP(O)(OCH2Ph)], 69.9 [OP(O)(OCH2Ph)], 70.0 
[OP(O)(OCH2Ph)], 106.3 (2 × ArCH), 109.4 (ArCH), 124.3 (ArCH), 124.6 (=C-C), 126.9 
(=C), 127.8 (4 × OCH2ArCH), 127.9 (4 × OCH2ArCH), 128.3 (2 × OCH2ArCH), 128.4 
(2 × OCH2ArCH), 128.4 (8 × OCH2ArCH), 131.6 (C=), 132.1 (C-C=), 135.6 (2 × 
OCH2C), 135.7 (2 × OCH2C), 135.9 (ArCO), 136.0 (ArCO), 137.7 (ArCO), 151.6 
(ArCO), 152.9 (2 × ArCO); 31P NMR (162 MHz, CDCl3) δ -5.56 (d, JP-P 1.7), -5.43 (d, 
JP-P 1.7).  All data in accordance with the literature apart from in the 
1H NMR data in the 
literature they reported the 4 × CH2 peaks as multiplet and the peaks in the 
31P NMR were 











4``-meth oxyphenyl]ethene 56 (0.200 g, 0.234 mmol) was dissolved in acetonitrile (6 mL) 
and cooled to -10 °C.  Trimethylsilyl bromide (0.15 mL, 1.17 mmol) was added dropwise 
and the reaction left to stir at -10 °C for 1.5 hours.  The solvent was then removed under 
reduced pressure and the residue dissolved in methanol (3 mL) at -10 °C.  Potassium 
methoxide (0.164 g, 2.35 mmol) in methanol (3 mL) was added dropwise to the phosphate 
solution via a syringe pump.  The reaction was warmed to room temperature over 15 
minutes then the solvent removed under reduced pressure at 30 °C.  The residue was 
dissolved in water (5 mL) and the pH adjusted to pH 4.8using hydrochloric acid (0.1 M)).  
The reaction mixture was then filtered and ethanol (5 mL) added to the filtrate and stirred 
for 10 minutes.  The resulting precipitate was filtered off and washed with ethanol (5 mL) 
to give the title compound 151 (71 mg, 58%) as a white solid; max (ATR)/ cm
-1 3287 (C-
H), 2513 (O=P-OH), 2159 (O=P-OH), 1578; 1H NMR (400 MHz, D2O) δ 3.68 (s, 6H, 2 
× OCH3), 3.73 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 6.64 (d, J 12.2, 1H, C=CH), 6.66 (s, 
2H, 2 × ArH), 6.68 (d, J 8.8, 1H, ArH), 6.75 (d, J 12.0, 1H, C=CH), 6.87 (d, J 8.8, 1H, 
ArH); 13C NMR (162 MHz, D2O) δ 56.0 (2 × OCH3), 56.1 (OCH3), 60.88 (OCH3), 106.7 
(2 × ArCH), 108.2 (ArCH), 124.0 (ArC), 125.1 (ArCH), 126.1 (C=C), 129.9 (C=C), 133.7 
(ArC), 134.4 (ArCO), 135.7 (ArCO), 143.6 (ArCO), 151.7 (ArCO), 152.0 (2 × ArCO); 
m/z (ES+) 493.0646 (100%, MH+. C18H23O12P2 requires 493.0665).  All data in 




4.3 Synthesis towards [13C]-CA1P 
 




Magnesium turnings (0.938 g, 38.6 mmol) were dry stirred for 5 min and diethyl ether 
(10 mL) was then added.  [13C]-Methyl iodide (5.00 g, 35.1 mmol) was added drop-wise 
to the reaction mixture at a rate to induce heating at a steady reflux.  The resulting methyl 
magnesium iodide was added dropwise to a solution of freshly recrystallised copper 
bromide dimethyl sulphide complex (10.83 g, 52.6 mmol) in diethyl ether (200 mL) at -
10 °C and left for 30 minutes.  Glutaric acid monomethyl ester chloride 79 (4.9 mL, 35.1 
mmol) was added to the reaction mixture left stirring for 18 hours and the reaction was 
quenched with a saturated solution of ammonium chloride (100 mL).  The precipitate was 
filtered under suction and the filtrate was extracted with diethyl ether (3 × 100 mL).  The 
combined organic layers were washed with brine (200 mL) and dried over magnesium 
sulfate.  After filtration and removal of the solvent under reduced pressure, the crude 
material was purified by flash column chromatography on silica gel using an eluent of 
20% ethyl acetate: 40 – 60 °C petroleum ether to afford the title compound [13C]-80 as 
pale yellow oil (2.75 g, 55%); 1H NMR (400 MHz, CDCl3) δ 1.91 (pent, J 7.2, 2H, 
CH2CH2CH2), 2.16 (d, JC-H 127.2, 3H, CH3), 2.37 (t, J 7.2, 2H, CH2), 2.53 (t, J 7.2, 2H, 
CH2), 3.69 (s, 3H, OCH3); 
13C NMR (101 MHz, CDCl3) δ 18.8 (CH2), 29.9 (enhanced, 
13CH3), 33.0 (CH2), 42.4 (d, JC-C 15.4, CH2), 51.6 (OCH3), 173.6 [d, JC-C 3.1, 










Potassium tert-butoxide (4.25 g, 38.0 mmol) was dissolved in tetrahydrofuran (60 mL) 
and 5-oxo-[6-13C]hexanoate [13C]-80 (2.75 g, 19.0 mmol) was added.  The reaction was 
heated at reflux for 7 hours, after which the organic solvents were removed under reduced 
pressure.  The residue was dissolved in water (20 mL) and acidified to pH 2 with 
concentrated hydrochloric acid.  The aqueous layer was extracted with ethyl acetate (3 × 
15 mL) and the combined organic layers dried over magnesium sulfate and filtered.  
Removal of the solvent under reduced pressure yielded the crude product which was 
purified by flash column chromatography on silica with an eluent of 80% ethyl acetate: 
40 – 60 °C petroleum ether to afford the title compound [13C]-78 (1.31 g, 61%) as a 
yellow solid; mp 105 – 108 °C [lit. (12C 75) 106 – 108 °C]; 1H NMR (400 MHz, CDCl3) 
δ 1.95 – 2.03 [m, 2H, CH2 (keto) and CH2 (enol)], 2.38 [td, 2.4H, J 11.2, 3.2, 2 × CH2 
(keto) and CH2 (enol)], 2.60 [t, 1.6H, J 6.4, CH2 (enol)], 3.42 [d, 0.4H, J 130.4, CH2 
(keto)], 5.48 [d, 0.8H, J 160.0, =CH (enol)], 10.61 [s, 0.8H, OH (enol)]; 13C NMR (101 
MHz, CDCl3) δ 18.5 [d, J 11.7, CH2 (keto)], 21.0 [CH2 (enol)], 32.2 [d, J 7.7, CH2 (enol)], 
39.8 [d, J 11.7, CH2 (enol) and 2 × CH2 (keto)], 58.4 [enhanced 
13CH2 (keto)], 104.3 
[enhanced, =13CH (enol)], 192.6 [d, J 63.0, C=O and C-O (enol)], 204.4 [d, J 40.1, C=O 








[2-13C]Cyclohexan-1,3-dione [13C]-78 (1.22  g, 10.8  mmol) was dissolved in methanol 
(20 mL).  Iodine (8.19 g, 32.4 mmol) was added and the reaction mixture was heated at 
reflux for 1.5 hours.  The methanol was removed under reduced pressure and the residue 
dissolved in dichloromethane (20 mL).  The organic layer was washed with sodium 
hydrogen carbonate (20 mL), 10% aq. sodium thiosulfate (20 mL) and 5% sodium 
hydroxide (20 mL).  The combined aqueous layers were then extracted with 
dichloromethane (3 × 30 mL) and the resulting combined organic layers were dried over 
magnesium sulfate, filtered and the solvent was removed under reduced pressure.  
Purification of the crude material by flash column chromatography using an eluent of 5% 
ethyl acetate: 40 – 60 °C petroleum ether afforded the title compound [13C]-157 as a pale 
yellow oil (1.013 g, 67%); 1H NMR (400 MHz, CDCl3) δ 3.70 (s, 6H, 2 × OCH3), 6.50 
(dt, JC-H 158.0, J 2.4, 1H, 
13CH), 6.56 – 6.52 (m, 2H, 2 × ArH), 7.21 (td, JH-H 8.2, JC-H 
1.2, 1H, ArH); 13C NMR (101 MHz, CDCl3) δ  55.3 (d, JC-C 4.4, 2 × OCH3), 100.5 
(enhanced, 13C), 106.2 (d, JC-C 2.8, 2 × ArCH), 129.9 (d, JC-C 4.8, ArCH), 160.8 (d, JC-C 
60.3, 2 × ArC). NMR data in accordance with the literature apart in the 1H NMR spectrum 
the peak at 3.70 was reported as 3H in the literature and the triplet of doublets at 7.21 was 









1,3-Dimethoxy-[2-13C]benzene [13C]-157 (1.42 g, 10.1 mmol) and N,N,N`,N`- 
tetramethylethylene diamine (1.7 mL, 11.5 mmol) dissolved in tetrahydrofuran (20 mL) 
and cooled to 0 °C.  n-Butyllithium (4.9 mL, 2.5 M in hexanes, 12.2 mmol) was added 
and the mixture was stirred for 30 minutes.  Dimethylformamide (1.2 mL, 15.2 mmol) 
was added dropwise and the solution stirred for a further 1 hour.  The reaction was then 
quenched with 1 M hydrochloric acid (20 mL) whilst maintaining the temperature below 
25 °C and the organic solvent was removed under reduced pressure.  The aqueous layer 
was extracted with diethyl ether (3 × 15 mL) and the combined organic layers were 
washed with brine (30 mL), dried over magnesium sulfate, filtered and the solvent 
removed under reduced pressure.  The residue was washed with 40 – 60 ºC petroleum 
ether (25 mL) then filtered to afford the title compound [13C]-158 (1.51 g, 89%) which 
was used without further purification; mp 96 – 98 °C [lit. (12C 88) 95 – 98 °C]; max 
(ATR)/ cm-1 2980 (C-H), 1673 (HC=O), 1586 (aromatic), 1570 (aromatic); Found: C, 
64.82; H 6.10; 12C8
13CH10O3 requires C, 65.26; H, 6.03; 
1H NMR (400 MHz, CDCl3) δ 
3.86 (s, 6H, 2 × OCH3), 6.55 (dd, JH-H 8.5, JC-H 5.2, 2H, 2 × ArH), 7.42 (td, JH-H 8.5, JC-H 
1.3, 1H, ArH), 10.48 (d, JC-H 22.4, 1H, CHO); 
13C NMR (101 MHz, CDCl3) δ 56.1 (d, JC-
C 2.4, 2 × OCH3), 103.0 (d, JC-C 2.3, 1 × ArCH), 114. 3 (enhanced, 
13C), 136.0 (d, JC-C 
4.8, 2 × ArCH), 162.2 (d, JC-C 70.2, 2 × ArC), 189.5 (d, JC-C 54.3, HC=O); m/z (ES
+) 
168.0746 (100%, MH+. C8











2,6-Dimethoxy-[1 – 13C]benzaldehyde [13C]-158 (1.00 g, 5.98 mmol) was dissolved in 
dichloromethane (10 mL) and cooled to 0 °C.  meta-Chloroperbenzoic acid (2.68 g, 12.0 
mmol) was added dropwise as a dichloromethane solution (10 mL) and the reaction was 
left at 0 °C for 3 hours.  The organic layer was washed with sodium sulfite solution (10 
mL) then sodium hydrogen carbonate (10 mL).  The combined aqueous layers were 
extracted with dichloromethane (3 × 15 mL).  The combined organic layers were washed 
with brine (20 mL), dried over magnesium sulfate, filtered, and the solvent removed under 
reduced pressure.  The resulting formate ester was dissolved in methanol (10 mL) and 
cooled to 0 °C.  Potassium hydroxide (1.22 g, 21.7 mmol) in methanol (10 mL) was added 
dropwise and the reaction left for 45 minutes.  Water (15 mL) was added and the solution 
was acidified to pH 2 using concentrated hydrochloric acid.  The aqueous layer was 
extracted with diethyl ether (6 × 10 mL) and the combined organic layers were washed 
with brine, dried over magnesium sulfate, filtered and the solvent removed under reduced 
pressure.  The crude reaction material was purified by flash column chromatography 
using an eluent of 20% ethyl acetate: 40 – 60 °C petroleum ether and afforded the title 
compound [13C]-159 (0.77 g, 80%) as a white solid; mp 54 – 55 °C [lit. (12C 89) 52 – 53 
°C];  max (ATR)/ cm
-1 3491 (O-H), 3004 (C-H), 2837 (C-H), 1573 (aromatics), 1260 (C-
OH);  1H NMR (400 MHz, CDCl3) δ 3.89 (s, 6H, 2 × OCH3), 5.53 (d, J 2.8, 1H OH), 6.59 
(t, J 8.2, 2H, 2 × ArH), 6.81 (td, JH-H 8.2, JC-H 1.6, 1H, ArH); 
13C NMR (101 MHz, CDCl3) 
δ 56.3 (d, JC-C 2.7, 2 × OCH3), 104.9 (d, JC-C 5.2, 2 × ArCH), 119.1 (d, JC-C 6.4, ArCH), 
134.8 (enhanced, 13C), 147.2 (d, J 80.1, 2 × COCH3); m/z (ES
+) 178 (34%, MNa+), 
156.0743 (100, MH+. 12C7
13CH11O3 requires 156.0742), 124 (36).  NMR data corresponds 









2,6-Dimethoxy-[1 – 13C]phenol [13C]-159 (0.958 g, 6.17 mmol) was dissolved in acetone 
(20 mL), potassium carbonate (1.28 g, 9.26 mmol) was added and the reaction mixture 
cooled to 0 °C.  18-Crown-6 (0.2 mL) and methyl iodide (0.58 mL, 9.26 mmol) were 
added at 0 °C and the reaction was stirred overnight. after which the resulting mixture 
was poured in diethyl ether (20 mL), filtered and the filtrate concentrated under reduced 
pressure to yield the title compound [13C]-160 (0.836 g 80%) as a white solid which was 
used without further purification; mp 43 – 44 °C [lit. (12C 119) 40 – 42 °C]; max (ATR)/ 
cm-1 2991 (C-H), 2965 (C-H), 2940, 2836, (aromatics); Found: C, 64.34; H 7.35; 
12C8
13CH13O3 requires C, 64.48; H, 7.15; 
1H NMR (400 MHz, CDCl3) δ 3.85 (d, JC-H 3.6, 
3H, OCH3), 3.86 (s, 6H, 2 × OCH3), 6.58 (dd, J 8.3, JC-H 7.4, 2H, 2 × ArH), 6.99 (td, J 
8.3, JC-H 2.0, 1H, ArH); 
13C NMR (101 MHz, CDCl3) δ  56.1 (d, JC-C 2.7, 2 × OCH3), 60.8 
(d, JC-C 3.5, OCH3), 105.2 (d, JC-C 4.8, 2 × ArCH), 123.6 (d, JC-C 6.3, ArCH) 138.1 
(enhanced, 13C), 153.5 (d, JC-C 80.2, 2 × ArC); m/z (ES
+) 170.0902 (100%, MH+. 
12C8
13CH13O3 requires 170.0898).  NMR data corresponds with 









[2 – 13C]-1,2,3-Trimethoxybenzene [13C]-160 (0.451 g, 2.67 mmol) was dissolved in 
dichloromethane (5 mL) at 0 °C.  Titanium (IV) chloride (0.58 mL, 5.33 mmol) was added 
dropwise followed by dichloromethyl methyl ether (0.48 mL, 5.33 mmol).  The reaction 
mixture was warmed to room temperature and left stirring for 3 hours.  Cold water (5 mL) 
was added to reaction mixture and the aqueous layer extracted with dichloromethane (3 
× 5 mL).  The combined organic layers were washed with hydrochloric acid (1 M, 10 
mL), saturated aqueous sodium bicarbonate (10 mL) and brine (15 mL).  The organic 
layers were combined, dried over magnesium sulfate, filtered and the solvent removed 
under reduced pressure.  The crude reaction material was purified by flash column 
chromatography using an eluent of 10% ethyl acetate: 40 – 60 °C petroleum ether and 
afforded the title compound [13C]-161 (0.372 g, 71%) as a white solid; mp 31 – 32 °C [lit. 
(12C 120) 32 – 33 °C]; max (ATR)/ cm
-1 2949 (C-H), 2978 (C-H), 1671 (HC=O), 1586 
(aromatics);  1H NMR (400 MHz, CDCl3) δ 3.89 (d, JC-H 3.6, 3H, 
13COCH3), 3.94 (s, 3H, 
OCH3), 4.03 (s, 3H, OCH3), 6.76 (dd, JH-H 8.6, JC-H 7.6, 1H, ArH), 7.61 (dd, JH-H 8.6, JC-
H 1.6, 1H, ArH), 10.25 (d, JC-H 0.4, 1H, CHO); 
13C NMR (101 MHz, CDCl3) δ  56.2 (d, 
JC-C 2.8, OCH3), 61.0 (d, JC-C 3.4, OCH3), 62.4 (OCH3), 107.4 (d, JC-C 5.2, ArCH), 123.3 
(d, JC-C 6.3, ArC), 124.3 (d, JC-C 4.7, ArCH), 141.6 (enhanced, 
13C), 157.0 (d, JC-C 78.9, 
ArC), 159.3 (d, JC-C 77.2, ArC), 188.9 (d, JC-C 3.4, CHO); m/z (ES
+) 198.0851 (100%, 
M+. 12C9
13CH13O4 requires 198.0847).  NMR data corresponds with 









[3 – 13C]-2,3,4-Trimethoxybenzaldehyde [13C]-161 (0.152 g, 0.77 mmol) was dissolved 
in dichloromethane (2 mL) and boron trichloride (1M in dichloromethane, 0.77 mL, 0.77 
mmol) was added dropwise.  The reaction was left stirring for 2 hours before another 
equivalent of boron trichloride (1M in dichloromethane, 0.77 mL, 0.77 mmol) was added 
dropwise and the reaction was left stirring for 24 hours.  The reaction was quenched with 
NaHCO3 (5 mL) and acidified to pH 2 using concentrated hydrochloric acid.  The aqueous 
layer was then extracted with dichloromethane (3 × 5 mL) and the combined organic 
layers washed with brine (10 mL), dried over magnesium sulfate and filtered.  The solvent 
was removed under reduced pressure, and the crude material recrystallised with ethyl 
acetate/hexane to afford the title compound [13C]-162 (0.109 g, 84%) as a white solid; 
mp 113 – 114 °C [lit. (12C 118) 113 – 114 °C];max (ATR)/ cm
-1 3363 (O-H), 2950 (C-
H), 1644 (HC=O), 1503 (aromatic);  1H NMR (400 MHz, CDCl3) δ 3.98 (s, 3H, OCH3), 
5.49 (d, J 3.2, 1H, OH), 6.62 (dd, JH-H 8.8 JC-H 7.2, 1H, ArH), 7.14 (dd, JH-H 8.8 JC-H 1.2, 
1H, ArH), 9.75 (d, JC-H 2.8, 1H, CHO), 11.12 (d, JC-H 6.0, 1H, OH); 
13C NMR (101 MHz, 
CDCl3) δ  56.4 (d, JC-C 2.7, OCH3), 103.6 (d, JC-C 5.6, ArCH), 116.1 (d, JC-C 4.8, ArC), 
126.1 (d, JC-C 4.9, ArCH), 133.0 (enhanced, 
13C), 149.1 (d, JC-C 80.6, ArC), 153.0 (d, JC-
C 80.4, ArC), 195.2 (d, JC-C 3.6, CHO); m/z (ES
+) 170.0528 (100%, M+. 12C7
13CH8O4 









[3 – 13C]-2,3-Dihydroxy-4-methoxybenzaldehyde [13C]-162 (0.119 g, 0.70 mmol) was 
dissolved in dichloromethane (2 mL).  Triethylamine (0.29 mL, 2.11 mmol) and 4-
dimethylaminopyridine (18 mg, 0.021 mmol) were added and the mixture was stirred for 
10 minutes.  tert-Butyldimethylsilyl chloride (0.254 g, 1.69 mmol) was added to the 
reaction mixture in portions and stirred for 12 hours at room temperature.  After addition 
of water (5 mL), the aqueous layer was extracted with dichloromethane (3 × 5 mL) and 
the combined organic layers were washed with brine (20 mL) and dried over magnesium 
sulfate.  Filtration, followed by the removal of solvent under reduced pressure gave the 
crude material which was purified by recrystallisation from methanol to afford the title 
compound [13C]-163 (0.154 g, 55%) as colourless crystals; mp 74 – 75 °C [lit. (12C 22) 
72 – 73 °C];max (ATR)/ cm
-1 2928 (C-H), 2856 (C-H), 1679 (HC=O), 1579 (aromatic);  
1H NMR (400 MHz, CDCl3) δ 0.13 [s, 12H, 2 × OSi(CH3)2C(CH3)3], 0.98 [s, 9H, 
OSi(CH3)2C(CH3)3], 1.04 [s, 9H, OSi(CH3)2C(CH3)3], 3.83 (s, 3H, OCH3), 6.62  (t, J 8.0, 
1H, Ar-H), 7.48 (dd, JH-H 8.0, JC-H 1.8, 1H, Ar-H), 10.21 (s, 1H, CHO); 
13C NMR (101 
MHz, CDCl3) δ -3.8 [2 × OSi(CH3)2C(CH3)3], 18.6 [OSi(CH3)2C(CH3)3], 18.7 
[OSi(CH3)2C(CH3)3], 26.0 [OSi(CH3)2C(CH3)3], 26.2 [OSi(CH3)2C(CH3)3], 55.2 (d, JC-H 
2.8, OCH3), 105.4 (d, JC-H 5.6, ArCH), 121.4 (d, JC-H 4.7, ArCH), 123.4 (d, JC-H 7.4, ArC), 
136.8 (enhanced, 13C), 151.0 (d, JC-H 80.5, ArC), 157.5 (d, JC-H 77.8, ArC), 189.2 (d, JC-
H 3.6, CHO); m/z (ESI) 398.2258 (100%, MH
+. 12C19
13CH36O4Si2 requires 398.2258).  










3,4,5-Trimethoxybenzyltriphosphonium bromide 139 (0.132 g, 0.25 mmol) was 
dissolved in tetrahydrofuran (1 mL) and cooled to -10 °C.  n-Butyllithium (1.9 M in 
hexanes, 0.13 mL, 0.25 mmol) was added dropwise and the reaction left for 30 minutes.  
The reaction mixture was cooled to -78 °C and [3 – 13C]-2,3-di[(tert-
butyldimethylsilyl)oxy]-4-methoxybenzaldehyde [13C]-163 (0.100 g, 0.25 mmol) in 
tetrahydrofuran (1 mL) and cooled to (0.5 mL) was added dropwise to the reaction 
mixture and was left to warm to 0 °C.  The reaction was quenched with water (5 mL) and 
the organic layer removed under reduced pressure.  The aqueous layer was extracted with 
diethyl ether (3 × 5 mL) and the combined organic layers were washed with brine (15 
mL), dried over magnesium sulfate, filtered and the solvent removed under reduced 
pressure.  The crude reaction material was purified by flash column chromatography 
using an eluent of 10% ethyl acetate: 40 – 60 °C petroleum ether and recrystallised from 
ethanol to yield the Z-isomer [13C]-165 (44 mg, 31%) as white crystals; mp 120 – 121 °C 
[lit. (12C 24) 118 – 120 °C]; max (ATR)/ cm
-1 2829 (C-H), 2856 (C-H), 1580 (C=C), 1500 
(aromatic); 1H NMR (400 MHz, CDCl3) δ 0.10 [s, 6H, OSi(CH3)2C(CH3)3], 0.19 [s, 6H, 
OSi(CH3)2C(CH3)3], 1.00 [s, 9H, OSi(CH3)2C(CH3)3], 1.04 [s, 9H, OSi(CH3)2C(CH3)3], 
3.67 (s, 6H, OCH3), 3.74 (s, 3H, OCH3), 3.83 (s, 3H, OCH3), 6.36 (d, J 12.6, 1H, HC=C), 
6.37 (d, J 8.3, 1H, ArH), 6.58 (d, J 12.6, 1H, C=CH), 6.62 (s, 2H, 2 × ArH), 6.91 (dd, JH-
H 8.3, JC-H 1.4 1H, ArH); 
13C NMR (101 MHz, CDCl3) δ -3.9 [OSi(CH3)2C(CH3)3], -3.2 
[OSi(CH3)2C(CH3)3], 18.6 [OSi(CH3)2C(CH3)3], 18.7 [OSi(CH3)2C(CH3)3], 26.1 
[OSi(CH3)2C(CH3)3], 26.4 [OSi(CH3)2C(CH3)3], 54.9 (OCH3), 55.8 (2 × OCH3), 60.9 
(OCH3), 104.2 (d, JC-C 5.6, ArCH), 105.9 (2 × ArCH), 122.2 (d, JC-C 4.9, ArCH), 123.2 
(d, JC-C 7.9, ArC-C=), 127.4 (C=), 127.7 (=C), 132.8 (ArC-C=), 136.8 (enhanced, 
13C), 
137.0 (COSi), 146.5 (COCH3), 151.3 (COCH3), 152.7 (2 × COCH3); m/z (ESI) 584 (69%, 
MNa+), 562.3097 (100, MH+. C29
13C1H48O6Si2 requires 562.3096).  NMR data in 








3,4,5-Trimethoxybenzyltriphosphonium bromide 139 (0.132 g, 0.35 mmol) was 
dissolved in tetrahydrofuran (1 mL) and cooled to  -10 °C.  n-Butyllithium (1.9 M in 
hexanes, 0.13 mL, 0.25 mmol) was added dropwise and the reaction left for 30 minutes.  
The reaction mixture was cooled to -78 °C and [3 – 13C]-2,3-di[(tert-
butyldimethylsilyl)oxy]-4-methoxybenzaldehyde [13C]-163 (0.100 g, 0.25 mmol) in 
tetrahydrofuran (0.5 mL) was added dropwise to the reaction mixture and was left to 
warm to 0 °C.  The reaction was quenched with water (5 mL) and the organic layer 
removed under reduced pressure.  The aqueous layer was extracted with diethyl ether (3 
× 5 mL) and the combined organic layers were washed with brine (15 mL), dried over 
magnesium sulfate, filtered and the solvent removed under reduced pressure.  The crude 
reaction material was purified by flash column chromatography using an eluent of 10% 
ethyl acetate: 40 – 60 °C petroleum ether and recrystallised from ethanol to yield the Z-
isomer [13C]-164 (14 mg, 10%) as a white solid; mp 135 – 136 °C [lit. (12C 23) 138 – 139 
°C]; max (ATR)/ cm
-1 2928 (C-H), 2855 (C-H), 1594 (C=C), 1500 (aromatic); 1H NMR 
(400 MHz, CDCl3) δ 0.11 [s, 6H, OSi(CH3)2C(CH3)3], 0.13 [s, 6H, OSi(CH3)2C(CH3)3], 
1.00 [s, 9H, OSi(CH3)2C(CH3)3], 1.09 [s, 9H, OSi(CH3)2C(CH3)3], 3.79 (s, 3H, OCH3), 
3.86 (s, 3H, OCH3), 3.88 (s, 6H, 2 × OCH3), 6.56 (app. t, J 8.5, 1H, ArH), 6.72 (s, 2H, 2 
× ArH), 6.81 (d, JH-H 16.4, 1H, HC=C), 7.20 (dd, JH-H 8.5, JC-H 1.6, 1H, ArH), 7.31 (d, 
JH-H 16.4, 1H, C=CH); 
13C NMR (101 MHz, CDCl3) δ 137.0 (enhanced, 
13C); m/z (ESI) 
584 (8%, MNa+), 562.3091 (100, MH+. C29
13CH48O6Si2 requires 562.3096).  NMR data 





(Z)-1-(3′,4′,5′-Trimethoxyphenyl)-2-(2′′,[3′′ – 13C]-dihydroxy-4′′-methoxyphenyl) 





methoxy phenyl]ethene [13C]-165 (0.144 g, 0.26 mmol) was dissolved in tetrahydrofuran 
(1 mL).  Tetrabutylammonium fluoride (1M in THF, 1.0 mL, 1.0 mmol).  The mixture 
was left stirring for 30 minutes after which hydrochloric acid (1M, 3 mL) was added the 
mixture extracted with ethyl acetate (3 × 5 mL).  The combined organic layers were 
washed with brine (15 mL), dried over magnesium sulfate, filtered and the solvent 
removed under reduced pressure.  The crude material was purified by flash column 
chromatography on silica with an eluent of 50% ethyl acetate: 40 – 60 °C petroleum ether 
to reveal the title compound [13C]-154 (79 mg, 92%) as an off-white solid; mp 111 – 112 
°C [lit. (12C 8) 113 – 115 °C]; max (ATR)/ cm
-1 3366 (O-H), 2960 (C-H), 2925 (C-H), 
1580, 1505 (aromatic); 1H NMR (400 MHz, CDCl3) δ 3.67 (s, 6H, 2 × OCH3), 3.83 (s, 
3H, OCH3), 3.86 (s, 3H, OCH3), 5.37 (s, 1H, OH), 5.38 (s, 1H, OH), 6.38 (t, J 8.5, 1H, 
ArH), 6.52 (s, 2H, 2 × ArH), 6.54 (d, J 11.8, 1H, HC=CH), 6.59 (d, J 11.8, 1H, HC=CH), 
6.76 (dd, JH-H 8.5, JC-H 1.2 1H, ArH); 
13C NMR (101 MHz, CDCl3) δ 132.6 (enhanced, 
13C); m/z (ESI) 334.1366 (100%, MH+. C17
13C1H20O6 requires 334.1366).  NMR data 







(Z)-1-(3′,4′,5′-Trimethoxyphenyl)-2-(2′′,[3′′ – 13C]-di-({[bis-(benzyl)oxy]phosphoryl 





([13C – CA1) [13C]-154 (85 mg, 0.256 mmol) was dissolved in acetonitrile (1 mL) and 
cooled to -20 °C.  Carbon tetrachloride (0.49 mL, 5.13 mmol) was added followed by the 
addition of N,N-diisopropylethylamine (0.07 mL, 0.41 mmol) and 4-
dimethylaminopyridine (6.3 mg, 0.051 mmol).  The reaction was stirred for 5 minutes 
then dibenzyl phosphite (80%, 0.281 g, 1.07 mmol) was added and the reaction warmed 
to 0 °C over 2 hours.  Monopotassium phosphate (1 mL, 0.5 M) was added and the 
aqueous layer extracted with ethyl acetate (3 × 2 mL).  The organic layers were combined 
and washed with brine (5 mL), dried over magnesium sulfate, filtered and the solvent 
removed under reduced pressure.  The crude reaction material was purified by flash 
column chromatography on silica with an eluent of 50% ethyl acetate: 40 – 60 °C 
petroleum ether and afforded the title compound [13C]-166 (0.115 g, 53%) as a light 
brown oil; max (ATR)/ cm
-1 2924 (C-H), 2851 (C-H), 1579 (aromatic); 1H NMR (400 
MHz, CDCl3) δ 3.62 (s, 6H, 2 × OCH3), 3.76 (s, 3H, OCH3), 3.79 (s, 3H, OCH3), 5.07 (d, 
J 2.8, 2H, CH2), 5.09 (d, J 2.4, 2H, CH2), 5.17 (d, J 76.8, 4H, 2 × CH2), 6.45 (s, 2H, 2 × 
ArH), 6.50 (d, J 12.2, 1H, HC=C), 6.64 (d, J 12.2, 1H, C=CH), 6.66 (d, J 8.6, 1H, ArH), 
7.00 (d, J 8.6, 1H, ArH), 7.28 – 7.20 (m, 20H, 4 × C6H5); 
13C NMR (101 MHz, CDCl3) δ 
55.9 (2 × OCH3), 56.4 (d, JC-C 2.6, OCH3), 60.8 (OCH3), 69.7 [OP(O)(OCH2Ph)], 69.8 
[OP(O)(OCH2Ph)], 69.9 [OP(O)(OCH2Ph)], 70.0 [OP(O)(OCH2Ph)], 106.1 (2 × ArCH), 
109.2 (ArCH), 124.3 (ArCH), 124.6 (=C-C), 126.8 (=C), 127.8 (4 × OCH2ArCH), 127.9 
(4 × OCH2ArCH), 128.3 (2 × OCH2ArCH), 128.4 (2 × OCH2ArCH), 128.4 (8 × 
OCH2ArCH), 131.6 (C=), 132.1 (C-C=), 132.94 (enhanced, dd, J 7.5, 3,8, 
13C) 135.6 (2 
× OCH2C), 135.7 (2 × OCH2C), 135.8 (ArCO), 136.0 (ArCO), 151.7 (ArCO), 152.8 (2 × 
ArCO); 31P NMR (162 MHz, CDCl3) δ -5.60 – -5.44 (m); m/z (ESI) 854.2571 (100%, 
MH+. C45
13CH46O12P2 requires 854.2571).  NMR data corresponds with 
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